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Abstract 
Despite remarkable medical advances, including improved sanitation, effective vaccines, and 
antibiotics, bacterial infections remain a serious threat to human health. Annually, over 17 million people 
succumb to bacterial infections, with an increasing proportion due to antibiotic resistance. Therefore, there 
is urgent and continuous need for new antibiotics. Small molecule metabolites from microbes have been a 
highly productive source of chemical matter that ultimately led to most of today’s clinically used antibiotics. 
Many of these natural products are derived from polyketide synthase (PKS) or non-ribosomal peptide 
synthetase (NRPS) families, including well-known antibiotics such as the beta-lactams, tetracyclines, 
macrolides, and glycopeptides. With the rising resistance to these proven antibiotic classes, alternative 
sources of antibiotics must be discovered. The ribosomally synthesized and post-translationally modified 
peptides (RiPPs) have been attracting interest as one such source of untapped potential. Owing to the unique 
“promiscuous-yet-specific” biosynthetic paradigm that RiPPs offer, this class of natural products have been 
an area of intense research. Chapter 1 provides an overview of various RiPP classes, their antibiotic 
activities, the biosynthesis that creates these remarkable molecules, and discusses their engineering 
potential.  
Chapters 2, 3, and 4 all elaborate further on the thiopeptide class of RiPP antibiotics. Thiopeptides 
typically display nanomolar activity against pathogenic Firmicutes, such as Staphylococcus aureus, 
Enterococcus faecalis, and Clostridium difficile. Despite their potent activity, thiopeptides suffer from poor 
aqueous solubility which has hampered their clinical development. In order to investigate this problem, we 
endeavored to investigate the enzymes that give rise to these molecules. Prior to the work described herein, 
thiopeptide enzymology was a largely undeveloped field, with almost all investigations previously being 
performed in vivo and introducing the drawback that comes with the cellular “black box.” In order to 
obviate this issue, we reconstituted the core biosynthetic framework that synthesizes the thiopeptide 
antibiotic, thiomuracin (Chapter 2). This enabled not only the total in vitro biosynthesis of bioactive 
thiopeptide, but also the in-depth investigation into the enzymatic steps at each point along the biosynthetic 
path which was previously impossible due to the inherent obfuscation of in vivo biosynthesis. Armed with 
this system, we elucidated the details of biosynthetic timing, including order of post-translational 
modifications, substrate tolerance, and substrate recognition (Chapter 3). These investigations have laid the 
ground work for further thiopeptide engineering and have already spawned multiple side-projects (see 
Appendix A).  
Chapter 4 deviates from the thiomuracin system and focuses instead on bioinformatically surveying 
the entire thiopeptide class in sequenced organisms. This survey revealed that thiopeptide biosynthetic 
space is a largely unexplored territory, with many detected gene cluster families having no characterized 
member. More importantly, we predict that there may exist other macrocycle sizes beyond those already 
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represented in thiopeptides; this metric has previously served as a predictor of bioactivity and thus novel 
thiopeptides may in turn have novel modes of action. Canvassing the genomic landscape of thiopeptides 
also enabled an assessment of post-translational modifications. Specifically, we focused on thiopeptide 
thioamidation. Although in a highly divergent context, thioamidation has been recently shown to be carried 
out by TfuA/YcaO enzyme pairs in methanogenic archea. Using TfuA/YcaO as a marker, we discovered 
an additional thiopeptide featuring thioamidation (saalfelduracin), and associated the previously-orphaned 
two thioamidated thiopeptides with biosynthetic gene clusters (Sch 18640 and thiopeptin). We also 
demonstrated that thioamidation features “plug and play” activity by incorporating these enzymes into the 
genome of the thiostrepton producer, S. laurentii, resulting in the production of a thioamidated analog. 
Lastly, Chapter 5 diverges from thiopeptide work and into the realm of sactipeptides, which feature 
a radically-installed thioether linkage between a Cys donor residue to the Cα of an acceptor residue. Using 
bioinformatics, we surveyed the entire family and found a novel sactipeptide featuring a previously-unseen 
configuration of crosslinks, huazacin. We further delved into this family and found that another thioether-
containing group of RiPPs which had been loosely conflated with sactipeptides, the SCIFFs (six-cysteines 
in forty-five residues), featured non-alpha linkages. Specifically, we discovered a novel RiPP, freyrasin, 
which also features radically-installed thioethers, but rather than S–Cα linkages, contains six S–Cβ 
crosslinks to Asp residues. Lastly, we demonstrated using stable isotope labeling that the only previously-
characterized SCIFF in the literature, thermocellin, does not contain a S–Cα thioether between Cys and Thr 
as previously reported, but instead a S-Cɣ. As these findings demonstrate “SCIFFs” as a divergent 
biosynthetic paradigm from sactipeptides, we proposed to rename this group of natural products to 
ranthipeptides (radical non-alpha thioether peptides). 
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“To witness secrets sealed, one must endure the harshest punishment.” 
-The Pale King, “Hollow Knight” 
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Chapter 1: RiPP Antibiotics: Biosynthesis and Engineering Potential1 
 
1.1 Introduction 
Despite remarkable medical advances, including improved sanitation, effective vaccines, and 
antibiotics, bacterial infections remain a serious threat to human health.1 Annually, over 17 million people 
succumb to bacterial infections, with an increasing proportion due to antibiotic resistance.1,2 Therefore, 
there is urgent and continuous need for new antibiotics. Small molecule metabolites from microbes have 
been a highly productive source of chemical matter that ultimately led to most of today’s clinically used 
antibiotics.3-5 Many of these natural products are derived from polyketide synthase (PKS) or non-ribosomal 
peptide synthetase (NRPS) families, including well-known antibiotics such as the beta-lactams, 
tetracyclines, macrolides, and glycopeptides. With the rising resistance to these proven antibiotic classes, 
alternative sources of antibiotics must be discovered. The ribosomally synthesized and post-translationally 
modified peptides (RiPPs) have been attracting interest as one such source of untapped potential. 
Unfortunately, the clinical deployment of RiPPs has been hindered due to issues such as poor solubility and 
bioavailability despite many displaying potent antibiotic activity and modes of action distinct from currently 
used drugs. However, the single property that sets RiPPs apart from polyketides and non-ribosomal peptides 
is their extraordinary biosynthetic malleability. Owing to this, on-going RiPP engineering efforts appear to 
be poised to mitigate the abovementioned issues.6,7  
RiPP biosynthesis begins with the ribosomal synthesis of a precursor peptide. Most commonly, 
RiPP precursors are comprised of an N-terminal leader region and a C-terminal core region. The former 
contains a recognition sequence that is bound directly by a particular biosynthetic protein while the latter 
receives post-translational modifications to ultimately become the mature RiPP (Figure 1.1). Through the 
physical separation of the sites responsible for substrate binding and residues that are modified, RiPP 
biosynthetic pathways can be highly specific yet promiscuously process highly variable core sequences. 
Many RiPP classes have been characterized using in vivo and in vitro methods to better understand their 
substrate tolerance and promiscuity. These studies have provided a starting point for utilizing RiPP 
biosynthetic enzymes to generate novel compounds to address the rise of antibiotic resistance.   
Below, several RiPPs with antibiotic activity will be examined. We detail their defining structural 
features, mode of action, as well as their biosynthetic malleability with an emphasis on how each class 
might be exploited to create analogs of future biotechnological or medicinal value.  
 
                                                     
1 This chapter has been reproduced with permission from Hudson, G.A. and Mitchell, D.A. RiPP antibiotics: biosynthesis and 
engineering potential. Curr. Opin. Microbiol. 2018, 45, 61-69. Copyright 2019 Elsevier B.V. G.A.H wrote this work which was 
reviewed and edited by D. A. Mitchell.  
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1.2 Lasso Peptides 
 Lasso peptides are topologically interesting RiPPs that feature an isopeptide-linked macrocycle 
from the N-terminus of the core region to the side chain of a recipient Asp/Glu residue. Lasso peptide 
uniquely display a catenane-like structure where the C-terminal tail is threaded through the macrocycle and 
locked into place by disulfide bonds and/or steric interactions (Figure 1.2).8 Despite their relative simplicity, 
lasso peptides display a striking array of bioactivities with several notable examples functioning as 
antibiotics. These include microcin J25, produced by certain strains of Escherichia coli to kill other strains 
of E. coli and closely related Salmonella strains. Microcin J25 gains entry to the cell by hijacking FhuA, an 
outer membrane siderophore receptor. Once inside, microcin J25 potently inhibits RNA polymerase. 
Capistruin, produced by Burkholderia thailandensis, also targets RNA polymerase. Streptomonomicin, 
isolated from Streptomonospora alba, causes cell lysis in Bacillus sp., especially B. anthracis, and is 
thought to operate by modulating the activity of the WalR response regular.9 LP2006, lariatin, and 
lassomycin all harbor activity towards various Mycobacterium sp., with the latter reported to target the 
ClpC1 ATPase of Mycobacterium tuberculosis.8,10-13 RODEO-enabled genome mining has revealed many 
more lasso peptides await characterization.13 
 Lasso peptide biosynthesis requires a minimum of two enzymes. The first is a transglutaminase 
homolog that functions as a leader peptidase. The second enzyme is homologous to asparagine synthetase 
and responsible for forming the threaded macrocycle.8,14 While a detailed mechanism for lasso peptide 
biosynthesis has yet to be reported, numerous heterologous expression studies suggest that the pathways 
are extraordinarily tolerant towards alternative substrates. Several studies have modified the precursor 
peptide and determined that the lasso peptide biosynthetic enzymes tolerate most substitutions, except for 
residues involved directly in isopeptide bond formation or leader peptide cleavage.15-18 Lasso peptides may 
prove to be a useful scaffold for specific chemical biology or biomedical applications.  
 
1.3 Plantazolicin 
Plantazolicin is a member of the linear azol(in)e-containing peptide class of RiPPs. After extensive 
spectrum of activity testing, plantazolicin only displayed significant activity towards B. anthracis (Figure 
1.2). Remarkably, plantazolicin lacked activity against other members of the Bacillus cereus group, despite 
these organisms sharing considerable genetic identity with B. anthracis.19 Based on a series of detailed 
genetic, transcriptomic, and fluorescent labeling studies, plantazolicin localizes to cardiolipin-rich lipid 
microdomains of the plasma membrane. Unusually, B. anthracis appear to accumulate 
plantazolin:cardiolipin complexes in a discontinuous helix around the longitudinal axis of the cell, rather 
than at the poles where cardiolipin is usually found in rod-shaped bacteria.20 Ultimately, plantazolicin 
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causes cell lysis, a feature that is enhanced by addition of exogenous cardiolipin, which contrasts with 
daptomycin, another cardiolipin-dependent antibiotic.19,21  
As a linear azol(in)e-containing peptide, plantazolicin biosynthesis shares features with one of the 
best-studied RiPPs, the DNA gyrase inhibitor microcin B17. Knowledge into how peptidic azol(in)e 
heterocycles are formed was greatly aided from studies on microcin B17 biosynthesis.22-24 The biosynthesis 
of plantazolicin involves the cyclodehydration of Cys, Ser, and Thr to yield ten azoline heterocycles, nine 
of which undergo dehydrogenation to the azole heterocycle. Next, a type II CAAX protease family removes 
the leader peptide and the newly created N-terminus is dimethylated.22 Unlike the highly permissive lasso 
peptide synthases, the plantazolicin heterocycle synthetase features significant stringency. Substrate 
tolerance was initially investigated using an E. coli heterologous expression system and precursor peptide 
variants. While this led to detectable generation of some analogs, these were largely limited to amino acid 
substitutions at sites not naturally cyclized.25 In a separate study that reconstituted the activity of the purified 
azol(in) synthetase, it was demonstrated that the enzymes were significantly more promiscuous in vitro, 
which enabled production of analogs that were not detected through the earlier heterologous expression 
study.25,26 Conserved motifs in the leader region, verified by binding studies, and the distance between this 
recognition sequence and the core peptide played determinant roles in recognition and processing by the 
cyclodehydratase.26 The plantazolicin biosynthetic enzymes are somewhat atypical in their stringency for 
particular positions of the core peptide, which translates to aborted processing when a cyclizable residue is 
missing. Instead, more tolerant azol(in)e synthetases would likely be more suitable for library generation 
or targeted modification of custom precursor peptides.27 
 
1.4 Lanthipeptides 
 Lanthipeptides are distinguished from other RiPPs by their namesake lanthionine residues, which 
are thioether crosslinks between a donor Cys and Cα of a recipient residue (Figure 1.2).28,29 Characterized 
lanthipeptides with antibiotic activity (lantibiotics) kill Gram-positive bacteria by three possible 
mechanisms: sequestration of lipid II, pore formation, and binding of phosphatidylethanolamine. Some 
lantibiotics employ more than one of these mechanisms resulting in synergistic killing and correspondingly 
low rates of resistance. This is exemplified in nisin, which sequesters lipid II and induces pore formation. 
Despite wide usage as a food preservative for over 40 years, appreciable resistance to nisin has not been 
reported (Figure 1.2).28,29  
Lanthipeptides are biosynthesized over two steps. First, a lanthipeptide dehydratase will convert 
certain Ser and Thr residues to dehydroalanine and dehydrobutyrine (Dha/Dhb), respectively. This is 
accomplished by activating Ser/Thr for dehydration by either a tRNA-dependent glutamylation or ATP-
dependent phosphorylation. The activated esters then undergo elimination to yield the Dha/Dhb residues. 
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The second step of lanthionine formation involves a cyclase that carries a 1,4-nucleophilic addition of a 
Cys thiols onto specific Dha/Dhb residues to form28,30 This process generates the lanthionine or 
methyllanthionine, respectively.29  
 Lanthipeptide dehydratases rank among the most substrate tolerant RiPP enzymes characterized to 
date. This feature is exemplified by the prochlorosins, which have on the order of 30 precursor peptides 
with hypervariable core regions, each giving rise to a distinct product. Additional, uncharacterized 
lanthipeptide biosynthetic gene clusters have as many as 80 predicted precursors.31-34 The promiscuity of 
lanthipeptide dehydratases has been harnessed in numerous ways by synthetic biologists. One example 
involves fusing the core regions of lanthipeptide precursors from cryptic gene clusters to the nisin leader 
peptide to produce novel lantibiotics.35 
Lanthipeptides libraries have been produced to diversify a naturally occurring scaffold with the aim 
of identifying a novel lanthipeptide with a desired activity. One such study design included the heterologous 
expression of ProcM (from procholorosin biosynthesis) in E. coli along with a library of ProcA precursor 
peptide variants. This effort yielded a library of 106 distinct lanthipeptides. Detected among these variants 
was a new protein-protein interaction inhibitor for the HIV p6 protein and the human tumor susceptibility 
gene 101, a lynchpin interaction for viral budding.36 Phage display has also been employed to rapidly 
generate lanthipeptide analogs which can be screened for desired activity. Two independent studies have 
demonstrated that upon fusion of a lanthipeptide precursor library to the M13 phage coat protein pIII, along 
with co-expression of a substrate-tolerant lanthipeptide synthetase, new lanthipeptide activities can be 
identified.37,38 This  led to the discovery of  new ligands for urokinase plasminogen activator and 
streptavidin.37 In addition to phage display, yeast display has been used in a similar manner to diversify 
lacticin 481, resulting in a αvβ3 integrin-binding variant.38 While phage and yeast display methods have 
not yet been employed to generate lanthipeptides with new antibiotic modes of action, we anticipate that 
future efforts will be aimed squarely on this objective.  
 
1.5 Thiopeptides 
 Thiopeptides are macrocyclic RiPPs that feature azol(in)e heterocycles, Dha/Dhb residues, and a 
class-defining six-membered N-heterocycle.39 Many thiopeptides also feature either a quinaldic- or indolic 
acid-containing secondary macrocycle, C-terminal amidation, methylation, oxidation, and glycosylation 
(Figure 1.2).39 The unique confluence of functional groups found in other RiPPs grants the thiopeptides a 
special designation of being a natural “hybrid” RiPP. 
 Thiopeptides primarily exert antibiotic activity by inhibiting protein synthesis with few exceptions: 
the cyclothiazomycins are reported to inhibit RNA polymerase while lactazole purportedly lacks antibiotic 
activity.40,41 Of the majority that interrupt protein synthesis, the size of the primary macrocycle correlates 
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with the physical target of the thiopeptide. Those with 29-membered macrocycles target elongation factor 
Tu while those with 26- and 32-membered macrocycles bind to the protein L11 and 23S rRNA interface 
within the 50S ribosomal subunit.39 Thiopeptides typically display nanomolar activity against pathogenic 
Firmicutes, such as Staphylococcus aureus, Enterococcus faecalis, and Clostridium difficile. Semi-
synthetic derivatization has been successful in fine-tuning thiopeptide spectrum of activity. For example, a 
derivative of GE2270A has been reported to be highly selective towards Propionibacterium acnes.42 
Despite their potent activity, thiopeptides suffer from poor aqueous solubility which has hampered their 
clinical development. Separate semi-synthetic efforts have converted GE2270A into a significantly more 
soluble derivative, LFF571, with efficacy comparable to vancomycin in treating C. difficile infections.43 
Despite these successes, very little is known regarding the structure-activity relationships within the 
thiopeptide class. Therefore, intense efforts have been undertaken to understand their biosynthesis and to 
leverage this knowledge towards analog generation. 
The first step of thiopeptide biosynthesis is identical to the linear azol(in)e-containing peptide class. 
For thiopeptide substrates, the cyclodehydratase primarily acts upon Cys residues but to a lesser extent, 
Ser/Thr residues are found in the form of (methyl)oxazoline heterocycles. Azolines are typically 
dehydrogenated to the corresponding azole although thiazolines are observed in mature thiopeptides.14,27,44 
Secondly, the azole-bearing intermediate is acted upon by a tRNA-dependent lanthipeptide-like 
dehydratase which installs Dha/Dhb from Ser/Thr via a glutamylation and elimination reaction sequence. 
At this point, two Dha residues, one presumably present as the iminol tautomer, undergo a formal [4+2] 
cycloaddition to generate the six-membered nitrogenous heterocycle. In the case of pyridine synthases, the 
leader peptide is ejected as a C-terminal carboxamide while in dehydropiperidine synthases, the leader 
region is proteolytically removed during a later maturation step.27,44 While these core biosynthetic steps are 
common to all thiopeptides, additional tailoring distinguishes the thiopeptides into a diverse set of 
subclasses.45 
 The biosynthetic promiscuity of thiopeptides has primarily been investigated through in vivo 
expression of reprogrammed precursor peptides with thiocillin and thiostrepton being the most studied.46-49 
Thiopeptide precursor variants tolerated by the full array of maturation enzymes are observable in culture 
extracts by mass spectrometry. To summarize a multitude of efforts in this area, thiopeptide biosynthetic 
pathways display varying permissiveness on a per-residue basis with only pyridine/dehydropiperidine-
incorporated Ser being universally indispensable for successful analog production. Thiopeptide precursor 
peptides with substitutions, insertions, or deleted amino acids have produced variants with altered 
peripheral properties and macrocycle size to investigate structure-activity relationships.47-50 For example, 
Ala-substituted and contracted/expanded variants of thiocillin have revealed that certain residues of the core 
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are crucial for bioactivity while others are readily substituted. Further, it has been noted that the rigidity 
imparted by azole heterocycles is crucial for adopting an active conformation.48,49  
 In vitro reconstitution has enabled a more intimate study of each transformation during thiopeptide 
biosynthesis while overcoming the greater biosynthetic stringency encountered in vivo.27,44,45,51,52 Most 
notably, the thiomuracin thiazole synthetase appears to only require an ~8 residue recognition sequence to 
facilitate heterocyclization of virtually any core Cys residue.27 Additionally, it has been demonstrated that 
the thiocillin and thiomuracin [4+2] cycloaddition enzymes are remarkably permissive toward variable core 
sequences and only require the two Dha residues involved in cycloaddition and a small portion of the leader 
peptide.27,51,53 Owing to their promiscuity, thiopeptide biosynthetic enzymes harbor the potential to generate 
analogs with enhanced properties or unnatural functional groups for the de novo generation of new RiPPs. 
 
1.6 Sactipeptides 
 The hallmark modification of a sactipeptide is a sactionine modification, whose name derives from 
a thioether that is sulfur-to-alpha carbon linked (Figure 1.2). Only five sactipeptides have been 
characterized of which all demonstrate a narrow spectrum of activity towards various human pathogens 
such as C. difficile, Listeria monocytogenes, and B. cereus.54-58 While there have been limited studies 
regarding the mode of action of sactipeptides, thuricin CD and subtilosin A disrupt the cell membrane.54 
Sporulation killing factor, a sactipeptide produced by B. subtilis, induces lysis in neighboring B. subtilis as 
a scavenging strategy under starvation conditions.59   
Sactionines are installed by a radical S-adenosylmethionine enzyme which mediates hydrogen atom 
abstraction from an acceptor residue which is then covalently linked to the sulfur of a Cys donor.55 
Sactionine linkages in known sactipeptides are exclusively formed between the most N-terminal Cys and 
the most C-terminal acceptor and radiate inward, resulting in rigid hairpin-like structures (Figure 1.2).55 
While there is limited data regarding the biosynthetic promiscuity of these enzymes, the subtilosin synthase 
exhibits relaxed specificity in both the position of installed sactionines as well as the identity of acceptor 
residues when heterologously expressed in E. coli.60 These results suggest that sactionine synthases may be 
sufficiently substrate tolerant to enable sactionine formation in unnatural contexts to facilitate broader scale 
production of custom sactipeptides, although further enzyme characterization is required to identify the 
limits of substrate tolerance.  
 
1.7 New-to-Nature Hybrid RiPPs 
 One motivation for studying RiPP biosynthesis is that such knowledge could be leveraged for 
specific applications in synthetic biology. The past decade has greatly enhanced our knowledge of substrate 
recognition and tolerance in various RiPP classes (Figure 1.3) and it has become apparent that many RiPP 
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enzymes require only a nominal recognition sequence (4-10 residues) and sufficient length between this 
sequence and the core region to facilitate recruitment and catalysis.27,61,62 This concept has been harnessed 
to generate new-to-nature “hybrid RiPPs” that employ enzymes from disparate RiPP classes to introduce 
sets of modifications that are not known to naturally coexist. By rationally designing precursor peptides, 
bearing in mind recognition sequences, substrate tolerances, and enzyme kinetics, this approach generated 
hybrid RiPPs decorated with thiazolines with (methyl)lanthionines, sactionines, and D-amino acids (Figure 
1.4).61 To further elaborate this approach will require extensive characterization of RiPP biosynthetic 
enzymes that is not necessarily known for all classes. Considerations such as substrate recognition, 
specificity, and tolerance must all be taken into account not only the context of a particular modification, 
but also how each successive modification impacts the competence for intended subsequent modifications. 
Layers of complexity are also added when choosing a means of production: in vivo systems offer a high 
throughput means of production but also require suitable hosts and means of screening produced molecules 
for desirable activity while in vitro systems are more difficult to employ in library-based approaches and 
require purified, stabled enzymes. In theory, if every idiosyncrasy of a biosynthetic enzyme is known, then 
such an enzyme becomes as useful as a general synthetic reagent. To realize this vision, however, will 
require the continued investigation and characterization of RiPP biosynthetic enzymes.  
 
1.8 Summary and Outlook 
 RiPP natural products are structurally diverse molecules often displaying potent antimicrobial 
properties. If properly developed, RiPPs could contribute new scaffolds to drug discovery programs with 
the future potential of offsetting the rise of clinically problematic antibiotic-resistant infections. Unlike 
other biosynthetic paradigms (e.g., NRPS and PKS), RiPP biosynthetic enzymes typically display high 
levels of substrate tolerance. This biosynthetic promiscuity is attributed to a short recognition sequence 
being localized in a leader region of the precursor peptide which is later removed during maturation. This 
specific-yet-tolerant substrate processing ability endows RiPPs with unprecedented engineering potential. 
The community of RiPP researchers is just beginning to produce novel molecules with desired properties. 
We envision a future where preexisting knowledge of substrate recognition and tolerance are brought to 
bear on the custom design and diversification of RiPPs. Such efforts could be guided by a desire to rationally 
design a particular RiPP scaffold or to bind a specific target, perhaps one that is critical for a pathogenic 
bacterium. Encouraged by the past several years of successful RiPP research, we remain confident this class 
of natural products will continue to provide useful molecules and enzymes that serve the greater scientific 
community.   
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1.10 Figures 
 
Figure 1.1 A generalized RiPP biosynthetic gene cluster complete with a precursor peptide, 
modifying enzymes, and proteolysis/export enzymes. RiPP precursor peptides feature leader and 
core regions that separate substrate recognition residues from residues that undergo modification.  
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Figure 1.2 Representative members of several RiPP classes. RiPPs display an array of structural 
diversity and antimicrobial activity. Sites of post-translational modifications are indicated in red. 
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Figure 1.3 Post-translational modifications (PTMs), mode of substrate recognition, and substrate 
tolerance of various RiPP enzymes covered in this review. RiPP biosynthetic enzymes display a 
spectrum of substrate tolerances. The most promiscuous enzymes are ideally suited to be 
repurposed for synthetic biology endeavors. Az = azole. 
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Figure 1.4 New-to-nature hybrid RiPPs generated through RiPP engineering. By leveraging 
knowledge of substrate recognition from various RiPP classes, chimeric precursor peptides have 
been designed to recruit biosynthetic enzymes not naturally found in the same context. The 
resulting hybrid RiPPs have functional groups not currently found together in any natural product 
such as thiazolines/lanthionines, thiazolines/sactionines, and thiazolines/lanthionines/D-Ala; the 
latter is generated by enzymatic reduction of Dha.  
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Chapter 2: In Vitro Biosynthesis of the Core Scaffold of the Thiopeptide Thiomuracin2
 
2.1 Introduction 
The genome sequencing programs of the past decade have revealed that ribosomally synthesized 
and post-translationally modified peptides (RiPPs) form a large class of natural products that are produced 
in all domains of life.1 These compounds are made from a linear precursor peptide that is composed of a 
leader peptide (LP), which is removed in the late stages of maturation, and a core peptide that is converted 
into the RiPP. The leader peptide carries important recognition elements for key biosynthetic enzymes, 
which in turn allows these enzymes a high degree of tolerance with respect to sequence variation in the core 
peptide.2 As a result, these pathways are highly evolvable.3 Recent studies have illustrated that leader 
peptide recognition in very diverse classes of RiPPs is achieved in a common manner, relying on 
structurally conserved domains that are present in otherwise highly divergent biosynthetic enzymes.4-6 This 
finding offers the tantalizing opportunity to engineer hybrid RiPPs, not only within RiPP classes,7-9 but also 
between different RiPP classes. Indeed, Nature already uses this hybrid strategy in the biosynthesis of the 
thiopeptides. These compounds are made by utilizing Ser/Thr dehydratases that produce dehydro amino 
acids alongside cyclodehydratases that convert Ser, Thr and Cys residues to the corresponding azolines.10-
13 The presence of both types of post-translational modifications facilitated the evolution of new chemistry, 
including a formal [4+2] cycloaddition that forms the six-membered, nitrogen-containing heterocycles, 
which are characteristic of thiopeptides.14 This report presents the in vitro reconstitution of the activities of 
six proteins that together biosynthesize the core structure of thiomuracin via 22 chemical transformations 
(Figure 2.1), which provides insights into the order of and requirements for catalysis. The thiopeptide 
antibiotics block bacterial protein translation by interacting with either the 50S ribosomal subunit or 
elongation factor Tu.14 Thiopeptides exhibit potent activity towards multi-drug resistant pathogenic 
bacteria. Unfortunately, poor physicochemical properties have plagued this otherwise-promising class of 
antibiotics; thus far, only two agents are in commercial use, with both restricted to animal usage 
(thiostrepton for skin infections; nosiheptide for growth promotion).15 Impressive efforts in the semi-
synthetic derivatization of GE2270A led to LFF571,16 which recently completed a phase II trial for 
moderate Clostridium difficile infections.17,18 This trial underscores the opportunities for improving the 
pharmacological properties of thiopeptides. 
Recent advances in our mechanistic understanding of RiPP cyclodehydratases19-22 and 
dehydratases4,23 prompted us to attempt the in vitro biosynthetic reconstitution of a thiopeptide. This class 
                                                     
2 This chapter has been reproduced with permission from Hudson, G.A.; Zhang, Z.; Tietz, J.I.; Mitchell, D.A.; van der Donk, W.A. 
In vitro biosynthesis of the core scaffold of the thiopeptide thiomuracin. J. Am. Chem. Soc. 2015, 137, 16012-16015. Copyright 
2015 American Chemical Society. G.A.H and Z.Z designed and performed experiments. J.I.T collected and analyzed spectroscopic 
data. All authors wrote and edited the manuscript. G.A.H and Z.Z are co-first authors.  
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of natural products leverages both RiPP biosynthetic platforms in addition to a formal [4+2] cycloaddition 
enzyme that converts two dehydroalanine (Dha) moieties to the class-defining central pyridine [or 
(dehydro)piperidine].24,25 The thiopeptide family comprises >100 members, with many compounds adorned 
with a second macrocycle (e.g. thiostrepton).14 To begin this effort, we restricted our thiopeptide in vitro 
reconstitution targets to mono-macrocyclic compounds whose gene clusters and bioactivities were firmly 
established. Our top candidates thus became GE2270A and thiomuracin (Figure 2.1).12 Although mono-
macrocyclic thiopeptides are more “minimalistic”, they harbor formidable chemical complexity and 
biological activity. Planobispora rosea ATCC53733 and Nonomuraea sp. Bp3714-39 are the canonical 
producers of GE2270A and thiomuracin, respectively.12 We did not have access to a thiomuracin-producing 
strain of Nonomuraea, but genome-mining efforts predicted that Thermobispora bispora DSM 43833 
would produce an identical molecule owing to the presence of a nearly identical biosynthetic gene cluster 
(Figure 2.1B). Derived from a thermophilic organism, the T. bispora proteins might be expected to have 
the desired stability for efficient heterologous expression in E. coli. 
 
2.2 Results and Discussion 
All genes encoding the biosynthetic proteins from T. bispora (tbt) were codon optimized for E. coli 
expression (Table 2.2). Based on previous reports, genes for F-protein dependent cyclodehydratase (tbtF, 
tbtG), thiazoline dehydrogenase (tbtE), and the [4+2] cycloaddition enzyme (tbtD) were subcloned into a 
previously-described plasmid that fuses maltose-binding protein (MBP) to the N-terminus of the protein of 
interest.22 In contrast, genes encoding the precursor peptide (tbtA) and the split LanB-type dehydratase4 
(tbtB, tbtC) were expressed as N-terminally His6-tagged proteins. The purity of all proteins used in the study 
was assessed visually by Coomassie-stained SDS-PAGE analysis (Figure 2.5). 
The precursor peptide TbtA was initially expressed and purified as an N-terminally His6-tagged fusion 
protein (1) (Figure 2.2). Reaction of TbtA with purified TbtB/C under conditions previously reported for 
the NisB dehydratase4,23 did not result in any chemical transformation (Figure 2.6). In contrast, reaction of 
1 with the cyclodehydratase TbtG, the dehydrogenase TbtE and TbtF, an ortholog of HcaF that was recently 
shown to function as an auxiliary leader peptide binding protein,22 resulted in a mass shift of -120 Da 
(Figure 2.2B). This observation is consistent with successful cyclodehydration and dehydrogenation of the 
six cysteines in the core peptide to the corresponding thiazoles. When TbtE was omitted, a mass consistent 
with six thiazoline modifications was observed by matrix-assisted laser desorption/ionization time-of-flight 
mass spectrometry (MALDI-TOF-MS, Figure 2.7). Further, when TbtF or ATP were omitted from the 
reaction, no product formation was detected. 
TbtB is an ortholog of the glutamylation domain of the NisB dehydratase that uses glutamyl-tRNA 
to glutamylate Ser residues.4 TbtC is a member of the SpaB_C family of proteins (PF14028) and has 
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sequence homology to the second domain of NisB that eliminates the glutamate from the glutamylated Ser 
to install Dha. Reaction of the purified hexazole-containing intermediate 2 with TbtB in the presence of 
Glu, ATP, E. coli tRNAGlu and E. coli glutamate tRNA transferase (GluRS) did not result in any change in 
mass (Figure 2.8). We reasoned that sequence differences between E. coli and T. bispora tRNAGlu might 
contribute to the lack of activity. Hence, the two tRNAGlu isoacceptors encoded in the T. bispora genome 
were prepared by in vitro transcription. Reaction of 2 with Glu, ATP, T. bispora tRNAGlu(CUC) and E. coli 
GluRS resulted in glutamylation of 2 (Figure 2.2C). When TbtC was added to an otherwise identical 
reaction, four-fold dehydration of 2 was observed (Figure 2.2D). Use of T. bispora tRNAGlu(UUC) resulted 
only in partial dehydration (Figure 2.9); this result may either indicate that TbtB preferentially uses T. 
bispora tRNAGlu(CUC) or that E. coli GluRS is less efficient in charging T. bispora tRNAGlu(UUC). Using 
the same conditions with 1 did not result in an observable reaction (Figure 2.6), demonstrating for the first 
time that dehydration activity requires prior cyclodehydration. Further, all assay components were required 
for activity (Figure 2.9). These experiments establish the first activity of a split LanB and extend the use of 
Glu-tRNAGlu to dehydration during thiopeptide biosynthesis. 
Treatment of the hexazole-containing, tetradehydrated His6-TbtA (3) with TbtD resulted in the 
consumption of 3 and appearance of two new masses consistent with the excised leader peptide and the 
desired macrocycle (Figure 2.2E & 2.10). The identity of the leader peptide was confirmed by high-
resolution, tandem electrospray ionization MS (HR-ESI-MS/MS, Figure 2.3). The data indicated that the 
leader peptide terminates in a carboxamide rather than a carboxylic acid, providing the first evidence that 
the cycloaddition enzyme uses elimination chemistry, rather than hydrolysis, to release the leader peptide. 
The generation of the macrocyclic core scaffold of thiocillin by the TbtD-ortholog TclM using a semi-
synthetic substrate was also recently reported.26 Interestingly, like TbtC, TbtD (and TclM) is a member of 
the SpaB_C protein family, suggesting that elimination reactions may be common in PF14028.4 Removal 
of the N-terminal 31 (of 34) amino acids of the leader peptide from 2 by treatment with endoproteinase 
GluC resulted in a peptide that was no longer a substrate for TbtD (Figure 2.10). In NisB, where the 
glutamylation enzyme is covalently linked to the SpaB_C elimination domain, leader peptide binding 
occurs in the glutamylation domain.4,6 To probe whether TbtB, which contains this binding domain, would 
accelerate catalysis by TbtD, TbtB was added to the cycloaddition reaction. Analysis of macrocycle 
formation suggested that TbtB afforded no rate enhancement (Figure 2.11). The same was observed upon 
addition of TbtF, which also contains a leader peptide-binding domain.22 Thus it appears that TbtD 
independently engages the leader peptide by an unknown strategy. 
To obtain the quantities of 4 required for structure confirmation, the entire in vitro process was 
optimized and scaled up using MBP-TbtA as starting material (see Supporting Information). The purity of 
4 was assessed by HPLC and ESI-MS (Figure 2.12), the molecular formula of 4 was deduced by HR-ESI-
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MS (Figure 2.13), and its structure was confirmed by NMR spectroscopy (Figures 2.14-2.21 and Table 2.4). 
The overall chemical shift values were highly consistent with those of the closely-related thiomuracin series 
reported by Morris et al.12 Correlations obtained via 1H-1H TOCSY, 1H-1H COSY, 1H-1H NOESY, 1H-13C 
HSQC, and 1H-13C HMBC experiments (Figure 2.4) allowed assignment of all 1H and 13C resonances in 
the molecule, with the exception of the carboxylic acid proton, which was not observed. All 13C resonances 
were indirectly detected through the HSQC and HMBC experiments. A combination of NOESY and HMBC 
correlations allowed positional assignment of each of six thiazole and two Dha moieties. Importantly, the 
presence of the pyridine moiety resulting from the formal [4+2] cycloaddition was evidenced by a pair of 
characteristic doublets at 8.38 and 8.51 ppm and the accompanying HSQC and HMBC correlations; the 
thiazole protons were likewise observed as sharp singlets at 7.55, 8.13, 8.17, 8.27, 8.55, and 8.67 ppm. Due 
to the high similarity of chemical shifts and coupling constants of 4 to thiomuracin D, as well as the 
biosynthetic logic of the enzymes employed, all amino acids were assigned L-stereochemistry.  
To assess the bioactivity of 4, we determined the minimal inhibitory concentration (MIC) towards 
a panel of Gram-positive, Gram-negative, and fungal species by microbroth dilution (Table 2.1). While 4 
was inactive against the tested Gram-negative bacteria and fungi, growth inhibition was found against all 
Gram-positive bacteria in the panel. The most potent activity was toward vancomycin-resistant strain 
Enterococcus faecium U503 (VRE), followed by methicillin-resistant Staphylococcus aureus USA300 
(MRSA). These drug-resistant bacteria are increasingly problematic human pathogens. Despite lacking 
other posttranslational modifications including C-methylation of thiazole, beta-hydroxylation of Phe, and 
oxidation/cyclization of Ile, the bioactivity reported here in on par with fully modified thiomuracin A, which 
has MICs of 0.25 μg/mL and 0.5 μg/mL against VRE and MRSA, respectively.12,27 We term the structure 
of 4 thiomuracin GZ. 
GE2270A has a similar macrocyclic structure to thiomuracin (Figure 2.22), differing in three of the 
four amino acids that are present in the macrocycle.12 We therefore wondered whether the TbtD ortholog 
in the GE2270A biosynthetic gene cluster (PbtD) would also be able to catalyze the non-cognate [4+2] 
cycloaddition of 3. Reaction of PbtD with 3 indeed resulted in the clean formation of 4 with concomitant 
elimination of the leader peptide (Figure 2.22). This observation is promising with respect to thiopeptide 
engineering for structure-activity relationship efforts, since it illustrates that the [4+2] enzyme is tolerant of 
substantial changes in the amino acid sequence of the macrocycle (Phe, Tyr, Ile in thiomuracin are Val, 
Gly, Phe in GE2270A, respectively). 
To investigate the importance of conserved residues within the [4+2] cycloaddition clade of the 
SpaB_C superfamily, a multiple sequence alignment was generated, and twenty-three residues were 
replaced with alanine (Figure 2.23). The activity of these mutant enzymes was qualitatively assessed by an 
endpoint MALDI-TOF-MS assay under two reaction conditions. In the first, a high concentration of 
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substrate (100 μM) and enzyme (5 μM) were used in order to probe for any residual enzymatic activity. 
Only two mutant proteins (R332A and Y319A) were diminished in activity under these conditions (Table 
2.5). Lowering the reactant concentrations to 15 μM substrate and 1 μM enzyme implicated an additional 
set of residues (W47, E105, H191, H290, and S287) as possibly involved in substrate binding or catalysis. 
In summary, this work presents the first in vitro biosynthesis of a thiopeptide core scaffold. We establish 
the functions of the split LanB proteins, demonstrate that the use of Glu-tRNAGlu is not confined to 
lanthipeptide biosynthesis, and show that thiomuracin GZ harbors potent antibacterial activity, despite the 
lack of ancillary tailoring. A compelling application of the data and methods presented herein would be to 
generate unnatural thiopeptide analogues for improvement of pharmacological properties. 
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2.4 Methods 
2.4.1 General materials and methods  
Reagents used for molecular biology experiments were purchased from New England BioLabs 
(Ipswich, MA), Thermo Fisher Scientific (Waltham, MA), or Gold Biotechnology Inc. (St. Louis, MO). 
Other chemicals were purchased from Sigma-Aldrich (St. Louis, MO). Escherichia coli DH5α and BL21 
(DE3) strains were used for plasmid maintenance and protein overexpression, respectively. Thermobispora 
bispora DSM 43833 was obtained from DSMZ (Braunschweig, Germany). Planobispora rosea 
ATCC53733 was obtained from the USDA Agricultural Research Service (ARS) Culture Collection. 
Plasmid inserts were sequenced at ACGT Inc. (Wheeling, IL). MALDI-TOF-MS analysis was performed 
using a Bruker UltrafleXtreme MALDI TOF-TOF mass spectrometer (Bruker Daltonics) in reflector 
positive mode at the University of Illinois School of Chemical Sciences Mass Spectrometry Laboratory. 
ESI-MS/MS analyses were performed using a SYNAPT ESI quadrupole TOF Mass Spectrometry System 
(Waters) equipped with an ACQUITY Ultra Performance Liquid Chromatography (UPLC) system 
(Waters). Kinetic assays were performed using a Varian Cary 4000 UV-Vis spectrophotometer. HiTrap 
columns for Ni-NTA affinity chromatography were purchased from GE Healthcare.  
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2.4.2 Molecular biology techniques  
Oligonucleotides were purchased from Integrated DNA Technologies Inc. (Coralville, IA). Primers 
for E. coli tRNAGlu were designed and the dsDNA template for in vitro transcription was prepared as 
previously described.28 Thermobispora bispora was identified as a potential producer of a thiomuracin-like 
thiopeptide using BLAST to identify homologs of genes from the relevant biosynthetic gene cluster of 
thiomuracin producer Nonomurea sp. Bp3714-39.12 Genes optimized for recombinant expression in 
Escherichia coli were synthesized by GenScript (Piscataway, NJ) in pUC57 (kanamycin, Kan) vectors with 
BamHI and XhoI sites flanking each gene at the 5′ and 3′ ends, respectively. The GenBank locus tag and 
E. coli optimized sequence for each gene is provided in Table 2.2. E. coli DH5α were transformed with 
pUC57-Kan vectors containing each gene for replication and subsequent isolation using a QIAprep Spin 
Miniprep Kit (Qiagen). The isolated DNA was then treated with BamHI-HF and XhoI-HF (New England 
Biolabs). The digested genes were separated on a 1% (w/v) agarose gel, purified using a QIAQuick gel 
extraction kit (Qiagen), and ligated into an appropriately endonuclease-digested and gel-purified pET28 
vectors using T4 DNA ligase (NEB). Ligation reactions were used to transform chemically competent 
DH5α cells, which were plated on Luria-Bertani (LB) agar plates containing 50 μg/mL kanamycin and 
grown at 37 °C. Colonies were picked at random and grown in LB broth for 16–20 h prior to plasmid 
isolation using a QIAprep Spin Miniprep Kit. For TbtA and TbtD, the vector encoded a tobacco etch virus 
(TEV) cleavable, N-terminal maltose binding protein (MBP) affinity tag, while TbtE, TbtF, and TbtG 
constructs did not encode a TEV proteolysis site. All recombinant constructs featuring an MBP-tag were 
sequenced using a custom MBP forward primer, whereas constructs encoding His6-tagged proteins were 
sequenced using the T7 forward primer. All constructs were sequenced using a T7 reverse primer as well 
as an internal primer if necessary (Table 2.2). 
 
The gene encoding PbtD (TbtD ortholog) from Planobispora rosea ATCC 23866 was amplified 
from genomic DNA using the primers listed in Table 2.2. The resulting DNA was purified using a QIAprep 
Spin Miniprep Kit. The purified DNA was then digested using BamHI-HF and XhoI-HF before being 
ligated into an appropriately digested pET28 vector encoding an N-terminal MBP tag featuring a TEV 
proteolysis site. The resulting construct was then used to transform E. coli, propagated, and sequenced as 
described above.  
 
Site-directed mutagenesis on TbtD was performed using the QuikChange method (Agilent) as per 
the manufacturer’s instructions using PfuTurbo DNA polymerase. The primers for each mutant are listed 
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in Table 2.2. The mutations were verified by sequencing using the MBP forward primer or the T7 reverse 
primer. 
 
The tbtA gene was cloned into pRSFDuet-1 with an N-terminal His6-tag following standard cloning 
procedures. In addition, the GlySerSer residues preceding the His6 tag were mutated to a single Pro to 
suppress gluconoylation.29 The PCR product was purified by gel extraction on a 1% (w/v) agarose gel using 
the QIAquick Gel Extraction Kit (Qiagen). The vector pRSFDuet-1 was digested using BamHI-HF and 
HindIII-HF (NEB) restriction endonucleases and purified by gel extraction as described above. Insertion of 
the DNA fragment was achieved by Gibson one-step isothermal DNA assembly as previously described.30 
An aliquot (20 μL) of the Gibson assembly reaction was used to transform E. coli DH5𝛼 cells using the 
heat shock method. The cells were plated on LB plates supplemented with kanamycin (50 μg/mL) and 
single colonies were grown at 37 °C for 12–15 h. The plasmid His6-TbtA-pRSFDuet-1 was isolated using a 
QIA Spin Miniprep Kit. Insert integrity was verified by sequencing the plasmids with the appropriate 
primers (Table 2.2). 
 
The gene coding for the dehydratase TbtB was cloned into pET28a encoding an N-terminal His6-
tag. The tbtB gene was amplified by PCR, and purified by gel extraction from a 1% (w/v) agarose gel using 
the QIAquick Gel Extraction Kit. The vector pET28a and the tbtB PCR fragment were digested using 
BamHI-HF and XhoI-HF (NEB) restriction endonucleases, and purified by gel extraction as described 
above. The DNA fragment was inserted by Gibson one-step isothermal DNA assembly, and an aliquot of 
20 μL of the Gibson assembly reaction was used to transform E. coli DH5α cells using the heat shock 
method. The cells were plated on LB plates supplemented with kanamycin (50 µg/mL) and the plates were 
incubated at 37 °C for 12–15 h. Single colonies were picked and grown in LB supplemented with 
kanamycin (50 µg/mL) at 37 °C for 12–15 h and the plasmid His6-TbtB-pET28a was isolated using a QIA 
prep Spin Miniprep Kit. Insert integrity was verified by sequencing the plasmids with the appropriate 
primers (Table 2.2). All the other genes and their corresponding His6-tagged proteins were cloned using the 
same procedures.  
 
2.4.3 MBP-tagged peptide and enzyme overexpression and purification 
E. coli BL21(DE3) cells were transformed with a pET28 plasmid encoding the MBP-tagged 
enzyme or peptide of interest. Cells were grown for 24 h on LB agar plates containing 50 μg/mL kanamycin 
at 37 °C. Single colonies were used to inoculate 10 mL of LB containing 50 μg/mL kanamycin and grown 
at 37 °C for 16–18 h. This culture was used to inoculate 1 L of Terrific Broth (24 g/L yeast extract, 12 g/L 
tryptone, 0.4% glycerol (v/v), 17 mM KH2PO4, and 72 mM K2HPO4) and grown to an optical density at 
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600 nm (OD600) of 1.0 before being placed on ice for 15 min. Protein expression was then induced with the 
addition of 0.4 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for biosynthetic enzymes or 1 mM IPTG 
for the TbtA precursor peptide. Expression was allowed to proceed for 16-18 h at 22 °C. For expression of 
MBP-TbtE and MBP-TbtG, 70 μM riboflavin or 100 μM ZnCl2, respectively, were added at the time of 
induction. Cells were harvested by centrifugation at 3,000 × g for 20 min, washed with phosphate-buffered 
saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and 1.8 mM KH2PO4), and centrifuged again. 
The cell pellet was flash-frozen and stored at -80 °C for a maximum of one week before use. 
 
Cell pellets were resuspended in lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 2.5% 
glycerol (v/v), and 0.1% Triton X-100) containing 4 mg/mL lysozyme, 2 μM leupeptin, 2 μM benzamidine, 
and 2 μM E64. After 30 min at 4 °C, cells were further homogenized by sonication (3 × 45 s with 10 min 
nutation periods at 4 °C). Insoluble debris was removed by centrifugation at 20,000 × g for 90 min. The 
supernatant was then applied to a pre-equilibrated amylose resin (NEB; 20 mL of resin per L of cells). The 
column was washed with 10 column volumes (CV) of lysis buffer followed by 10 CV of wash buffer (lysis 
buffer with 400 mM NaCl and lacking Triton X-100). The MBP-tagged proteins were eluted using elution 
buffer (lysis buffer with 300 mM NaCl, 10 mM maltose, and also lacking Triton X-100) until the eluent no 
longer contained protein detectable with the Bradford reagent (assayed using 2 μL of eluent and 198 μL of 
Bradford solution at rt). Eluent was concentrated using an appropriate MWCO Amicon Ultra centrifugal 
filter (EMD Millipore). A buffer exchange with 10× volume of protein storage buffer (50 mM HEPES pH 
7.5, 300 mM NaCl, 2.5% glycerol (v/v)) was performed prior to final concentration and storage. Protein 
concentrations were assayed using both 280 nm absorbance (theoretical extinction coefficients were 
calculated using the ExPASy ProtParam tool; http://web.expasy.org/protparam/protpar-ref.html) and a 
Bradford colorimetric assay. Purity and possible truncation were assessed by Coomassie-stained SDS-
PAGE gel (Figure 2.5). All wash, elution, and storage buffers were supplemented with 0.5 mM tris-(2-
carboxyethyl)-phosphine (TCEP) except for those used for the preparation of MBP-TbtD (to avoid 
nucleophilic addition of TCEP to the dehydroalanine residues). 
 
2.4.4 Expression, and purification of His6-TbtA (1)  
E. coli BL21 (DE3) cells (50 μL) were electroporated with His6-TbtA-pRSFDuet-1 (50 ng), plated 
on LB agar plates supplemented with kanamycin (as above) and grown at 37 °C for 12–15 h. A single 
colony was used to inoculate 60 mL of LB broth supplemented with kanamycin, grown for 12–15 h at 37 
°C, and the culture was used to inoculate 6 L of LB media, supplemented with kanamycin, to an OD600 of 
0.025. Cultures were grown at 37 °C to an OD600 of 1.0. Peptide expression was induced by the addition of 
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IPTG to a final concentration of 1 mM and cultures were grown at 37 °C for 3 h. Peptide purification was 
performed following a previously described method.31 
 
 
2.4.5 Expression, and purification of His6-TbtB 
E. coli BL21 (DE3) cells (50 μL) were electroporated with His6-TbtB-pET28a (50 ng), and cells 
were plated on LB agar plates supplemented with kanamycin and grown at 37 °C for 12–15 h. A single 
colony was used to inoculate 20 mL of LB broth supplemented with kanamycin, grown for 12–15 h at 37 
°C, and the culture was used to inoculate 2 L of TB media, supplemented with kanamycin, to an OD600 of 
0.025. Cultures were grown at 37 °C to a final OD600 of 0.6–0.8. Protein overexpression was induced by the 
addition of IPTG to a final concentration of 0.2 mM, and cultures were grown at 18 °C for 18 h. Protein 
purification was performed following a similar protocol as described before.23 All other His6-tagged 
proteins were purified using the same procedure.  
 
2.4.6 Cyclodehydration of TbtA precursor peptide 
Thiazole installation was carried out with 50 μM MBP-tagged TbtA and 1.5 μM of MBP-tagged 
biosynthetic enzymes (TbtE, TbtF, and TbtG) in synthetase buffer [50 mM Tris pH 8.0, 125 mM NaCl, 2 
mM TCEP, 20 mM MgCl2, and 6 mM ATP]. The MBP-tag on the precursor peptide was removed using 
250 μM TEV protease, and reactions were allowed to proceed for 3 h at 25 °C; the MBP-tagged biosynthetic 
enzymes did not contain a TEV cleavage site. Aliquots of 50 μL were desalted via C18 ZipTip (EMD 
Millipore) according to the manufacturer’s instructions, and the peptide was eluted using a saturated 
solution of sinapinic acid in 50% aq. MeCN. The reaction was checked for completion by MALDI-TOF 
MS. The depletion of unmodified peptide and the appearance of the hexazole species were indicative of 
reaction completion. 
 
2.4.7 Purification of 2 
The cyclodehydration/dehydrogenation reaction mixtures were applied to Ni-NTA resin (Qiagen) 
equilibrated with 50 mM Tris-HCl pH 8.0, 150 mM NaCl using 1 mL resin per 1 mL of reaction. The flow-
through was collected, and the column was subsequently washed with 5 mL of wash buffer (50 mM Tris-
HCl pH 8.0, 1 M NaCl, 75 mM imidazole) per 1 mL of reaction mixture. The total volume was then applied 
to a Thermo C18 HyperSep cartridge equilibrated first with 10 CV of MeCN followed by 10 CV of 5% aq. 
MeCN containing 0.3% formic acid. The column was washed with 10 CV of 5% aq. MeCN containing 
0.3% formic acid to remove polar contaminants. 2 was eluted from the column using up to 5 CV of 80% 
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aq. MeCN. From a reaction using 26.51 mg TEV-cleaved TbtA, 20.00 mg of crude 2 was isolated (77% 
yield). 
 
2.4.8 In vitro transcription of T. bispora tRNAGlu (CUC)  
Primers for T. bispora tRNAGlu were designed according to a previously described method.28 The 
tRNAGlu dsDNA template was generated from two overlapping synthetic deoxyoligonucleotides. To 
prepare the dsDNA template for in vitro transcription, 5′ overhangs were filled in using the following 
conditions: NEB Buffer 2 (1×), primers (4 μM each), dNTP (100 μM each), DNA polymerase I large 
(Klenow) fragment (1 U μg–1 DNA) in a final volume of 50 μL. The reaction was incubated at 25 °C for 15 
min, quenched with EDTA (10 mM) at 75 °C for 25 min, and dsDNA tRNAGlu template was precipitated 
with cold EtOH overnight. In vitro transcription was performed using a previously described method.32 The 
transcribed tRNAGlu was then purified by acidic phenol extraction using a previously described method.33 
 
2.4.9 In vitro dehydration of 2 
The following reaction conditions were used for dehydration assays: HEPES pH 7.5 (100 mM), 
MgCl2 (5 mM), KCl (150 mM), glutamate (10 mM), ATP (5 mM), TbtA hexazole (50 μM), T. bispora 
tRNAGlu (10 μM), E. coli GluRS (10 μM), TbtB (5 μM), TbtC (5 μM), and thermostable inorganic 
pyrophosphatase (TIPP; 0.02 U μL–1) in a final volume of 25 μL. The reaction mixture was incubated at 30 
°C for 3 h, centrifuged to remove insoluble material (14,000 × g, 5 min, 25 °C), and desalted using C18 
ZipTips (EMD Millipore). The sample was mixed in a 1:1 ratio with 2,5-dihydroxybenzoic acid matrix, 
spotted on a Bruker MALDI plate, and analyzed by MALDI-TOF-MS. 
 
2.4.10 Purification of 3 
The reaction mixtures to produce 3 were lyophilized, and the residue was extracted with a volume 
of 40% aq. MeCN equal to the volume used for the dehydration reaction. The insoluble material was 
removed by centrifugation at 10,000 × g for 10 min, and the supernatant was purified on a Shimadzu 
Prominence Preparative Liquid Chromatography system equipped with a Phenomenex Luna C18 column 
(250 × 10 mm, 10 μm particle size, 100 Å pore size). Acetonitrile and 10 mM aq. NH4HCO3 were used as 
the mobile phases, and a gradient of 2-80% aq. MeCN over 45 min at 1 mL/min was used for separation. 3 
eluted from the column at 45% MeCN.  
 
2.4.11 Purification of TbtA-hexazole-tetradehydrate core 
HPLC-purified TbtA-hexazole-tetradehydrate was dissolved in 50 mM Tris-HCl (pH 7.5) to a final 
concentration of 100 M. GluC endoproteinase was added to a concentration of 0.02 mg/mL, and the 
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reaction mixture was incubated at 37 °C for 1 h, followed by addition of MeCN to 50% (v/v) to precipitate 
proteins. The insoluble material was removed by centrifugation at 16,100 × g for 10 min, and the 
supernatant was purified on an Agilent 1260 Infinity HPLC system with a Phenomenex Luna C18 column 
(250 × 4.6 mm, 10 μm particle size, 100 Å pore size). Acetonitrile and 10 mM NH4HCO3 were used as the 
mobile phases, and a gradient of 2–80% aq. MeCN over 45 min at 1 mL/min was used for separation.  
 
2.4.12 In vitro production of 4  
Purified 2 was dissolved in DMSO to a concentration of 1 mM. The in vitro production of 
macrocycle was performed using: HEPES pH 7.5 (100 mM), MgCl2 (5 mM), KCl (150 mM), ATP (5 mM), 
2 (100 μM), T. bispora tRNAGlu (10 μM), E. coli GluRS (10 μM), TbtB (5 μM), TbtC (5 μM), MBP-TbtD 
(5 μM), and TIPP (0.02 U μL–1). The reaction mixture was allowed to proceed at 30 °C for 4 h.  
 
2.4.13 Purification of 4 (thiomuracin GZ)  
Reaction mixtures containing crude 4 were lyophilized and extracted with an equal volume of 
dimethylformamide (DMF) with respect to the original volume of the reaction by heating to 50 °C with 
occasional agitation for 30 min. The insoluble material was removed by centrifugation at 18,000 × g for 15 
min. The supernatant was removed and evaporated in a Thermo Scientific Savant SpeedVac system. The 
resulting material was resuspended in 80% aq. MeCN prior to 3:1 dilution with H2O. The dissolved material 
was then purified using a Flexar HPLC system (PerkinElmer) equipped with a Betasil C18 column (4.6 × 
250 mm, 5 µm particle size, 100 Å pore size; Thermo Scientific) operating at 1 mL/min. Following a 10 
minute hold at 20% aq. MeCN, separation was achieved with a gradient of 20-90% aq. MeCN over 45 min 
and monitoring at the λmax for thiomuracin GZ of 315 nm. Collected fractions were confirmed to contain 
thiomuracin GZ through MALDI-TOF MS (m/z 1366 Da) analysis as previously described. The appropriate 
fractions were pooled and dried using the SpeedVac evaporator to yield purified thiomuracin GZ. A reaction 
using 20.00 mg 2 yielded 1.33 mg of purified 4, representing a yield of 27% for this step and an overall 
unoptimized yield of 21% for all biosynthetic steps. 
 
2.4.14 NMR spectroscopy  
Samples were prepared by dissolving ca. 1.1 mg of thiomuracin GZ (HPLC-purified and 
lyophilized) in 180 µL of DMSO-d6 (99.96 atom % D; Sigma-Aldrich). NMR spectra were obtained on a 
Bruker 900 MHz AVANCE NMR spectrometer equipped with an inverse 5 mm TCI cryogenic probe with 
z-axis pulsed field gradient (pfg) capability. Samples were held at 298 K during acquisition. Standard 
Bruker pulse sequences were used for each of the following experiments: 1H, 1H-1H COSY, 1H-1H TOCSY 
(60 ms mixing time), 1H-13C HSQC, 1H-13C HMBC (optimized for 6 Hz heteronuclear couplings), and 1H-
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1H NOESY (750 ms mixing time). Spectra were recorded with Bruker TopSpin 1.3 software, and data was 
processed using MestReNova 8.1.1. Chemical shifts (δ, ppm) were referenced internally to the solvent peak 
(DMSO). 
 
2.4.15 Evaluation of thiomuracin GZ antibiotic activity  
Escherichia coli MC4100, Pseudomonas aeuroginosa PA01, Bacillus anthracis strain Sterne, 
Mycobacterium smegmatis B-14616, Enterococcus faecium U503, and Staphylococcus aureus USA300 
were grown in 10 mL of brain-heart infusion (BHI) medium at 37 °C. The cultures were adjusted to an 
OD600 of 0.015 in the designated medium before being added to 96-well microplates. Successive two-fold 
dilutions of thiomuracin GZ in DMSO were added to the cultures (0.03–64 μg/mL). As a positive control, 
kanamycin (1–32 μg/mL) was added to samples of E. coli, B. anthracis, and P. aeruginosa. Gentamicin 
was used a positive control for S. aureus and E. faecium while streptomycin was used for M. smegmatis. 
As a negative control, 1% (v/v) DMSO was added to samples of each strain. Plates were covered and 
incubated at 37 °C for 20 h with shaking at 180 rpm. The minimum inhibitory concentration (MIC) reported 
are the values which suppressed all visible growth (n = 3). 
 
2.4.16 Evaluation of thiomuracin GZ antifungal activity  
Saccharomyces cerevisiae, Talaromyces stipitatus, and Aspergillus niger were grown for 36 h in 6 
mL of YPD medium (10 g/L yeast extract, 20 g/L peptone, and 20 g/L dextrose) at 30 °C. S. cerevisiae 
cultures were diluted to OD600 of 0.015 in YPD medium before being added to 96-well microplates. T. 
stipitatus and A. niger were not diluted prior to distribution on 96-well microplates. Successive two-fold 
dilutions of thiomuracin GZ in DMSO were added to cultures (1–128 μg/mL). As a positive control, 
amphotericin B was added to cultures in dilutions of 0.5–8 μg/mL. As a negative control, 1% DMSO (v/v) 
was added to samples of each fungal species. Plates were covered and incubated at 30 °C for 36 h with 
shaking at 180 rpm. The reported MICs are the values which suppressed all visible growth (n = 3).  
 
2.4.17 UPLC-MS of purified thiomuracin GZ  
Purified thiomuracin GZ was diluted in 20% aq. MeCN to 10 μM, and LC-MS was performed using 
a Waters SYNAPT mass spectrometer outfitted with an ACQUITY UPLC, an ACQUITY Bridged Ethyl 
Hybrid C8 column (2.1 × 50 mm, 1.7 μm particle size, 200 Å Waters), an ESI ion source, and a quadruple 
TOF detector. A gradient of 10–90% aq. MeCN with 0.1% formic acid (v/v) over 15 min was used, and the 
total ion chromatogram (TIC) was recorded (Figure 2.12). 
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2.4.18 HPLC of purified thiomuracin GZ  
50 μg of purified thiomuracin GZ was diluted in 20% aq. MeCN to a final concentration of 37 μM, 
and HPLC was performed using a Flexar HPLC system (PerkinElmer) equipped with a BetaBasic C18 
column (4.6 × 250 mm; 5 µm particle size; 100 Å pore size; Thermo Scientific) operating at 1 mL/min. 
Following a 10 minute hold at 20% aq. MeCN, separation was achieved with a gradient of 20–90% MeCN 
over 45 min; purity was assessed by monitoring both 220 nm and the λmax for thiomuracin GZ of 315 nm 
(Figure 2.12). 
 
2.4.19 UPLC-MS and MS/MS of ejected His6-TbtA leader  
Purified ejected His6-TbtA leader after the macrocylization reaction was dissolved in water, and 
LC-MS/MS was performed using the same procedure as above. A gradient of 2–100% aq. MeCN with 0.1% 
formic acid (v/v) over 20 min was used. A ramping of cone voltage of 16–19 kV during the scan was 
performed to generate peptide fragments for MS/MS analysis.  
 
2.4.20 Kinetic assay to probe if TbtB/TbtF accelerate the macrocyclization reaction 
HPLC-purified TbtA-hexazole-tetradehydrate was dissolved to a concentration of 200 M in 50 
mM Tris-HCl, 150 mM KCl, pH 7.5. Before starting the reaction, enzymes and the substrate were incubated 
at 30 °C for 5 min. MBP-TbtF was pre-treated with thrombin in order to release the MBP tag. The reaction 
was performed with 150 μM of substrate 3 and 5 μM of either protein at 30 °C. Macrocycle formation was 
monitored by absorbance at 315 nm. Time points were collected every 2 s and initial reaction rates were 
calculated.  
 
2.4.21 Bioinformatic identification of TbtD residues for mutagenesis  
The protein sequence for TbtD (gi: 915296818) was used to identify homologs via BLAST 
searching. Homologs with E-values < 5E-50 were aligned by sequence and highly conserved residues were 
chosen as targets for alanine scan mutagenesis.  
 
2.4.22 Enzymatic activity of alanine-substituted TbtD proteins 
The activity of the TbtD mutant proteins were assessed under two different reaction conditions with 
the first using a relatively high concentration of enzyme and substrate and the second using significantly 
lower concentrations. For the “high” concentration reaction conditions, tandem dehydration (TbtB/C) and 
macrocyclization (MBP-TbtD) reactions were set up identically as previously, with the exception that 100 
µM of 2 and 5 µM of TbtD mutant proteins were employed. For the “lower” concentration conditions, 15 
µM of 2 and 1 µM of TbtD mutant proteins were used. Samples were quenched by the addition of four 
32 
volumes of MeCN and evaporation to dryness in a Savant SpeedVac system. Samples were then 
resuspended in a volume of saturated, aqueous guanidine-HCl equal to the original reaction volume, 
desalted using C18 ZipTips and eluted in a saturated solution of sinapinic acid in 50% aq. MeCN. Each 
reaction was repeated three times, and the relative peak heights of starting material (2) and product (4) were 
compared by MALDI-TOF-MS.  
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2.5 Figures 
 
Figure 2.1 (A) Biosynthetic route to the thiomuracin core scaffold 4. (B) Gene clusters for the 
biosynthesis of thiomuracin, GE2270A, and thiocil-lin. Sequence of the His6-tagged LP: 
PHHHHHHSQVD-LNDLPMDVFELADSGVAVESLTAGHGMTEVGA. 
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Figure 2.2 MALDI-TOF MS of (A) His6-TbtA (1); calc. m/z 6173; (B) hexazole 2, calc. m/z, 
6053; (C) glutamylated 2; calc. m/z 6182; (D) tetradehydrated hexazole 3, calc. m/z, 5981; and 
(E) thiomuracin GZ 4, calc. m/z, 1366. For panels C and D, ATP, Mg2+, E. coli GluRS and T. 
bispora tRNAGlu(CUC) were present in the assays. 
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Figure 2.3 ESI-MS/MS of the His6-TbtA leader peptide ([M+4H]4+ = 1149) generated by 
macrocyclization. 
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Figure 2.4 NMR correlations used to assign the structure of 4. For all spectroscopic data, see 
Figures 2.14-2.21 and Table 2.4. 
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Figure 2.5 SDS-PAGE analysis of proteins used in this study. The minor impurity found at ~45 kDa is the 
result of endogenous protease activity on the MBP fusion proteins. Cleavage occurs in the linker region 
between MBP and the protein of interest. Enrichment occurs due to the use of amylose resin for affinity 
purification. 
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PHHHHHHSQVDLNDLPMDVFELADSGVAVESLTAGHGMTEVGA*SCNCFCYICCSCSSA 
 
 
Figure 2.6 TbtB/C do not process unmodified TbtA. The top MALDI-TOF mass spectrum shows 
unmodified TbtA precursor peptide (1). The middle spectrum spectrum shows 1 treated with TbtB/C in the 
presence of other necessary reaction components [E. coli GluRS and E. coli tRNAGlu]. The bottom spectrum 
is an equivalent reaction except with T. bispora tRNAGlu (CUC). These data suggest that the split LanB 
dehydratase (TbtB/C) requires a thiazol(in)e-containing substrate, implicating cyclodehydration (TbtF/G) 
and dehydrogenation (TbtE) as the initial two steps of thiopeptide biosynthesis. 
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PHHHHHHSQVDLNDLPMDVFELADSGVAVESLTAGHGMTEVGA*SCNCFCYICCSCSSA 
 
Figure 2.7 MALDI-TOF-MS analysis of TbtE/F/G reaction requirements. Unmodified TbtA (1) is shown 
in the top spectrum. Reaction of 1 with the F-protein dependent cyclodehydratase (TbtF/G) and ATP results 
in a six-fold cyclodehydrated product (hexa-thiazoline). Addition of the dehydrogenase (TbtE) to an 
otherwise identical reaction yields a 6-fold dehydrated and 6-fold dehydrogenated product (hexazole, 2). 
Omission of ATP, a requirement of the cyclodehydratase, results in no product formation. Similarly, 
omission of either TbtF or TbtG results in no product formation. Residues undergoing thiazol(in)e 
formation in the complete reaction are colored blue in the sequence above the spectra. 
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PHHHHHHSQVDLNDLPMDVFELADSGVAVESLTAGHGMTEVGA*SCNCFCYICCSCSSA 
 
 F 
GGTCCCGTCGTCTAGAGGCCTAGGACGCCGCCCTCTCAAGGCGGTAACGGCGGTTCGAATCCGCTCGGGACTACCA 
GCCCCCATCGTCTAGCGGTCTAGGACACCGCCCTTTCAAGGCGGCGGCACGGGTTCGAATCCCGTTGGGGGCACCA 
GTCCCCTTCGTCTAGAGGCCCAGGACACCGCCCTTTCACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGACGCCA 
*  *** ******** ** * ***** ******* *** *****   *   ***********  * ***    *** 
Figure 2.8 TbtB/C is selective for a particular tRNAGlu. (A) MALDI-TOF mass spectrum of 2 (starting 
material). (B) E. coli tRNAGlu (UUC) is not accepted by TbtB/C. (C) In contrast, four dehydrations are 
observed upon treating 2 with TbtB/C and tRNAGlu(CUC) from T. bispora.  (D) An identical reaction with 
the alternative tRNAGlu(UUC) from T. bispora yielded a mixture of dehydrated species, primarily the 
didehydrated peptide. (E) A reaction that omitted TbtC (elimination domain), while employing the optimal 
tRNA and d5-Glu, yielded a mono-glutamylated species. (F) Sequence alignment of the three pertinent 
tRNAGlu. Top, T. bispora tRNAGlu(CUC); middle, T. bispora tRNAGlu(UUC); bottom, E. coli tRNAGlu. 
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PHHHHHHSQVDLNDLPMDVFELADSGVAVESLTAGHGMTEVGA*SCNCFCYICCSCSSA 
 
Figure 2.9 MALDI-TOF-MS analysis of TbtB/C reaction requirements. The product of the six-fold 
cyclodehydration and dehydrogenation of TbtA (hexazole, 2) is shown in the top spectrum. Reaction of 2 
with the split LanB dehydratase (TbtB/C) in the presence of E. coli GluRS and T. bispora tRNAGlu(CUC) 
results in the formation of a four-fold dehydrated product (3). The formation of 3 was dependent on the 
presence of all reaction components, as individual omission of TbtB/C, E. coli GluRS, or T. bispora 
tRNAGlu(CUC) did not result in any change in mass. Residues modified to the thiazole are shown in blue, 
and residues that are transformed to dehydroalanine are colored green. All reactions also contained Glu, 
ATP, and MgCl2 (see methods). 
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(PHHHHHHSQ)VDLNDLPMDVFELADSGVAVESLTAGHGMTEVGA*SCNCFCYICCSCSSA 
 
Figure 2.10 TbtD requires the leader peptide for activity. The majority of the TbtA leader peptide (31 of 
34 residues, underlined region) was proteolytically removed from 3 using endoproteinase GluC (the 
additional N-terminal residues are the non-natural cloning/expression remnants). The natural leader peptide 
cleavage site is indicated with an asterisk. Modified residues of 3 are shown in blue (thiazoles) and green 
(dehydroalanines). * designates the end of the leader peptide. (A) HR-ESI-MS of the TbtA leader peptide 
generated by macrocyclization (Theoretical [M+H]+, 4593.143 Da). (B) 3 with leader peptide 
proteolytically removed by GluC. (C) Reaction of GluC-treated 3 with TbtD. 
  
43 
 
Figure 2.11 TbtD activity is not enhanced by known leader peptide-binding Tbt proteins. Addition of 
neither TbtB nor TbtF enhanced the rate of macrocycle formation by TbtD, which owing to a unique 
chromophore, can readily be monitored by UV-Vis spectroscopy at 315 nm. Both TbtB and TbtF contain 
RiPP leader peptide Recognition Elements (RREs)6 while TbtD does not appear to, despite its activity being 
leader peptide-dependent (Figure 2.9). 
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Figure 2.12 Purity analysis of 4 (macrocyclized product). (A) Total ion chromatogram (TIC) of HPLC-
purified 4. (B) Extracted ion chromatogram of the m/2 (EIC, m/z 683.61 Da) for 4. (C) Analytical HPLC 
analysis of purified 4 showing UV traces for absorbance at 220 and 315 nm. Hydrolysis of the C-terminal 
dehydroalanine tail of 4 occurs on-column, as indicated by asterisks and verified by re-injection of the 42.4 
min eluting product. Including the in situ hydrolysis peaks, the purity was judged to be ~95%, as measured 
by area-under-the-curve analysis. Retention times (min) are given for 4 and the in situ hydrolysis products. 
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Figure 2.13 HR-ESI-MS and MS/MS analysis of 4 (macrocyclized product). (A) The molecular formula 
of the protonated form of 4 was deduced from HR-ESI-MS to be C61H56N15O11S6. (B) Tandem MS of m/z 
1366 Da gives a fragmentation pattern consistent with the expected structure. 
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Figure 2.14 Structurally overlaid assignments for atom numbering and 1H/13C NMR chemical shifts of 4. 
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Figure 2.15 1H NMR (900 MHz, DMSO-d6) spectrum of 4.  
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Figure 2.16 1H-1H COSY (900 MHz, DMSO-d6) spectrum of 4.  
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Figure 2.17 1H-1H TOCSY (900 MHz, DMSO-d6) spectrum of 4.   
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Figure 2.18 1H-13C HMBC (900 MHz, DMSO-d6) spectrum of 4.  
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Figure 2.19 1H-13C HSQC (900 MHz, DMSO-d6) spectrum of 4 (downfield).  
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Figure 2.20 1H-13C HSQC (900 MHz, DMSO-d6) spectrum of 4 (upfield).  
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Figure 2.21 1H-1H NOESY (900 MHz, DMSO-d6) spectrum of 4.  
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PHHHHHHSQVDLNDLPMDVFELADSGVAVESLTAGHGMTEVGA*SCNCFCYICCSCSSA 
 
 
 
Figure 2.22 PbtD accepts 3 as a substrate. (A) The amino acid composition and post-translational 
modification status of 3 (TbtA-derived) are given, with thiazoles shown in blue and dehydroalanines in 
green. In the top spectrum, 3 is not visible owing to the mass window shown. Reaction of 3 with PbtD 
(homolog of TbtD from the GE2270A biosynthetic gene cluster) shows the formation of m/z 1366 Da 
(compare to Figure 2E) and the corresponding sodium adduct. (B) The aligned amino acid sequences of the 
thiomuracin GZ and GE2270A precursor peptides, labeled TbtA and PbtA, respectively. (C) Structural 
comparison between thiomuracin GZ and GE2270A. While structurally related, there exist key differences 
in amino acid composition and post-translational modifications. 
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Figure 2.23 Sequence alignment of TbtD homologs. GI numbers are given to the left of the alignment 
(green indicates the sequence from the canonical thiomuracin producer, Nonomuraea sp. Bp3714-39; blue 
indicates the sequence from the GE2270A producer, Planobispora rosea). Shown in red are residues 
replaced with alanine for enzymatic activity assessment. 
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2.6 Tables 
Table 2.1 Bioactivity of thiomuracin GZ. 
Organism MICa (μg/mL) MICa (μM) 
Staphylococcus aureus USA300 0.25 0.18 
Enterococcus faecium U503 0.063 0.046 
Bacillus anthracis str. Sterne 2 1.5 
E. coli MC4100 >64 >47 
Pseudomonas aeruginosa PA01 >64 >47 
Mycobacterium smegmatis B-14616 >64 >47 
Aspergillus niger >128 >94 
Saccharomyces cerevisiae >128 >94 
Talaromyces stipitatus >128 >94 
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Table 2.2 Sequence of tbt biosynthetic genes for optimal E. coli expression. All sequences are provided 5′ 
to 3′. Restriction sites for cloning are underlined (5′ BamHI, 3′ XhoI). These gene constructs were 
synthesized by GenScript (Piscataway, NJ, USA). 
 
tbtA 
GGATCCATGGACCTGAATGATCTGCCGATGGATGTTTTTGAACTGGCAGATAGCGGTGTTGCAGTTGAAAGCCTGAC
CGCAGGTCATGGTATGACCGAAGTTGGTGCAAGCTGTAATTGCTTTTGTTATATTTGTTGTAGCTGCAGCAGCGCCT
AACTCGAG 
 
tbtB  
GGATCCATGCGTCTGGTGGAACGTCGCTTTCCGGTTGCCATGACCTCGACGGCTCCGAAAGTCGCAGTGCGTGAATG
CGGTCTGCCTGTGAGCGCGATTGAATCTCTGTGCTGTACCGATAGCTTCGCACTGATCCGTCGCCAGGTTCGCGAAA
CGGCGTGGCTGAAAGGCGAAGGTAAACGTCTGGCCGTGGATCTGGGCCTGCTGATTGGTGAACGTGGTGACGGTGAT
GATGGTCTGCGTCCGGTTCTGGTCGGTCTGCGTCGCGCACTGCATACCGGTCGTCTGCCGGATGCACGCGAATGGAC
GCCGCGTGTGGCATCTGCTCTGCCGGCAGAACTGGCAGCCCGCGTCGCTGATTGGGTGACCCGTATGCGTGCACTGA
CGCGTGCACGTCGCGAACTGCCGGAACTGTTTGCAGCTGAAGCACGCGTTAAAGAAAAAGTCCTGGCACAGGTGGCA
GCCGATCCGGGTTTCCGTCGCGCTCTGAGTCTGGCATCCCCGGAACTGGCAGCTGATCTGGACCGTTGGCTGGCAGA
ACCGGCACGTCGCCCGAAAACCCAAAAACTGCTGCGCCTGGCCAAATATGTTGCACGTGCGGCCGTCAAAACGTCAC
CGTACTCGACCTTTACGAGCATGGGTGTGGCCGTTTGGGAAAACGGCGAAGATTGGGCAGACGGTGCTATTGTTCGT
TTCGCACCGCGCGAACCGCCGTCAGTCATCCTGGAACCGTCGGGTGAATGGCTGCATGGTGCACTGCGTGCATGGCT
GGCACGTCCGGAAAACCTGGTGCGCAGCCGTCTGCGCCTGAATCCGTCTCTGGTTATTCGCGCTGATAAAGCGGAAT
TTCTGGGCTTCCCGCCGCGCGAACCGATTATCCGTATGGGTCTGACCCCGGTGGTTGCAACGGTTCTGCGTCTGGCA
GAACCGGCAGCTGATGCTGACGGCTGGATCGATCCGATGGGTTTTCGTGATCGTCTGGCTCGTGACCTGCCGGCAGA
ACCGGAACAGGTCGACCGTCTGCTGCGCTCCCTGATTGAAGCCGGCGTGCTGGAAGCACACCCGCTGACCCGTGCGG
GTCTGCCGGAAACGGGTGAATGGGCAGAAATCCGTGCAGCACTGCGTCATGATCCGCACGGCGAAGACCCGGAAGCG
TATCGTGTGCGCCTGGCTCGTCTGAAACGCGCGATGACCATGATGTGGCCGCAAGGTGATACCACGGCGCTGCTGCA
TGAAACCGCAGTCGTGACGCGTCCGGTTGCAAGCCTGAATCCGACCGCTTGGGGCCGTGGTCTGAGTGATCTGGACG
TTGTCCGTCGCTGGCTGTCCGTGTTTGATGGCAAACTGCCGATTCGCATCGTGGTTGCCGAATATCTGCGTGCACGT
TACGGTGAACACGCCCGCGTGCCGTTTCTGACCTTCCATCGTCACGTTCAGGAAGAAATTGCAGGTGATGCACCGTC
AGGTGCAGACCTGCGCACGTTCGTTGGTCGTTCGGCAGCTATCTGGGCTCCGCCGCTGGCACATAGCCGCCTGCCGC
GTCTGCGTGAACTGGCAAAACTGCGTGAAGCAGCCCGCGAACTGGCACTGGGTCGTCCGGAACACGATGGTATTCAG
CGTGTGGACCCGGAAGAACTGATCAAACAAATGGCGACCTGGCCGGAATGGATTGTCGTGCCGCGTTCTTGCGCGTG
TTATGTCCAGCCGGCACCGGAAGGCCGCCTGGTGCTGAACGTTGTCCATGGCGGTCACGGTCGTGGTCTGCGTCGCC
TGAGTCATCTGATCGGCCGTGTGCGCGGTGAAGCGGTTGATCACCCGATGGTCGCCGACGAACCGGAAGGTACCGTG
TACGCGGAACTGAGCGGCTCTCTGGGTTCAACCCTGAATGTCCATGTGCCGGGCACGCGTTATGAAATTGATTACCC
GTTTAGTCCGGGTGATCGTTCCCGCGACCGTCGCCTGCCGCTGTCTGACCTGGAAGTGGTTCTGGCACCGGAAACCG
GTCTGGCTGAACTGCGCAGTCGTCGCCTGGGCTTTCGTGTTATTCCGCTGCATCTGGGTATGGCAGCTGAATTCCAG
CTGCCGCCGGCAGCACGTTTTCTGGAACGTGCCTTCGGCGTGACCTATCTGCTGCACCCGAGTGCACCGCCGCTGCT
GCGTATCGGCGAAGTGCCGCCGCCGCAGGAAGTGACGCGTTACCCGCGCGTTGAAGTCGGTCGTGTCGTGGTTCAAC
GTCGCCGTTGGCTGGCACCGGCAGGTACCCTGCCGATTCGCGCGAAAGGTGAAGATGACGCCTCCTATCTGCTGCGT
CTGGTTGCCTGGACCGATGCAAACGGCATCCCGACGCGTTCATTTGTTCGCGCCTGGCAGGAACGCATGGTCCAGGC
TGGTCAAGATAAAGCGCGTAAACCGCTGTTCCTGGACCTGGCGAATCCGTTTCTGGTGAAAGTTTTCGAACGTCAAA
TTCGCGATTGTGCATTTGTGCTGTTCGAAGAAGCTCTGCCGGACCCGGCAGACGCTCCGCCGCGCGAAGGCAGCGAT
CTGCCGCGTGTGATCGAATTTCTGGTTGAACTGGGTGAATAACTCGAG 
 
tbtC  
GGATCCATGACCCCGCACGAAGCCGAAGTTATTTGGGTTTCAGCACACATTTTCCATCAAGGCCCGCTGGACCGTCT
GGTTACCGAAGTCGCAGGCCCGCTGTTTGTCGAACTGGCAGCAGCAGGTCTGTCCACCCAGGGCTTTTTCCTGCGCT
ATTGGGAAGGCGGTCCGCATCTGCGTTTCCGTGTTCGTCTGCTGCCGGGTGCAGATGCTGCAGAAACGCGTCGCCTG
ATTCGCGAACGTGCTTGCGCGTATCTGCGTCGCTACCCGAGCCAGGATGTTCTGGACCGTGAAGAATATGCTCGTCT
GGCGGAAGTCCTGGCAGCACGCGAAGGTCTGACCGGTCACGCGCGTGAACTGTACCCGAACGATAGTGTGCAATTTA 
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TCTCCTATCGCCCGGAACATCACCGTTACGGTCGTGGTCCGAGCCTGGAAGCAGTTGAACGCCATTTCGCAGAAAGC
TCTCGTATTGCTCTGGAACTGCTGCACGCAGGTCTGACCATCCCGCAGCGTGGTGCAGTGTGGCTGACCATGCTGAT
GGCAACGTGGCTGCTGGCAGGCTCTCGTGGTGAAGATGCGTTTCGCCCGTGGCCGGACGCTCGTAAAGAACAAGCGT
TCGATCGTGAACGTGAACGTCTGACCGGTCTGGCACGTCATGCACGTCAGCTGACGCTGCGCCCGCCGGACCCGGAA
GCACAAGGCGTCCTGGCTGCATGGCACGGTTCAGTGGCACGTCTGGCAGATGCACTGGCAGCATCGGGCTTTACCGC
CACGCGTACCGCAACGGTTCTGGACCTGTGTGCTCATCTGCTGGCGAATCGTCTGGGTATTCGCATCCAGGATGAAG
CACGTCTGCGCTACCTGGCTAGTCGTGCGCTGGACGAAGCGGAAGTGACCGTTTAACTCGAG 
 
tbtD  
GGATCCATGGCAGCAGGTGAACGTTGGTGGCGTTTCCGTGTCGATTATCATGCAGGCCCGATGGACGATCTGATTCT
GGATGGTGTGCGCCCGGCATTTGCAGCATTCGCAGCTCAGGCACCGATGGCATATTTTCTGCGTCATTGGCGTCGCG
GTCCGCACCTGCGCATTTACGTTAGTACCACGCGTGAAGCACTGGAAGCTGTGGTTCGTCCGGCAATCGAACATGTC
GTGGGCGGTTATCTGCGTGCACGTCCGAGTCCGGGTATGGCTGATCCGTCCGCGTTCCTGCCGCTGCATGAACGCCT
GGCCGAACTGGAAGGCGAAGATGGTCCGCTGATGCCGTGGTCTCCGGACAACACGATTCACGCAGAAGGTGAACGTC
CGGAACCGCTGACCGTGCGTGATGTTCTGCTGGCCGATTTTTATGCAGACACCACGCCGAGCGTTTACCACGCGCTG
GAACGTGTCCGCAGTGGTGCTTCCCTGCCGACGATCGCCTTCGATCTGGTTGTCGCTACGGCACATGCACTGAGTAC
CGGCGGTCTGCCGGTCGCACGTACCTCACTGCGTTCGCACGCAGAAGCTTATCTGGCACGTCGCTCCGATGGTGTGC
GTCTGCGTGAACTGTGGCGTGACCATTACGCCCGTAACCGCGAAGCATTTACGGAACGTCTGATTGCGGTGGCCAGC
TCTGCGGAAAGCGCCGAAAATGGTGCGCATCTGCCGCACGTCCGTGAATGGGTGCGTCGCCTGCGTCCGATCCGTGA
ACGTGCACGTGCTCTGCTGGAATCAGGCGAACTGACCCTGGAATATGCATCGCCGGCTGAAGGTGCGCGCGATCTGC
CGAGCCTGGCTGAAGTTTCTGCGTTTCATCGCGAACTGGAAAGCCGTCCGGAATGGGCACGTCTGCGTGACTCTCCG
GCATTCGGCGCATATCGTCTGGTTATTAATTGCACCTACCTGCACCTGACGCGTCTGGGTCTGACCCCGCATCAACG
TTTCCTGGTCTGTCACCTGGCAGCAGATGCAGCTGCAGACGTGTACGGCATCGCCGCACATGAAGAAGTTGCGACCC
GTTAACTCGAG 
 
tbtE  
GGATCCATGACCATTCCGCCGGGCCTGACCGAACGCTATGCCCTGCGTGCGGGTGTTCACTCTGCTGTGCTGCCGGA
CGGTGTTATGCGCCTGTTTGCGTGGCCGCATGCCGAATCAATTGGTGCGCTGTCGGCCGATGAAACCACGCTGCTGA
AAGAACTGGCGGAAGGCCCGCGCGAAATCGCAGATCCGGCTCTGCGTCCGTTTGTGGAACGCCTGTTCCGTGGCGGT
TGGCTGAAACGCACCCTGAGCCGTGGCGAACACGACCTGTATACGCTGGACCCGCTGCGTCGCCCGGGTAGTCGCCC
GGCACCGCCGGATGACCCGGTCCTGTCCCGTTTTGCAGCAGTGCGTCGCCGTCCGAGCGGTTTCGTTATTGAATCTC
CGCTGGCGTGGTGCGACGTGCATGTTCACGATCCGGCACTGCTGCCGGATCTGCTGGAACCGGCAGGCGGTCGTGCT
GGTCGTAGCTCTCTGGCACCGCAGATCCGCCGTCAAGCACTGGCTGATCTGGCATGGGCAGGCCTGGTGGTTCCGCG
TGGCGCAGAAGACGGTGCACTGCGTACCCGTCAGTGGGCACCGCATGAACTGGATTTTCACCAACGCTCCCGTCTGT
ATCATCGCGGCTACCTGGGCGATGGTTTTGGCGGTACCTTCTGGGCACGTGGTACCTTCGACCCGCCGCAGGCTCGT
CCGCAACGTTATCCGGGCGACCCGATTCCGCTGCACCGTCCGGATCTGAACGCACTGCGTGCAGCTGACCCGCCGCT
GACCGCTGTTCTGGAAGATCGCCGTAGCGTCCGTGAATATGATGACGATGCACCGATGACGGTGGAACAGCTGGGTG
AACTGCTGTACCGCTCTGCGCGCATTCGTGACGTCAAAGTGATCGATGGCGTGGAATATGTTCGTAAACCGTACCCG
TCAGGCGGTTCGGTGTATGAACTGGAAATTTACCCGGTCGTGCGTCATGTTGCAGGTCTGGCACCGGGCATGTATCA
TTACGATGCGTATGAACACGTTCTGCGTCCGGTCCGTCCGGCAGGTCATCCGGCTGTGCGCCGTATGCTGACCGTTG
CAAGCCACGGCTCTGCAGTGGGTATCCGTCCGCAGCTGCTGCTGGTTGTCAGTGCCCGCGTCGGTCGTGTGATGTGG
AAATATGAAGGCATGGGTTACGCACTGATTCTGAAACATGTTGGTGTCCTGTATCAAACCCTGTACTGCGTTGCAAC
GGCTATGGGCCTGGCACCGTGTGCTATCGGCAGTGGTGATTCCGCGGCCTTTTCTGAAGCGACCGGTCGCGATCCGC
TGGAAGAATGTGCCGTCGGCGACTTCCTGCTGGGTTCACGTCCGGCGAGTGGCTCCACGGTTGAAGAATCGTAACTC
GAG 
 
tbtF  
GGATCCGTTATTCCGGCTCGTCCGGTTCTGACCCCGGGCGTTCGTTATGCTCCGACCAGTGATGGCGTTGCTTTCCT
GACCCGTGATGGTATTGTGAGTATTACCGGCGTTTCCATCCACCGCTGGATTGACCGTATCGCACCGCATCTGACCG
GTGAACGCAGCGTTGCAGAACTGACGGATGGTCTGGCACCGGAACGTCGCGCATTCGTGCTGCGTCTGCTGCAGGCA
CTGGCAGATCGCGGTCTGATTATCGACGCAGCCGGCGGTCGTGAACCGCGTCTGGAACGTGGTACCGCTTGCGCACT 
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GCACGTTACCGAAACGTGTGGTCCGTATCGTGAATCACTGCCGAAACTGGCACGTTCGCTGGCAGATGCACTGACCC
GTGCCGGTCTGGACGTGCGTCTGGCTAGTGCGTCCGAACCGTGCGATCCGGAACGTTGTCATGCGCTGGTTCACCTG
ACGGCAGCTGACGAAGTCGGTCTGGCAGCAGCAGAACGTCTGGATCGTCTGTCAGAACGTTGGGGTGTTCCGATTGC
ACATGTGGTTGTCTGGGGCGGTGAAATCTGGCGTACCGAAGCCGGTACGGTGGGTGAAGACGGTCTGCCGCTGGCTG
CAGGTTGGCGTCGCCTGACCGCGCTGCGTCCGGATACGGAAGAACGCGTTCCGATTTCGCCGACCGCAGCAGTGGTT
GTCGCCGGTCAGGTCGCTGCAGATGTGCGTGACCGTCTGACCACGGCAACCCGTGCTGGTCGTCGCCCGCGTCTGCA
CGTGGTTGAACCGGCTCGTCTGACGTGCCGTGCACATCACTTTATTCCGCATTTCCACACCATGCCGCTGACGGGTG
ATGCACCGCTGGCAGAAGAACTGACCGAAGAAGAATTTTCCCGTCGCGCCGCAGCTCTGATGGATGACCGCACCGGT
GTGTTTACGGAAATCGCGGAGGGTGATTTCGGCCAACTGCCGCTGCATGTGGCTGTTACCACGGTTGCCGATCCGGT
CGGTCTGCTGGGTCCGGCAGGTGACCGTCCGCGCGTGATTGGCGTTGGTCCGGATTTCGCAACCGCACGTTATCGTA
CGGCGCGTGCGGCAATCGCACTGTACGGTCTGCTGGCAGTTGATCCGCGTCGCCTGGTCGATGCAGACGGTGAACCG
CTGGCAGGTCCGCGTACCAGCGCAGCTGAACTGGAAGATCTGCTGGGTCGTATTCGCGCGGGCGGTCTGCCGGCATT
TGTCCGTGCCGAAGATGTGCGTGGCGGTCCGCCGCGTCTGCTGCCGGCCAGCTCTGTGTTTCCGTTCGCTACCGCGC
GTGCCCTGCTGGCCGGTACGGTGCCGACCGGCACGGCAGTTGGTTACTCTGAAGAAGGTGCACTGCGTGCAGCACTG
CTGGATCACTGCCGTGAACGCACCCTGGCAGACCTGGCTAGTCGTCGCGTCGCTCGTCTGACCCCGGATACGGCACC
GTCCGACCCGGTGACCGCACGTTATCTGGCTTTTCTGCGCGCGATCGGCCTGCCGTTCGATGTTCTGGACGCAACGG
GTCCGCTGGGTGTCCCGGTGTACGTTGGCGTCCTGGATGGTCGCGTCGTGGCAGCTGAAGCAGGTGCTAGCCCGGGT
GAAGCGTTTCGTTCTGTGCTGGAAGGTATTCTGCGCGGCCTGCAAGGTATCCCGGCAGCACGTAGTCTGCCGGACAC
CCTGCCGCCGGTCCTGCCGGAAGCAATGGCAGTGCCGGATGGCAGCCCGCTGTCTGCAGAAGCTCTGGCAGCTGCAC
TGGCGCGTGCCGGTCTGTCAGTGTCGGTTGTCCGCCTGGATCATGACCGTCGCGTTCACGCCCTGATTCCGCATTGT
GTGCGTGTTATGGTCACCGGCGAAGAATCTGCACATGTGTAACTCGAG 
 
tbtG  
GGATCCATGTCCGACGCTCTGGCTGCTGCTATTATTGGTGCTGGTCTGCTGGCCGATGAACTGGCTGCTGCCTTTCG
CCCGTATGGTGAAGTCATTCGTCTGGATGAAGTCGAACGCGCTGAAACCGAAGCGCATCGTCTGCGCGCCCTGGTTA
TGGCATGCGATGGCTGGGACACCAGTATTTACCGTGAAACGCGTGAACGCTGCCGTCGCCTGGGTATCCCGTGGCTG
CCGGTTCGTACGGAACATGGCATTGCAGTCATCGGTCCGCTGGAACGTCCGGGTGAACCGGGTTGCGCCCACTGTTT
TGAACTGCGTCGCGAACGTGCACGTCCGGATGCAGCCGCATACCGTGCAATCCTGAACCATCACGGTCCGGAACTGG
CAAAACGTCCGTCACCGTATCTGGACGAACTGGCTGCGGCCACCATTGCAGCTCTGGGTGTGCGTATGATCGATCAG
GGCTCGGGTTGCCATGTCTGGTATGTGCGTCTGAATGGCCTGACGGTTGAACGTCACGCGTTCCTGCCGGAACCGCT
GTGCCCGGAATGTGGTAGCCTGCCGATGGATGACCGCGATAGCGCTGTTATTGTCCTGCGTTCTCAGCCGAAACGCG
CCCCGGATGACTACCGTACCCGCGATATCGTGGACGAACTGGATGCCCTGGTTGCAGACTATGTCGATGGCGAATCT
GGTCTGATTCGCCCGCTGGTGCGTGATACCCAAGGCGGTCTGGTTATCGCAGGTGCAATGCTGCCGCTGCGTTTTGC
GGGCGGTTCAGAACCGGGCGTTGGTCGTACGCGCGGTTATCGTACCTCGGAAGTCACGGCTATTCTGGAAGCGCTGG
AACGTTGGGGCGGTGTCGAACCGGGCGGTAAACGCACCGTGATTCGTGCGGCCTTCCGCGATATCGCAGCTGACGCA
CTGGACCCGCGTACGCTGGGCGTGCATAGCCCGGAAGCATACGCGGCCGAAGACTTTCCGTTCCGCCCGTTTACCGA
AGATGAAGAAACGGAATGGGTGTGGGGTTATAGTTTCGCACGTCGCTCCCCGATTCTGGTGCCGGAAACCGTTGCGT
ATTACTATGTTCACCGTGACCGCCCGCGTCAAGAACGTCCGTTTCTGTATGAAATCAGTAACGGCTGCGCTCTGGGC
TCCGGTATGGAAGAAGCGATTCTGTACGGTATCCTGGAAGTGGTTGAACGCGATGCGTTCCTGATGACCTGGTATGG
CCGTCTGGGTGTTCCGCGCATTGATCTGGACAGCGCAAAAAATCGTATGGTCCCGCTGCAGGCAGCTGCGATTTCTG
CGGAAACCGGCTACCGCATCGAAGTCTATGATACCACGATGGAACATGGTATTCCGAGCGTGTGGGCTCTGGCAATC
CGTGGCGGTGAAGAACCGACGGCAGCACCGCGTCCGCGTATGGTGTGTGCTGCAGCAGCACACCTGGACCCGGAACA
AGCAGTTCTGAGCGCACTGTCTGAACTGGGTCCGCTGCTGGCAGACCTGCTGCGTCGCTACCCGGATGAAGCTGAAC
GTGCGCGTCGCATGGTCGATGACCCGGGTCTGGTGACCACGATGCATGACCACAGTACCCTGTATGGCGCCGATGAA
GCATTTGGTCGCCTGGAATTCCTGACCGGTACGGCATCCACCCGTGACCTGGCTGCAATGCGCGAATCAACGGTGGC
TTTTCGTTCGGCGGATCTGCGCGATGACCTGCTGGAAGTGATTGGCCGTATCCTGGCGGAGGGTATGGACGTTATTG
TCGTGGATCAGACCACGCCGGAACATCGCGTGCACGGTTTTACCTGTGTGAAAGTTCTGATTCCGGGCATGATCCCG
ATGACCTTCGGTCATCGTAACCGTCGCCTGGATGGTCTGACGCGTCCGCTGGTTATCCCGTACCGTCTGGGTTATCG
TCCGGCACCGCTGACCCCGGAAGCACTGAATCCGCATCCGCACCCGTTTCCGTAACTCGAG 
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Table 2.3 Oligonucleotide primers used in this study. All sequences are provided 5′ to 3′. F indicates 
a forward primer while R indicates the reverse. Lowercase m indicates 2′ O-methylation of the following 
residue; methylation suppresses random addition of bases at the end of the RNA by T7 RNA polymerase. 
Primer Name Oligonucleotide Sequence 
mbp F (sequencing) GAGGAAGAGTTGGCGAAAGATCCACGTA 
T7 F (sequencing) TAATACGACTCACTATAGGG 
T7 R (sequencing) GCTAGTTATTGCTCAGCGG 
tbtA Gibson F GCATCACCATCATCACCACAGCCAGATGGACCTGAATGATCTGCC 
tbtA Gibson R GACTTAAGCATTATGCGGCCGCATTAGGCGCTGCTGCAG 
tbtB Gibson F CTGGTGGACAGCAAATGGGTCGCGGAATGCGTCTGGTGGAAC 
tbtB Gibson R GTGGTGGTGCTCGAGTGCGGCCGCATTATTCACCCAGTTCAACCAG 
tbtC Gibson F CTGGTGGACAGCAAATGGGTCGCGGAATGACCCCGCACGAAG 
tbtC Gibson R GTGGTGGTGCTCGAGTGCGGCCGCATTAAACGGTCACTTCCGCTTC 
E. coli gluRS Gibson F CTGGTGGACAGCAAATGGGTCGCGGAATGAAAATCAAAACTCGCTTC 
E. coli gluRS Gibson R GTGGTGGTGCTCGAGTGCGGCCGCTTACTGCTGATTTTCGCG 
E. coli tRNA F AATTCCTGCAGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGACACC 
E. coli tRNA R mUmGGCGTCCCCTAGGGGATTCGAACCCCTGTTACCGCCGTGAAAGGGCGGTGTCCTGG 
T. bispora tRNA(CUC) F AATTCCTGCAGTAATACGACTCACTATAGGTCCCGTCGTCTAGAGGCCTAGGACGC 
T. bispora tRNA(CUC) R mUmGGTAGTCCCGAGCGGATTCGAACCGCCGTTACCGCCTTGAGAGGGCGGCGTCCTAGG 
T. bispora tRNA(UUC) F AATTCCTGCAGTAATACGACTCACTATAGCCCCCATCGTCTAGCGGTCTAGGACACCGCC 
T. bispora tRNA(UUC) R mUmGGTGCCCCCAACGGGATTCGAACCCGTGCCGCCGCCTTGAAAGGGCGGTGTCC 
tbtG Internal GTGATACCCAAGGCGGTCT 
tbtF Internal TGCACATCACTTTATTCCGCA 
tbtB Internal 702 CTTTACGAGCATGGGTGTGG  
tbtB Internal 1496 TCCATCGTCACGTTCAGGAA  
tbtB Internal 2116 GTTATTCCGCTGCATCTGG 
pbtD (BamHI) F AAGGATCCGTGACCTGGCGACGCTTTGAC 
pbtD (XhoI) R AACTCGAGTCACATGCCTCCTACGGCGATC 
tbtD H46A F ATTTTCTGCGTGCTTGGCGTCGCGGTCCGCACCTGCGCATTTAC 
tbtD H46A R CCGCGACGCCAAGCACGCAGAAAATATGCCATCGGTGCCTG 
tbtD W47A F TTCTGCGTCATGCGCGTCGCGGTCCGCACCTGCGCATTTAC 
tbtD W47A R GGACCGCGACGCGCATGACGCAGAAAATATGCCATCGGTGC 
tbtD R49A F GTCATTGGCGTGCCGGTCCGCACCTGCGCATTTACGTTAG 
tbtD R49A R CAGGTGCGGACCGGCACGCCAATGACGCAGAAAATATGCCATC 
tbtD H52A F GTCGCGGTCCGGCCCTGCGCATTTACGTTAGTACCACGCGTG 
tbtD H52A R GTAAATGCGCAGGGCCGGACCGCGACGCCAATGACGCAG 
tbtD R54A F GTCCGCACCTGGCCATTTACGTTAGTACCACGCGTGAAGCAC 
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Table 2.3 (cont.) 
tbtD R54A R CTAACGTAAATGGCCAGGTGCGGACCGCGACGCCAATGACG 
tbtD S85A F GTGCACGTCCGGCTCCGGGTATGGCTGATCCGTCCGCGTTC 
tbtD S85A R GCCATACCCGGAGCCGGACGTGCACGCAGATAACCGCCCAC 
tbtD H98A F GTTCCTGCCGCTGGCTGAACGCCTGGCCGAACTGGAAGGCGAAG 
tbtD H98A R GCCAGGCGTTCAGCCAGCGGCAGGAACGCGGACGGATCAGC 
tbtD E105A F CTGGCCGAACTGGCAGGCGAAGATGGTCCGCTGATGCCGTGG 
tbtD E105A R CCATCTTCGCCTGCCAGTTCGGCCAGGCGTTCATGCAGCGG 
tbtD N118A F GGTCTCCGGACGCCACGATTCACGCAGAAGGTGAACGTCCGG 
tbtD N118A R GCGTGAATCGTGGCGTCCGGAGACCACGGCATCAGCGGACC 
tbtD T144A F TTTATGCAGACGCCACGCCGAGCGTTTACCACGCGCTGGAAC 
tbtD T144A R ACGCTCGGCGTGGCGTCTGCATAAAAATCGGCCAGCAGAAC 
tbtD R189A F GTACCTCACTGGCTTCGCACGCAGAAGCTTATCTGGCACGTC 
tbtD R189A R TCTGCGTGCGAAGCCAGTGAGGTACGTGCGACCGGCAGACC 
tbtD S190A F CCTCACTGCGTGCGCACGCAGAAGCTTATCTGGCACGTCGC 
tbtD S190A R GCTTCTGCGTGCGCACGCAGTGAGGTACGTGCGACCGGCAG 
tbtD H191A F CACTGCGTTCGGCCGCAGAAGCTTATCTGGCACGTCGCTCC 
tbtD H191A R TAAGCTTCTGCGGCCGAACGCAGTGAGGTACGTGCGACCGG 
tbtD E193A F GTTCGCACGCAGCAGCTTATCTGGCACGTCGCTCCGATGGTG 
tbtD E193A R GCCAGATAAGCTGCTGCGTGCGAACGCAGTGAGGTACGTGC 
tbtD S287A F TGGCTGAAGTTGCTGCGTTTCATCGCGAACTGGAAAGCCGTC 
tbtD S287A R CGATGAAACGCAGCAACTTCAGCCAGGCTCGGCAGATCGCG 
tbtD H290A F GTTTCTGCGTTTGCTCGCGAACTGGAAAGCCGTCCGGAATGG 
tbtD H290A R TCCAGTTCGCGAGCAAACGCAGAAACTTCAGCCAGGCTCGG 
tbtD R291A F CTGCGTTTCATGCCGAACTGGAAAGCCGTCCGGAATGGGCAC 
tbtD R291A R CTTTCCAGTTCGGCATGAAACGCAGAAACTTCAGCCAGGCTC 
tbtD N316A F GTCTGGTTATTGCTTGCACCTACCTGCACCTGACGCGTCTG 
tbtD N316A R CAGGTAGGTGCAAGCAATAACCAGACGATATGCGCCGAATGC 
tbtD Y319A F TTAATTGCACCGCCCTGCACCTGACGCGTCTGGGTCTGACC 
tbtD Y319A R GTCAGGTGCAGGGCGGTGCAATTAATAACCAGACGATATGC 
tbtD R324A F CTGCACCTGACGGCTCTGGGTCTGACCCCGCATCAACGTTTC 
tbtD R324A R GTCAGACCCAGAGCCGTCAGGTGCAGGTAGGTGCAATTAATAAC 
tbtD R332A F CCCCGCATCAAGCTTTCCTGGTCTGTCACCTGGCAGCAGATG 
tbtD R332A R CAGACCAGGAAAGCTTGATGCGGGGTCAGACCCAGACGCGTC 
tbtD C336A F GTTTCCTGGTCGCTCACCTGGCAGCAGATGCAGCTGCAGAC 
tbtD C336A R GCTGCCAGGTGAGCGACCAGGAAACGTTGATGCGGGGTCAG 
tbtD H337A F TCCTGGTCTGTGCCCTGGCAGCAGATGCAGCTGCAGACGTG 
tbtD H337A R TCTGCTGCCAGGGCACAGACCAGGAAACGTTGATGCGGGGTC 
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Table 2.4 1H and 13C NMR chemical shift assignments of 4. 
Positio
n 
Grou
p 
13C δ 
(ppm
) 
1H  δ 
(ppm
) 
m  
(J, 
Hz) 
Residu
e  
Positio
n 
Grou
p 
13C δ 
(ppm
) 
1H  δ 
(ppm
) 
m  
(J, 
Hz) 
Residu
e 
92 NH — 8.55 br m Ala  43 NH — 8.92 d (7.3) Phe 
93 CH 48.9 4.27 m    44 CH 52.9 5.60 q (7.0)   
94 CH3 17.7 1.35 d (7.3)    45 CH2 41.1 3.38 m   
95 C=O 174.4 — —        3.32 m   
2 C=O 163.5 — — Dha-1  46 C 137.1 — —   
3 C 135.8 — —    47 CH 129.8 7.13 d (7.5)   
4 CH2 107.8 6.02 s    48 CH 128.7 7.22 t (7.5)   
    5.78 s    49 CH 127.1 7.17 t (7.3)   
5 NH — 9.54 s    50 CH 128.7 7.22 t (7.5)   
6 C=O 162.8 — — Dha-2  51 CH 129.8 7.13 d (7.5)   
7 C 135.2 — —    53 C 170.3 — — Thz-4 
8 CH2 106.7 6.36 s    55 C 148.1 — —   
    5.83 s    56 CH 153.7 8.13 s   
9 NH — 10.12 s    58 C=O 159.9 — —   
10 C=O 159.5 — — Thz-1  59 NH — 8.05 m Tyr 
14 C 150.8 — —    60 CH 53.9 4.91 m   
15 CH 129.3 8.67 s    61 CH2 38.1 3.20 m   
17 C 168.1 — —        2.80 m   
19 C 150.7 — — Pyr  62 C 127.6 — —   
20 CH 119.1 8.38 d (8.0)    63 CH 130.5 7.06 d (obs)   
21 CH 141.5 8.51 d (8.0)    64 CH 115.5 6.64 d (8.0)   
22 C 128.9 — —    65 C 156.8 — —   
23 C 150.7 — —    66 CH 115.5 6.64 d (8.0)   
25 C 164.8 — — Thz-2  67 CH 130.5 7.06 d (obs)   
27 CH 127.4 8.53 s    68 OH — 9.24 s   
28 C 149.8 — —    69 C=O 160 — —   
30 C=O 160.6 — —    71 C 174.7 — — Thz-5 
31 NH — 8.95 d (7.8) Asn  73 CH 116.9 7.55 s  
32 CH 49.3 5.41 m    74 C 147.7 — —  
33 CH2 39.1 2.24 m    76 C 161.4 — — Thz-6 
    2.81 m    78 C 153.7 — —  
34 C=O 171.8 — —    79 CH 123.5 8.27 s  
35 NH2 — 7.39 s    70 NH — 9.04 br s Ile 
      6.88 s    81 CH 57.3 4.91 m   
36 C 173.1 — — Thz-3  82 CH 38.7 2.01 m   
38 CH 124.5 8.17 s    83 CH2 25.5 1.59 m   
39 C 149 — —        1.33 m   
42 C=O 160.6 — —    84 CH3 11.0 0.91 t (7.4)   
       85 CH3 16.0 0.88 d (6.7)   
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Table 2.5 Yield and activity of alanine-substituted TbtD proteins. Twenty-three positions of TbtD were 
targeted for alanine replacement by site-directed mutagenesis using the alignment of Fig. S18. These 
proteins were expressed in E. coli as MBP fusions, purified to homogeneity (Fig. S1), then assayed for 
enzymatic activity using a MALDI-TOF-MS endpoint assay. In condition A, high concentrations of enzyme 
and substrate were used to assess the formation of 4. In condition B, both the enzyme and substrate 
concentration were lowered. Precise conditions follow for A: HEPES pH 7.5 (100 mM), MgCl2 (5 mM), 
KCl (150 mM), ATP (5 mM), 2 (hexazole, 100 μM), T. bispora tRNAGlu (10 μM), E. coli GluRS (10 μM), 
TbtB (5 μM), TbtC (5 μM), MBP-TbtD (5 μM), and TIPP (0.02 U/μL). The reaction was allowed to proceed 
at 30 °C for 4 h. Conditions for B were identical to A except for the following changes: 2 (hexazole, 15 
μM; lowered 6.67-fold), T. bispora tRNAGlu (10 μM), E. coli GluRS (10 μM), TbtB (5 μM), TbtC (5 μM), 
MBP-TbtD (1 μM; lowered 5-fold), and TIPP (0.02 U μL–1). The reaction was allowed to proceed at 30 °C 
for 4 h. +++ indicates enzyme activity roughly equal to wild-type (full conversion to product); ++ indicates 
modestly reduced enzyme activity (~50% conversion to product); + indicates severely reduced enzyme 
activity (low but detectable product formation); - indicates no detectable enzyme activity (no observed 
product formation). Isolated protein yields are given as a crude measure for protein stability (structurally 
destabilizing substitutions typically give lower yields and visible degradation by SDS-PAGE). 
 
TbtD 
Protein 
Protein 
Yield (mg/L) 
Relative Product 
(condition A)  
Relative Product 
(condition B)  
Wild-type 14 +++ +++ 
H46A 8 +++ +++ 
W47A 17 +++ - 
R49A 8 +++ +++ 
H52A 8 +++ +++ 
R54A 21 +++ +++ 
S85A 13 +++ +++ 
H98A 8 +++ +++ 
E105A 11 +++ - 
N118A 8 +++ +++ 
T144A 13 +++ +++ 
R189A 11 +++ +++ 
S190A 8 +++ +++ 
H191A 4 +++ - 
E193A 11 +++ +++ 
S287A 13 +++ - 
H290A 10 +++ ++ 
R291A 10 +++ +++ 
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Table 2.5 (cont.) 
 
N316A 13 +++ +++ 
Y319A 11 + - 
R324A 10 +++ +++ 
R332A 16 - - 
C336A 10 +++ +++ 
H337A 16 +++ +++ 
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Chapter 3: Biosynthetic Timing and Substrate Specificity for the Thiopeptide Thiomuracin3
 
3.1 Introduction 
Thiopeptides are a structurally complex class of antibiotics that belong to the rapidly expanding 
group of ribosomally synthesized and posttranslationally modified peptides (RiPPs).1 With rare exceptions, 
RiPP precursor peptides consist of a leader peptide (LP), generally believed to be important for recognition 
by select biosynthetic proteins,2 and a core peptide where the posttranslational modifications take place. 
Because of the direct link between the gene encoding the precursor peptide and the natural product structure, 
RiPPs have much bioengineering potential.3-5 We recently reported the in vitro reconstitution of the 
biosynthesis of thiomuracin GZ (4),6 which only lacks the ancillary tailoring posttranslational modifications 
found in naturally produced thiomuracins.7  The overall process converts a linear precursor peptide (TbtA, 
1) into a nanomolar potency antibiotic by cyclodehydration by TbtFG and dehydrogenation by TbtE of the 
six Cys residues to the corresponding thiazoles. Subsequently, four alcohol groups are dehydrated in a 
process that involves glutamylation with Glu-tRNA by TbtB and subsequent Glu elimination by TbtC. 
Finally, two of the dehydrated residues react in a formal [4+2] cycloaddition (TbtD), followed by 
elimination of water and the LP to yield 4 (Figure 1.1A).  
In this work, we determined the molecular details underlying this well-orchestrated set of 
enzymatic reactions. We show the order of thiazole and alkene formation, the minimal structural changes 
to render TbtA a substrate for dehydration, and reveal the parts of the TbtA peptide that are recognized by 
the various enzymes. Our results show that thiazole formation requires the LP, but dehydration surprisingly 
does not. These insights uncover which analogs of 4 will be accessible by in vitro biosynthesis using altered 
TbtA substrates. 
3.2 Results and Discussion 
We first focused on the substrate permissiveness of the TbtEFG thiazole synthetase. A series of 
TbtA variants were prepared (Figure 3.6) in which each Cys residue was systematically substituted with 
Ala starting from the C-terminus (Figure 3.7). These variants were treated with purified TbtEFG as 
previously reported.6 A complementary set of variants with Cys substituted beginning at the N-terminus of 
the core peptide was also prepared (Figure 3.8). All Ala-substituted TbtA variants were converted to the 
pan-thiazole species with incompletely processed peptides typically not observed (Figures 3.7 and 3.8). Six 
additional variants of TbtA were prepared that each contained a single Cys at the wild-type locations. 
                                                   
3 This chapter has been reproduced with permission from Zhang, Z.; Hudson, G.A.; Mahanta, N.; Tietz, J.I.; van der Donk, W.A.; 
Mitchell, D.A. Biosynthetic timing and substrate specificity for the thiopeptide thiomuracin. J. Am. Chem. Soc. 2016, 138, 15511-
15514. Copyright 2016 American Chemical Society. G.A.H and Z.Z designed and performed experiments. J.I.T collected and 
analyzed spectroscopic data. M.N. collected fluorescence polarization data. All authors wrote and edited the manuscript. G.A.H 
and Z.Z are co-first authors.  
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TbtEFG processed each variant to the expected monoazole (Figure 3.9), indicating that the installation of 
each thiazole is independent of the presence of other thiazoles.  
With the substrate permissiveness of TbtEFG towards Cys established, we next investigated the 
order of thiazole formation. After treating wild-type TbtA with TbtEFG, aliquots were removed and 
quenched at various times with excess iodoacetamide to alkylate any unmodified Cys residues. TbtA mono-
, di-, and triazole intermediates were intercepted whereas the tetra- and pentazole species were not, 
suggesting that the first three thiazoles are distributively installed with the remaining three processively 
introduced under our reaction conditions. Electrospray ionization (ESI) MS/MS analysis of these 
intermediates revealed a non-linear processing order: Thz4 -> Thz2 -> Thz12 (Figure 3.2).  
With the ability to process many variants of the TbtA core peptide, we reasoned that TbtEFG relied 
heavily on the LP to drive substrate binding. Indeed, previous studies on other RiPPs containing thiazole 
and oxazole heterocycles have shown that the LP is important and that it is bound by a specific RiPP 
recognition element (RRE) that exhibits homology to PqqD.8-11 For thiomuracin biosynthesis, PqqD-like 
domains are clearly present in the TbtF and TbtB proteins (Figure 3.1B) but the region(s) of the LP 
recognized are not known. Also, the [4+2] cycloaddition enzyme is known to be LP-dependent,6,12 yet TbtD 
lacks a bioinformatically identifiable RRE. Previous studies have shown that TbtF avidly binds the TbtA 
LP (Kd ~70 nM).8  We thus evaluated binding to maltose-binding protein (MBP) tagged TbtB and MBP-
TbtD using a synthetic TbtA LP derivatized with fluorescein isothiocyanate (FITC) at the N-terminus 
(FITC-TbtALP). Despite having a domain homologous to PqqD, TbtB only weakly bound the LP (Kd ~20 
µM, Figure 3.10), while the RRE-less TbtD bound the same peptide considerably tighter (Kd ~140 nM, 
Figure 3.11).  
To elucidate which parts of the LP were important for TbtF and TbtD binding, we generated a panel 
of TbtA variants and performed competition fluorescence polarization (FP) assays with FITC-TbtALP to 
determine relative IC50 values. This revealed a set of residues important for TbtF binding (Leu−29, Asp−26, 
Phe−24) and TbtD binding (Leu−29 as well, but also a number of acidic residues: Asp−30/−24/−20 and 
Glu−14, Table 3.1). Interestingly, many thiopeptide LPs are rich in Asp/Glu;13-15 we hypothesize that TbtD 
will display a binding site to electrostatically complement a polyanionic LP with a hydrophobic pocket to 
accommodate LP position −29.  
The regions of TbtA and TbtF important for binding were confirmed by measuring the affinity of 
the first 16 residues of TbtA (LP positions −34 to −19) versus the next 17 residues (−18 to −3). The N-
terminal portion was bound by TbtF with near wild-type affinity while the C-terminal half showed no 
binding (Figure 3.14). Additionally, the RRE of TbtF (residues 1-85) retained most of the binding affinity 
(Kd ~100 nM) whereas the TbtF protein lacking the RRE (residues 86-628) did not detectably interact with 
FITC-TbtALP (Figure 3.15).  
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Having characterized the substrate handling behavior of TbtEFG, we next evaluated the TbtBC-
catalyzed dehydration reaction (Figure 3.1A). Dehydration is a two-step process in which TbtB first 
glutamylates a targeted Ser hydroxyl of TbtA; subsequently, TbtC eliminates the glutamate to yield the 
alkene. We showed that dehydrations take place at positions 1/11/13/14 of the hexazole 2.6 To determine if 
a thiazoline-bearing TbtA would be accepted as a TbtBC substrate, the dehydrogenase component (TbtE) 
of the thiazole synthetase was omitted from reactions with TbtA. These reactions cleanly produced the 
expected hexazoline of TbtA, which upon reaction with TbtBC, resulted in at most two dehydrations (Figure 
3.16). These data show that although TbtFG do not require TbtE for activity, the hexazoline-containing 
TbtA is incompletely processed by TbtBC.  
We next used the TbtA hexazole 2 as substrate for TbtB in the absence of TbtC, which resulted in 
mostly one glutamylation event.6 Analysis by ESI MS/MS localized the glutamate to Ser14 (Figure 3.3). 
Similarly, assays that included both TbtB and TbtC that were quenched prior to full tetradehydration 
showed that Ser13/14 were dehydrated significantly faster than Ser1/11 (Figure 3.17). Thus, TbtBC prefer 
to modify the two isolated Ser residues over those adjacent to a thiazole where the Ser carbonyl group has 
been removed (Figure 3.1A). Alternatively, since dehydration of Ser1/11 sets up the [4+2] cycloaddition 
reaction, which we previously showed to be very efficient,6 TbtB may have evolved an increased level of 
substrate specificity at these positions, such that dehydration at Ser13/14 is a prerequisite for dehydration 
at Ser1/11. 
We next focused on the glutamate elimination step. TbtC is homologous to the C-terminal domain 
of LanB proteins, which exhibit reduced activity upon mutation of a conserved Arg.16 Therefore, we 
replaced this residue in TbtC with Ala (R58A), and carried out reactions with 2. Mass spectral analysis 
showed a tridehydrated and monoglutamylated intermediate, with the latter localized to position 1 (Figure 
3.18). Thus, Ser1 is acted on last, and glutamylation (and hence dehydration) progresses in a C-to-N 
terminal direction. 
These enzymatic preferences do not inform on whether earlier dehydrations are important for 
subsequent ones. Therefore, a series of TbtA variants were again investigated. Hexazole-bearing TbtA-
S13A and -S14A each were dehydrated predominantly twice by TbtBC, with Ser1/11 largely escaping 
dehydration (Figures 3.18-3.19). This observation suggests that dehydration at Ser1/11 is strongly promoted 
by prior dehydration at Ser13/14. In contrast, similarly treated hexazole-bearing TbtA-S1A and -S11A 
peptides each resulted in a tridehydrated product, underscoring that dehydration at Ser1/11 is not important 
for TbtBC to process Ser13/S14 (Figures 3.20-3.21). These data are consistent with C-to-N terminal 
dehydration. 
Given the comparatively weak interaction between TbtALP and TbtB (~100-fold weaker than TbtF 
and D), we next investigated whether TbtBC might act in a LP independent fashion. Peptide 2 was digested 
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with endoproteinase GluC, providing a hexazole core peptide that retains only three residues of the LP 
(Figure 3.1).6 Upon treatment with TbtBC, this peptide was tetradehydrated (Figure 3.4), in accord with the 
abovementioned weak binding to TbtALP (Kd ~20 µM). Strikingly, the affinity of TbtB towards FITC-
labeled 2 was nearly three orders of magnitude tighter (Kd ~30 nM, Figure 3.10). GluC-digested 2 also 
effectively competed for TbtB binding to FITC-labeled 2. These data demonstrate that the PqqD-like 
domain of TbtB is a non-functioning, vestigial RRE and that TbtB recognizes a specific conformation of 
the core peptide of TbtA induced by the posttranslational modifications. Ungapped sequence conservation 
analysis confirms that the defunct RRE of TbtB does not contain conserved motifs, whereas the RRE of 
TbtF contains several, including locations known to physically contact the LP (Figures 3.22-3.23).8,9,16,17 
Motif conservation analysis was also performed on TbtD, revealing two polybasic regions potentially 
involved in RRE-independent LP binding (Figure 3.24). 
The molecular details of the posttranslational modifications that confer TbtBC activity were next 
investigated using the aforementioned panel of TbtA variants that systematically replaced Cys with Ala 
starting from the C- or N-terminus (Figures 3.7 and 3.8). Each pan-thiazole version of these TbtA variants 
was tested as a substrate for TbtBC. Substituting Cys2 and Cys4 with Ala, yielding the corresponding 
pentazole and tetrazole species, did not greatly affect dehydration at Ser13/14; however, dehydration at 
Ser11, and especially Ser1, was reduced (Figures 3.5A-B and 3.25). Triple replacement of Cys with Ala at 
positions 2/4/6 (triazole species) abolished dehydration at positions 1/11, but again, Ser13/14 underwent 
dehydration (Figures 3.5C and 3.26). A similar trend was observed for tetra- and penta-substituted TbtA 
variants (diazole and monoazole species, respectively, Figures 5D-E, and S21). These data suggest that a 
thiazole at position 12 might be the gatekeeper modification to render TbtA a substrate for TbtB. However, 
the TbtA-C12A pentazole was still dehydrated twice at Ser13/14 (Figure 3.5F and 3.25B). Conversely, 
replacement of both Cys10/12 with Ala (tetrazole species) abolished processing by TbtBC and the Cys10 
TbtA monoazole was also not a substrate (Figure 3.27-3.28). Hence, it is a thiazole at Cys10 that is the 
gatekeeper modification to elicit TbtBC activity. 
Lastly, we investigated the substrate requirements of TbtD. Since many of the Cys variants 
precluded dehydration at positions 1/11, which are required for the [4+2] cycloaddition reaction, we focused 
on further defining the requirements of the leader peptide. We previously reported that treatment of TbtA 
hexazole tetradehydrate 3 with GluC, which removes all but three residues of LP,  resulted in loss of TbtD 
activity.6 In this work, we tested if retaining a larger portion of the LP would still be processed by TbtD. 
Thus, we treated 3 with endoproteinase AspN, retaining 20 residues of the LP, and found that TbtD accepted 
this peptide as a substrate for the [4+2] cycloaddition reaction (Figure 3.29). To further delineate which 
portion of the TbtA LP was required for TbtD activity, we next tested a TbtA variant where Glu(−4) was 
substituted with Ala. This variant was efficiently converted to the hexazole tetradehyrate species, analogous 
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to 3, after reaction with TbtEFG and TbtBC. We then treated this peptide with GluC, which owing to the 
E(-4)A substitution, now retained 13 residues of the LP. This variant was also a substrate for TbtD (Figure 
3.30), demonstrating that the minimal LP requirement of TbtD is between TbtA residues (-13) and (-3), 
consistent with a very recent report. These findings may appear to contradict the binding data in Table 3.1, 
but it is important to note that the binding experiments were performed with linear TbtA variants whereas 
the TbtD activity experiments with truncated TbtA variants were performed with cyclodehydrated and 
dehydrated core peptide. We hypothesize that TbtD recognizes both the aforementioned N-terminal 
residues of the LP and the posttranslationally modified core peptide. At present, we cannot readily measure 
the latter since the enzyme rapidly processes 3. 
In summary, this work presents the first insights into the substrate specificities, directionality, and 
timing of catalysis by six proteins involved in thiopeptide formation. The TbtEFG enzymes that convert 
Cys into thiazoles are remarkably substrate tolerant, and their specificity is governed only by the presence 
of the LP. Leu(−29) of TbtA was found to be the most critical residue for binding by the RRE-containing 
TbtF protein. The order of thiazole formation is unusual in that it is neither N-to-C nor C-to-N directional. 
Conversely, the subsequent four dehydrations installed by TbtBC are LP-independent and installed in a 
strict C-to-N fashion. TbtBC appear to recognize a specific conformation introduced into the TbtA core 
peptide, imparted by thiazole formation at Cys10. Despite the conformation-restricting nature of peptidic 
cyclodehydration, a hexathiazoline-containing TbtA peptide is an incompetent substrate for TbtBC. Akin 
to thiazole formation, the [4+2] cycloaddition reaction is also LP-dependent with Leu(−29) again important 
for LP binding, in addition to several acidic residues. Despite requiring particular residues found within the 
N-terminal portion of the LP, TbtD also requires C-terminal LP residues, which we have narrowed down 
to between positions (-13) and (-3).  The data reported here define the substrate scope for the in vitro 
biosynthesis of thiomuracin and will guide future bioengineering efforts to improve the pharmacological 
properties of the thiopeptide class of natural products. 
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3.4 Methods 
3.4.1 General materials and methods  
Reagents used for molecular biology experiments were purchased from New England BioLabs 
(Ipswich, MA), Thermo Fisher Scientific (Waltham, MA), or Gold Biotechnology Inc. (St. Louis, MO). 
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Other chemicals were purchased from Sigma-Aldrich (St. Louis, MO). Escherichia coli DH5α and 
BL21(DE3) strains were used for plasmid maintenance and protein overexpression, respectively. Plasmid 
inserts were sequenced at ACGT Inc. (Wheeling, IL). MALDI-TOF-MS analysis was performed using a 
Bruker UltrafleXtreme MALDI TOF-TOF mass spectrometer (Bruker Daltonics) in reflector positive mode 
at the University of Illinois School of Chemical Sciences Mass Spectrometry Laboratory. ESI-MS/MS 
analyses were performed using a SYNAPT ESI quadrupole TOF Mass Spectrometry System (Waters) 
equipped with an ACQUITY Ultra Performance Liquid Chromatography (UPLC) system (Waters). HiTrap 
columns for Ni-NTA affinity chromatography were purchased from GE Healthcare.  
 
3.4.2 Molecular biology techniques  
Oligonucleotides were purchased from Integrated DNA Technologies Inc. (Coralville, IA). Primers 
for T. bispora tRNAGlu were designed and the dsDNA template for in vitro transcription was prepared as 
previously described.18 Genes optimized for recombinant expression in Escherichia coli were synthesized 
by GenScript (Piscataway, NJ) as previously described.6 Site-directed mutagenesis on TbtA was performed 
using the QuikChange method (Agilent) as per the manufacturer’s instructions using PfuTurbo DNA 
polymerase. The primers for each mutant are listed in Table 3.2. The mutations were verified by sequencing 
using the forward primer or the T7 reverse primer. 
 
3.4.3 MBP-tagged peptide and enzyme overexpression and purification  
MBP-tagged precursor peptides and biosynthetic proteins were prepared as previously described.6 
Purity and possible truncation were assessed by Coomassie-stained SDS-PAGE gel (Figure 3.6).  
 
3.4.4 Expression, and purification of His6-tagged peptides and proteins  
His6-tagged peptides and proteins were prepared as previously described.2 
 
3.4.5 Cyclodehydration of TbtA precursor peptide  
Thiazole installation on TbtA precursor peptides was carried out as previously described.6 
Reactions were visualized using MALDI-TOF-MS.  
 
3.4.6 Determination of cyclodehydration order by TbtG  
Thiazole installation was carried out with 100 μM MBP-tagged TbtA and 10 μM of MBP-tagged 
biosynthetic enzymes (TbtE, TbtF, and TbtG) in synthetase buffer with 250 μM TEV protease prior to being 
quenched with 6 mM iodoacetamide at 5, 10, and 15 minute time points and allowed to alkylate for 2 h at 
25 °C. Contaminating MBP and enzymes were removed by applying the samples to 1 mL of Ni-NTA resin 
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(Qiagen) equilibrated with 50 mM Tris-HCl pH 8.0, 150 mM NaCl. The flow-through was collected, and 
the column was subsequently washed with 2 mL of wash buffer (50 mM Tris-HCl pH 8.0, 1 M NaCl, 75 
mM imidazole). The Ni-NTA-treated samples were then proteolytically digested with GluC endoproteinase 
(Roche) at a concentration of 0.02 mg/mL for 16 h at 25 °C prior to being lyophilized. The lyophilized 
mixtures were then reconstituted in 200 μL of 20% aq. MeCN and centrifuged to remove insoluble material 
(16,000 × g, 15 min, 25 °C) prior to MS/MS analysis by LC-MS.  
 
3.4.7 In vitro dehydration of TbtA mutants 
The following reaction conditions were used for dehydration assays: HEPES pH 7.5 (100 mM), 
MgCl2 (5 mM), KCl (150 mM), glutamate (10 mM), ATP (5 mM), TbtA hexazole (50 μM), T. bispora 
tRNAGlu (10 μM), E. coli GluRS (10 μM), TbtB (5 μM), TbtC (5 μM), and thermostable inorganic 
pyrophosphatase (TIPP; 0.02 U μL–1) in a final volume of 25 μL. The reaction mixture was incubated at 30 
°C for 1.5 h, centrifuged to remove insoluble material (14,000 × g, 5 min, 25 °C), and desalted using C18 
ZipTips (EMD Millipore). The sample was mixed in a 1:1 ratio with 2,5-dihydroxybenzoic acid matrix, 
spotted on a Bruker MALDI plate, and analyzed by MALDI-TOF-MS. 
 
3.4.8 Construction of the in vivo cyclodehydration system 
The genes coding for the MBP-tagged TbtF, MBP-tagged cyclodehydratase TbtG and 
dehydrogenase TbtE were amplified by PCR using appropriate primers (Table 3.2), and purified by gel 
extraction from a 1% (w/v) agarose gel using the QIAquick Gel Extraction Kit. The vector pTrc99 was 
digested using NcoI-HF and SalI-HF (NEB) restriction endonucleases, and purified by gel extraction as 
described above. The DNA fragment was inserted by Gibson one-step isothermal DNA assembly, and an 
aliquot of 20 μL of the Gibson assembly reaction was used to transform E. coli DH5α cells using the heat 
shock method. The cells were plated on LB plates supplemented with ampicillin (100 μg/mL) and the plates 
were incubated at 37 °C for 12–15 h. Single colonies were picked and grown in LB supplemented with 
ampicillin (100 μg/mL) at 37 °C for 12–15 h and the plasmid pTrc99-MBPTbtF-MBPTbtG-TbtE was 
isolated using a QIA prep Spin Miniprep Kit. Insert integrity was verified by sequencing the plasmids with 
the appropriate primers (Table 3.2).  
 
3.4.9 In vivo cyclodehydration and purification of progressive N- to C-terminal Cys to Ala 
substitutions of TbtA 
E. coli BL21(DE3) cells were co-transformed with a pTrc99 plasmid encoding the MBP-tagged 
TbtF,  MBP-tagged TbtG, and TbtE and a pRSF-Duet plasmid encoding the His6-TbtA mutant peptide of 
interest. Cells were grown for 16 h on LB agar plates containing 25 μg/mL kanamycin and 50 μg/mL 
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ampicillin at 37 °C. Single colonies were used to inoculate LB containing 25 μg/mL kanamycin and 50 
μg/mL ampicillin and the cells were grown at 37 °C for 16 h. This culture was used for 1:100 inoculation 
into Terrific Broth (24 g/L yeast extract, 12 g/L tryptone, 0.4% glycerol (v/v), 17 mM KH2PO4, and 72 mM 
K2HPO4) and grown at 37 °C to an optical density at 600 nm (OD600) of 0.6 before being placed on ice for 
20 min. Production of thiazole-installed TbtA mutant peptides was then induced with the addition of 0.5 
mM isopropyl β-D-1-thiogalactopyranoside (IPTG). The expression was allowed to proceed for 16-18 h at 
18 °C. Cells were harvested by centrifugation at 5,000 × g for 15 min. Cell pellets were resuspended in 
LanA start buffer (20 mM Na2HPO4, 150 mM NaCl, 20% glycerol, pH 7.5). Cells were further homogenized 
by sonication (50% amplitude, pulse on: 2.0 s, pulse off: 5.0 s, total pulse time: 5 min). Insoluble debris 
was removed by centrifugation at 13000 × g for 30 min and the supernatant was then applied to Ni resin 
pre-equilibrated with LanA start buffer. The column was washed with 20 column volumes (CV) of LanA 
washing buffer (20 mM Na2HPO4, 30 mM imidazole, 300 mM NaCl, pH 7.5). The thiazole-installed TbtA 
mutant peptides were eluted with elute buffer (20 mM Na2HPO4, 500 mM imidazole, 100 mM NaCl, pH 
7.5). The combined eluted fractions were dialyzed with buffer (20 mM HEPES, 150 mM KCl, pH 7.5) to 
remove imidazole, and the supernatant was purified on a Shimadzu Prominence Preparative Liquid 
Chromatography system equipped with a Phenomenex Luna C18 column (250 × 10 mm, 10 μm particle 
size, 100 Å pore size). Acetonitrile and 10 mM aq. NH4HCO3 were used as the mobile phases, and a gradient 
of 2-80% aq. MeCN over 45 min at 1 mL/min was used for separation. 
 
3.4.10 HPLC Purification of TbtA-hexazole core peptide 
HPLC-purified TbtA-hexazole (compound 2) was dissolved in 50 mM Tris-HCl (pH 7.5) to a final 
concentration of 100 M. GluC endoproteinase was added to a concentration of 0.02 mg/mL, and the 
reaction mixture was incubated at 37 °C for 1 h, followed by addition of MeCN to 20% (v/v) and TFA to 
2% (v/v) to precipitate proteins. The insoluble material was removed by centrifugation at 16,100 × g for 10 
min, and the supernatant was purified on an Agilent 1260 Infinity HPLC system with a Phenomenex Luna 
C18 column (250 × 4.6 mm, 10 μm particle size, 100 Å pore size). Acetonitrile and 10 mM NH4HCO3 were 
used as the mobile phases, and a gradient of 2–80% aq. MeCN over 45 min at 1 mL/min was used for 
separation. TbtA-hexazole core eluted at 38-40% MeCN. 
 
3.4.11 UPLC-MS and MS/MS of TbtA mutants 
GluC endoproteinase was added to a concentration of 0.02 mg/mL to His6-TbtA variants after 
treatment by TbtEFG and dehydration by TbtBC to remove the N-terminal leader peptide. After 30 min of 
incubation at 37 °C, MeCN was added to 20% (v/v), followed by addition of TFA to 2% (v/v) to precipitate 
proteins. The insoluble material was removed by centrifugation at 16,100 × g for 10 min, and the 
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supernatant was used for analysis. LC-MS was performed using a Waters SYNAPT mass spectrometer 
outfitted with an ACQUITY UPLC, an ACQUITY Bridged Ethyl Hybrid C8 column (2.1 × 50 mm, 1.7 μm 
particle size, 200 Å; Waters), an ESI ion source, and a quadruple TOF detector. A gradient of 2–100% aq. 
MeCN with 0.1% formic acid (v/v) over 20 min was used. A ramping of cone voltage of 20-25 kV during 
the scan was performed to generate peptide fragments for MS/MS analysis.  
 
3.4.12 Labeling of TbtA hexazole (2) with fluorescein isothiocyanate (FITC) 
HPLC purified TbtA hexazole (2) was dissolved in PBS buffer (pH 8.0) to a final concentration of 
50 M. Fluorescein isothiocyanate (FITC; Sigma-Aldrich) was dissolved in a 10 mg/mL DMSO stock and 
was added drop wise to the reaction (add a drop or two and vortex, repeat until done to prevent any type of 
localized precipitation) to a final concentration of 250 μM. Labeling was allowed to proceed for 18 h at 25 
°C, and then the reaction mixture was lyophilized. The residue was extracted with 20% aq. MeCN. The 
insoluble material was removed by centrifugation at 16,100 × g for 10 min, and the supernatant was purified 
on an Agilent 1260 Infinity HPLC system with a Phenomenex Luna C18 column (250 × 4.6 mm, 10 μm 
particle size, 100 Å pore size). Acetonitrile and 10 mM NH4HCO3 were used as the mobile phases, and a 
gradient of 2–80% aq. MeCN over 45 min at 1 mL/min was used for separation. FITC labeled TbtA-
hexazole was eluted at 30-31% MeCN. 
 
3.4.13 Fluorescence polarization (FP) binding assay 
The interaction between fluorescently labeled peptides and TbtF, TbtB and TbtD was quantified 
using an FP assay. To maximize the polarization signal, all proteins remained MBP tagged. In general, 
protein was serially diluted into binding buffer (50 mM HEPES, pH 7.5, 300 mM NaCl, 2.5% (v/v) glycerol, 
0.5 mM TCEP) and mixed with 25 nM of the appropriate FITC labeled peptides. Binding assays were 
carried out in nonbinding-surface, 384-black-well polystyrene microplates (Corning) and measured using 
a Synergy H4 Hybrid plate reader (BioTek) with λex = 485 nm and λem = 538 nm and data were recorded 
with Gen5 software. Prior to measurement, the dilutions were equilibrated with shaking for 30 min at 25 
°C. Dissociation constant (Kd) values were calculated from the 50% saturation point using a dose-response 
curve fit in Origin Pro 9.1 (OriginLab) with three independent titrations. Background fluorescence from the 
proteins alone was subtracted from the fluorescence polarization signal obtained with the fluorophore. 
 
3.4.14 Competition FP binding assay 
In general, 300 nM protein was mixed with 25 nM of the appropriate FITC-labeled peptide in 
binding buffer. MBP-tagged peptides for FP studies with TbtF and TbtD were first cleaved by TEV protease 
at 1:10 loading for 30 minutes prior to serial dilution. The peptides were serially diluted into binding buffer. 
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Binding assays were carried out on the same instrument and analyzed with the same software as above. IC50 
values were calculated from the 50% saturation point using a dose-response curve fit in Origin Pro 9.1 
(OriginLab) with three independent titrations. Kd values for unlabeled ligands were calculated using the 
following equation: 
 
Kd = IC50 / (1 + [L] / Kd,labeled) 
 
 Where: 
Kd  = Dissociation constant for the unlabeled peptide  
[L] = Concentration of labeled peptide  
Kd,labeled = Dissociation constant for the labeled peptide 
 
3.4.15 Thiopeptide dataset assembly 
Profile hidden Markov models (pHMMs) for six kinds of thiopeptide biosynthetic proteins (YcaO 
cyclodehydratase, dehydrogenase, [4+2] cycloaddition enzyme, large and small component of split LanB 
dehydratase, and ThiF-like protein) were generated using HMMER3 from alignments of known thiopeptide 
biosynthetic proteins present in the ThioBase and MIBiG databases.19,20 Potential thiopeptide 
cyclodehydratases were identified via a BLASTP search of the GenBank nr protein database using known 
thiopeptide cyclodehydratases as queries.21 The local genomic regions of the search results were annotated 
for the presence of the above thiopeptide pHMMs and potential precursor peptides using HMMER3 via the 
custom bioinformatic program RODEO (http://www.ripprodeo.org).22,23 Likely thiopeptide biosynthetic 
gene clusters (BGCs) were considered those having at least 5 of the above pHMMs, or at a minimum 4 
including the [4+2] cycloaddition enzyme. Each BGC was manually inspected for the presence of small 
ORFs (<100 aa) resembling thiopeptide precursor peptides. The final data set included 176 thiopeptide 
BGCs and 227 thiopeptide precursor peptides. 
 
3.4.16 Motif analysis 
Ungapped sequence motifs in precursor peptide, F protein, D protein, and B protein sequences were 
determined using MEME.24 For precursors, the parameters “-nmotifs 16 -mod zoops -minsites 80 -maxw 
15” were used. For F, D, and B proteins, the parameters “-nmotifs 16 -mod zoops” were used. The presence 
of sequence motifs within each sequence was determined using FIMO on default settings; an E-value 
threshold of 10-5 was employed.24,25 Motifs present in >70% of thiopeptide precursor peptides were retained. 
Sequence logos were generated upon MEME analysis. 
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3.5 Figures 
 
Figure 3.1 Thiomuracin biosynthesis. (A) Enzymatic route to the thiomuracin core scaffold 4. (B) 
Thiomuracin biosynthetic gene cluster. RRE, RiPP recognition element. LP, leader peptide. 
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Figure 3.2 Tandem MS analysis of intermediates intercepted from TbtEFG reactions. (A) monoazole, (B) 
diazole, and (C) triazole. Predicted masses and associated errors are in Table 3.3. 
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Figure 3.3 MS/MS of monoglutamylated 2. The b15 ion localizes glutamylation to either 
Ser13/14. The low intensity y2 ion supports Ser14 glutamylation. Predicted masses and associated 
errors are in Table 3.3. 
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Figure 3.4 MALDI-TOF mass spectra of (A) the TbtA core peptide containing six thiazoles and 
(B) treated with TbtBC. 
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Figure 3.5 MALDI-TOF mass spectra of (A) TbtA C2A pentazole, (B) TbtA C2A/C4A tetrazole, 
(C) TbtA C2A/C4A/C6A triazole, (D) TbtA C2A/C4A/C6A/C9A diazole, (E) TbtA 
C2A/C4A/C6A/C9A/C10A monoazole, and (F) TbtA C12A pentazole, treated with TbtBC. 
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Figure 3.6 SDS-PAGE analysis of proteins used in this study. All displayed proteins were expressed as 
N-terminal MBP fusions; the minor impurity found at ~45 kDa is the result of endogenous protease activity 
on the MBP fusion proteins. Cleavage occurs in the linker region between MBP and the protein of interest. 
Enrichment occurs due to the use of amylose resin for affinity purification. 
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SRRRGSMDLNDLPMDVFELADSGVAVESLTAGHGMTEVGA*SCNCFCYICCSCSSA 
 
 
Figure 3.7 Cyclodehydration of progressive C- to N-terminal Cys to Ala substitution in TbtA. The 
thiomuracin heterocycle synthetase (TbtEFG) tolerates progressive substitution of Cys residues to Ala. In 
the set of peptides shown here, Cys replacement starts from the C-terminus and progresses towards the N-
terminus. Enzymatic activity was visualized by MALDI-TOF-MS. With the exception of C12A/C10A 
(double substitution, green spectra) and C12A/C10A/C9A (triple substitution, purple spectra), all substrates 
were fully converted to the pan-thiazole species by TbtEFG. 
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PHHHHHHSQVDLNDLPMDVFELADSGVAVESLTAGHGMTEVGA*SCNCFCYICCSCSSA 
 
Figure 3.8 Cyclodehydration of progressive N- to C-terminal Cys to Ala substitution in TbtA. The 
thiomuracin heterocycle synthetase (TbtEFG) tolerates progressive substitution of Cys residues to Ala. In 
the set of peptides shown here, Cys replacement starts from the N-terminus and progresses towards the C-
terminus. The His6-TbtA precursor peptide variants were co-expressed with TbtEFG in E. coli. Purified 
peptides and intermediates were visualized by MALDI-TOF-MS.  
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TbtA core peptide sequence: SCNCFCYICCSCSSA 
 
 
 
Figure 3.9 Cyclodehydration of single-Cys TbtA variants. The thiomuracin heterocycle synthetase 
(TbtEFG) readily installs single thiazoles at each naturally-occurring location in TbtA (positions 2, 4, 6, 9, 
10, and 12) as visualized by MALDI-TOF-MS. Each TbtA variant for this experiment harbored only one 
Cys residue (all others were replaced with Ala).  
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Figure 3.10 Fluorescence polarization analysis of TbtB binding to the TbtA leader peptide, hexazole, 
and core peptide. TbtB shows considerably greater affinity for the hexazole-containing core peptide of 
TbtA than the leader peptide. (A) Fluorescence polarization (FP) binding experiments performed using N-
terminal FITC-labeled TbtA leader peptide and MBP-TbtB. (B) FP binding experiments performed using 
N-terminal FITC-labeled TbtA hexazole (2) and MBP-TbtB (thiazole installation increases affinity by 630 
fold). (C) FITC-labeled (2) displacement from MBP-TbtB by the hexazole-containing core peptide of TbtA 
(GluC digestion retains 3 residues of leader peptide). Error bars represent s.d. (n=3). Errors on Kd and IC50 
values are the standard error of the mean (s.e.m.) given by regression analysis.  
  
88 
 
Figure 3.11 Fluorescence polarization analysis of binding of TbtD to the TbtA leader peptide. TbtD 
engages the leader peptide of TbtA with nanomolar affinity as determined by fluorescence polarization. 
Error bars represent standard deviation (s.d.) of three independent replicates. Errors on Kd values are the 
standard error of the mean (s.e.m.) given by regression analysis. 
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Figure 3.12 (cont.) 
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Figure 3.12 (cont.) 
91 
 
Figure 3.12 (cont.) 
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Figure 3.12 Competitive binding of TbtA leader peptide variants to TbtF. Competitive fluorescence 
polarization traces for wild-type (wt) TbtA and TbtA variants. These peptides were titrated against TbtF 
(300 nM) complexed with FITC-labeled TbtA leader peptide (25 nM). Error bars represent standard 
deviation (s.d.) of three independent replicates. Errors on IC50 and Kd values are the standard error of the 
mean (s.e.m.) given by regression analysis.  
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Figure 3.13 (cont.) 
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Figure 3.13 (cont.) 
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Figure 3.13 (cont.) 
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Figure 3.13 Competitive binding of TbtA leader peptide variants to TbtD. Competitive fluorescence 
polarization traces for wild-type (wt) TbtA and TbtA variants. These peptides were titrated against TbtD 
complexed with FITC-labeled TbtA leader peptide. Error bars represent standard deviation (s.d.) of three 
independent replicates. Errors on IC50 and Kd values are the standard error of the mean (s.e.m.) given by 
regression analysis.  
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Figure 3.14 TbtF binds the first 16 residues of TbtA. The first 16 residues of the TbtA leader peptide 
(LP) are necessary and sufficient for recognition by TbtF. Using competitive fluorescence polarization, 
FITC-labeled TbtA LP was displaced from TbtF by the N-terminal 16-mer of the TbtA LP while the C-
terminal 17-mer demonstrated no detectable competitive binding activity. Error bars represent standard 
deviation (s.d.) of three independent replicates. Errors on IC50 and Kd values are the standard error of the 
mean (s.e.m.) given by regression analysis.  
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Figure 3.15 The RRE of TbtF is necessary and sufficient for binding TbtA. The TbtF RiPP recognition 
element (RRE), spanning the first 85 residues of TbtF, is necessary and sufficient for binding the leader 
peptide (LP) of TbtA. TbtF lacking the RRE (86-628) demonstrated no detectable affinity for the TbtA 
leader peptide. Error bars represent standard deviation (s.d.) of three independent replicates. Errors on Kd 
values are the standard error of the mean (s.e.m.) given by regression analysis. 
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TbtA: SRRRGSMDLNDLPMDVFELADSGVAVESLTAGHGMTEVGA*SCNCFCYICCSCSSA (1) 
 
 
Figure 3.16 Hexathiazoline TbtA is incompletely processed by TbtBC. MALDI-TOF mass spectra of 
(A) TEV-treated MBP-TbtA precursor peptide, (B) TbtA cyclodehydrated by TbtFG to yield a 
hexathiazoline species (indicated on the primary sequence in brown), and (C) the hexathiazoline treated 
with TbtBC to yield predominately a didehydrated species indicating the hexathiazoline version of TbtA is 
not a competent biosynthetic intermediate.  
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Figure 3.17 ESI-MS/MS analysis of dehydration intermediates of the TbtA hexazole. (A) Analysis of 
the tandem MS data for the monodehydrated, TbtA hexathiazole reveals that Ser14 is the first position to 
undergo dehydration by TbtBC. (B) Analogous analysis of the didehydrated hexathiazole shows that Ser13 
is the second residue to be processed by TbtBC. 
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His6-TbtA: PHHHHHHSQVDLNDLPMDVFELADSGVAVESLTAGHGMTEVGA*SCNCFCYICCSCSSA 
 
Figure 3.18 MS analysis of monoglutamylated and tridehydrated intermediate. MS analysis of 
reactions of 2 with TbtBC showed an intermediate carrying three dehydrations and one glutamylation, with 
the latter localized to position Ser1. (A) MALDI-TOF MS of 2 treated with TbtB and TbtC-R58A. 
Replacement of R58 in homologous dehydratases decreases catalytic efficiency.16 (B) ESI tandem MS and 
structure of the tridehydrated and monoglutamylated TbtA hexazole. 
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His6-TbtA S13A: 
PHHHHHHSQVDLNDLPMDVFELADSGVAVESLTAGHGMTEVGA*SCNCFCYICCSCASA 
His6-TbtA S14A: 
PHHHHHHSQVDLNDLPMDVFELADSGVAVESLTAGHGMTEVGA*SCNCFCYICCSCSAA 
 
 
Figure 3.19 Ser13 and Ser14 are important for dehydration at Ser1/11. (A) MALDI-TOF-MS spectrum 
of the TbtA hexazole with replacement of Ser13 with Ala (indicated with red in the primary sequence). (B) 
Treatment of TbtA hexazole S13A with TbtBC resulted only in didehydration instead of tridehydration. 
(C) MALDI-TOF-MS spectrum of TbtA hexazole with replacement of Ser14 with Ala. (D) Treatment of 
TbtA hexazole S14A with TbtBC also resulted in incomplete dehydration. 
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Figure 3.20 ESI-MS/MS analysis of didehydrated intermediate of (A) TbtA S13A hexazole and (B) 
TbtA S14A hexazole. The fragment ions show that Ser11 escapes dehydration when the Ser13 or Ser14 
are mutated and cannot be dehydrated. 
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His6-TbtA S1A:   
PHHHHHHSQVDLNDLPMDVFELADSGVAVESLTAGHGMTEVGA*ACNCFCYICCSCSSA 
His6-TbtA S11A: 
PHHHHHHSQVDLNDLPMDVFELADSGVAVESLTAGHGMTEVGA*SCNCFCYICCACSSA 
 
 
Figure 3.21 Ser1 and Ser11 are dispensable for dehydration at Ser13/14. (A) MALDI-TOF-MS 
spectrum of TbtA hexazole S1A (indicated in red in the primary sequence). (B) Upon treatment with TbtBC, 
the TbtA hexazole S1A is tridehydrated. (C) MALDI-TOF-MS spectrum of TbtA hexazole S11A. (D) After 
TbtBC treatment, TbtA hexazole S11A also undergoes tridehydration. These results stand in stark contrast 
to a parallel experiment with mutants of Ser13 and Ser 14 (Figure 3.20). 
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Figure 3.22 Sequence motif analysis of TbtA and TbtF homologs. (A) Sequence of the thiomuracin 
precursor peptide TbtA with two prevalent leader peptide sequence motifs shown with in logo form. 
Residues in bold indicate amino acids that match the most commonly found residue in the sequence motif. 
Circles below the diagram indicate residues that were substituted to Ala in this study and evaluated for 
binding. Closed circles indicated substantial disruption of binding to TbtF (red, top) or TbtD (purple, 
bottom) upon Ala substitution. (B) Diagram of TbtF (F protein) with sites of conserved sequence motifs 
indicated in dark grey. The PqqD homology domain (RRE, RiPP recognition element) is indicated in light 
grey and as an expansion with secondary structure predictions given as described by Burkhart et al.8 
Frequencies of sequence motifs within TbtF homologs are indicated. Note there are three conserved motifs 
within the RRE, with motif F3 appearing in the third alpha helix that has been linked directly to leader 
peptide binding in a number of studies.16,26 (C) Sequence of TbtF with motif locations highlighted in yellow. 
Residues in bold indicate amino acids that match the most commonly found residue in the sequence motif. 
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Figure 3.23 Sequence motif analysis of TbtB homologs. (A) Diagram of TbtB (part of the split LanB 
dehydratase) with sites of conserved sequence motifs indicated in dark grey. Frequencies of sequence motifs 
within TbtB homologs are indicated. The region of PqqD homology (RRE, RiPP recognition element) as 
described by Burkhart et al.8 is indicated in light grey. Note that the RRE of TbtB does not contain any 
conserved motifs, which is strikingly opposite to that found for TbtF (Figure S19). (B) Sequence of TbtB 
with motif locations highlighted in yellow. Residues in bold indicate amino acids that match the most 
commonly found residue across the thiopeptide family. 
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Figure 3.24 Sequence motif analysis of TbtD homologs. (A) Diagram of TbtD, the [4+2] cycloaddition 
enzyme, with sites of conserved sequence motifs indicated in dark grey. Frequencies of sequence motifs 
within TbtD homologs are indicated. Note that although TbtD binds the TbtA leader peptide with 
nanomolar affinity, it does not contain a recognizable region of homology to PqqD (RRE, RiPP recognition 
element). (B) Sequence of TbtD with motif locations highlighted in yellow. Residues in bold indicate amino 
acids in the corresponding TbtD sequence that match the most commonly found residue in the sequence 
motif. 
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Figure 3.25 ESI-MS/MS analysis of tridehydrated TbtA C2A/C4A tetrazole and didehydrated C12A 
pentazole. (A) The data show that substituting Cys2 and Cys4 with Ala dramatically reduces dehydration 
especially at Ser1, but not at Ser13/14. (B) Substitution of Cys12 with Ala results only in didehydration at 
Ser13/Ser14.  
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Figure 3.26 ESI-MS/MS analysis of (A) didehydrated TbtA C2A/C4A/C6A triazole and (B) 
didehydrated TbtA C2A/C4A/C6A/C9A/C10A monoazole. Dehydration at Ser1 and Ser11 was 
abolished, but Ser13/14 were still dehydrated. 
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TbtA C10,12A: SRRRGSMDLNDLPMDVFELADSGVAVESLTAGHGMTEVGA*SCNCFCYICASASSA  
 
 
Figure 3.27 TbtBC requires thiazole formation at Cys10 and Cys12. (A) MALDI-TOF MS spectrum 
of TbtA with Cys10 and Cys12 both replaced with Ala (indicated in red in the primary sequence). (B) 
Reaction of TbtA C10A/C12A with TbtEFG results in the nearly complete production of the expected 
tetrazole species. (C) Reaction of the TbtA C10A/C12A tetrazole with TbtBC does not result in observable 
dehydration. 
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Single Cys TbtA C10: SRRRGSMDLNDLPMDVFELADSGVAVESLTAGHGMTEVGA*SANAFAYIACSASSA  
 
7 
 
Figure 3.28 TbtBC cannot dehydrate Cys10 monoazole. (A) MALDI-TOF MS spectrum of TbtA bearing 
only one Cys at residue 10. (B) Reaction of single Cys TbtA (Cys10) with TbtEFG results in complete 
conversion to the monoazole species. (C) Reaction of the single Cys TbtA (Cys10) monoazole with TbtBC 
does not result in observable dehydration. We conclude that a thiazole at Cys10 is the minimal requirement 
for TbtBC activity. 
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AspN TbtA hexazole tetradehydrate: DSGVAVESLTAGHGMTEVGA*SCNCFCYICCSCSSA 
 
 
 
Figure 3.29 TbtD tolerates AspN-treated TbtA hexazole tetradehydrate as a substrate. (A) MALDI-
TOF MS spectrum of endoproteinase AspN-digested TbtA hexazole tetradehydrate (Calcd [M+H]+ 3271). 
(B) Reaction of AspN-digested TbtA hexazole tetradehydrate with TbtD results in the formation of 
thiomuracin core (calcd. [M+H]+ 1366) and the ejected leader peptide (calcd. [M+H]+ 1887). 
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GluC TbtA E(-4)A hexazole tetradehydrate: SLTAGHGMTAVGA*SCNCFCYICCSCSSA 
 
Figure 3.30 TbtD tolerates GluC-treated TbtA E(-4)A hexazole tetradehydrate as a substrate. (A) 
ESI-MS spectrum of endoproteinase GluC-digested TbtA E(-4)A hexazole tetradehydrate. Reaction of 
GluC-digested TbtA E(-4)A hexazole tetradehydrate with TbtD results in the formation of (B) thiomuracin 
core and (C) the ejected leader peptide. 
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3.6 Tables 
Table 3.1 Competitive binding IC50 values of TbtA Ala variants. Actual FP traces and Kd values 
are shown in Figures 3.12 and 3.13. 
TbtA LP 
variant 
IC50 
TbtF (μM) 
IC50 
TbtD (μM) 
 
TbtA LP 
variant 
IC50 
TbtF (μM) 
IC50 
TbtD (μM) 
Wild-type 0.67 ± 0.03 0.61 ± 0.03  D(-20)A 1.45 ± 0.46 4.13 ± 1.62 
D(-33)A 0.99 ± 0.22 0.72 ± 0.07  S(-19)A 1.57 ± 0.46 0.91 ± 0.11 
L(-32)A 1.58 ± 0.36 1.71 ± 0.47  V(-17)A 0.49 ± 0.05 0.69 ± 0.04 
N(-31)A 0.57 ± 0.07 1.13 ± 0.08  V(-15)A 0.63 ± 0.06 1.06 ± 0.06 
D(-30)A 0.94 ± 0.20 7.28 ± 0.77  E(-14)A 1.37 ± 0.15 4.47 ± 0.96 
L(-29)A >>10 >>10  S(-13)A 1.41 ± 0.07 2.76 ± 0.18 
P(-28)A 0.85 ± 0.14 2.66 ± 0.55  L(-12)A 0.70 ± 0.04 3.29 ± 0.68 
M(-27)A 2.75 ± 0.55 1.09 ± 0.19  T(-11)A 0.51 ± 0.06 0.45 ± 0.02 
D(-26)A 8.23 ± 1.45 6.00 ± 0.41  H(-8)A 0.98 ± 0.06 3.68 ± 0.31 
V(-25)A 0.62 ± 0.04 2.25 ± 0.20  M(-6)A 0.45 ± 0.03 0.49 ± 0.07 
F(-24)A >10 1.51 ± 0.09  E(-4)A 0.53 ± 0.03 0.70 ± 0.02 
E(-23)A 1.27 ± 0.15 3.46 ± 0.57  V(-3)A 0.58 ± 0.05 1.35 ± 0.14 
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Table 3.2 Oligonucleotide primers used in this study. All sequences are provided 5′ to 3′. F indicates a 
forward primer while R indicates the reverse primer. 
Primer Oligonucleotide Sequence 
tbtA D(-33)A F GTGGATCCATGGCCCTGAATGATCTGCCGATGGATGTTTTT 
tbtA D(-33)A R AGATCATTCAGGGCCATGGATCCACGACGACGGGATTGGAA 
tbtA L(-32)A F GATCCATGGACGCGAATGATCTGCCGATGGATGTTTTTGAA 
tbtA L(-32)A R GGCAGATCATTCGCGTCCATGGATCCACGACGACGGGATTG 
tbtA N(-31)A F CCATGGACCTGGCTGATCTGCCGATGGATGTTTTTGAACTG 
tbtA N(-31)A R ATCGGCAGATCAGCCAGGTCCATGGATCCACGACGACGGGA 
tbtA D(-30)A F TGGACCTGAATGCTCTGCCGATGGATGTTTTTGAACTGGCA 
tbtA D(-30)A R TCCATCGGCAGAGCATTCAGGTCCATGGATCCACGACGACG 
tbtA L(-29)A F ACCTGAATGATGCGCCGATGGATGTTTTTGAACTGGCAGAT 
tbtA L(-29)A R ACATCCATCGGCGCATCATTCAGGTCCATGGATCCACGACG 
tbtA P(-28)A F TGAATGATCTGGCGATGGATGTTTTTGAACTGGCAGATAGC 
tbtA P(-28)A R AAAACATCCATCGCCAGATCATTCAGGTCCATGGATCCACG 
tbtA M(-27)A F ATGATCTGCCGGCGGATGTTTTTGAACTGGCAGATAGCGGT 
tbtA M(-27)A R TCAAAAACATCCGCCGGCAGATCATTCAGGTCCATGGATCC 
tbtA D(-26)A F ATCTGCCGATGGCTGTTTTTGAACTGGCAGATAGCGGTGTT 
tbtA D(-26)A R AGTTCAAAAACAGCCATCGGCAGATCATTCAGGTCCATGGA 
tbtA V(-25)A F TGCCGATGGATGCTTTTGAACTGGCAGATAGCGGTGTTGCA 
tbtA V(-25)A R GCCAGTTCAAAAGCATCCATCGGCAGATCATTCAGGTCCAT 
tbtA F(-24)A F CGATGGATGTTGCTGAACTGGCAGATAGCGGTGTTGCAGTT 
tbtA F(-24)A R TCTGCCAGTTCAGCAACATCCATCGGCAGATCATTCAGGTC 
tbtA E(-23)A F TGGATGTTTTTGCACTGGCAGATAGCGGTGTTGCAGTTGAA 
tbtA E(-23)A R CTATCTGCCAGTGCAAAAACATCCATCGGCAGATCATTCAG 
tbtA D(-20)A F TTGAACTGGCAGCTAGCGGTGTTGCAGTTGAAAGCCTGACC 
tbtA D(-20)A R GCAACACCGCTAGCTGCCAGTTCAAAAACATCCATCGGCAG 
tbtA S(-19)A F AACTGGCAGATGCCGGTGTTGCAGTTGAAAGCCTGACCGCA 
tbtA S(-19)A R ACTGCAACACCGGCATCTGCCAGTTCAAAAACATCCATCGG 
tbtA V(-17)A F CAGATAGCGGTGCTGCAGTTGAAAGCCTGACCGCAGGTCATG 
tbtA V(-17)A R TTTCAACTGCAGCACCGCTATCTGCCAGTTCAAAAACATCC 
tbtA V(-15)A F GCGGTGTTGCAGCTGAAAGCCTGACCGCAGGTCATGGTATG 
tbtA V(-15)A R GTCAGGCTTTCAGCTGCAACACCGCTATCTGCCAGTTCAAA 
tbtA E(-14)A F GTGTTGCAGTTGCAAGCCTGACCGCAGGTCATGGTATGACC 
tbtA E(-14)A R GCGGTCAGGCTTGCAACTGCAACACCGCTATCTGCCAGTTC 
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Table 3.2 (cont.) 
tbtA S(-13)A F TTGCAGTTGAAGCCCTGACCGCAGGTCATGGTATGACCGAA 
tbtA S(-13)A R CCTGCGGTCAGGGCTTCAACTGCAACACCGCTATCTGCCAG 
tbtA L(-12)A F CAGTTGAAAGCGCGACCGCAGGTCATGGTATGACCGAAGTT 
tbtA L(-12)A R TGACCTGCGGTCGCGCTTTCAACTGCAACACCGCTATCTGC 
tbtA T(-11)A F TTGAAAGCCTGGCCGCAGGTCATGGTATGACCGAAGTTGGT 
tbtA T(-11)A R CCATGACCTGCGGCCAGGCTTTCAACTGCAACACCGCTATC 
tbtA H(-8)A F TGACCGCAGGTGCTGGTATGACCGAAGTTGGTGCAAGCTGT 
tbtA H(-8)A R TCGGTCATACCAGCACCTGCGGTCAGGCTTTCAACTGCAAC 
tbtA M(-6)A F CAGGTCATGGTGCGACCGAAGTTGGTGCAAGCTGTAATTGC 
tbtA M(-6)A R CCAACTTCGGTCGCACCATGACCTGCGGTCAGGCTTTCAAC 
tbtA E(-4)A F ATGGTATGACCGCAGTTGGTGCAAGCTGTAATTGCTTTTGT 
tbtA E(-4)A R CTTGCACCAACTGCGGTCATACCATGACCTGCGGTCAGGCT 
tbtA V(-3)A F GTATGACCGAAGCTGGTGCAAGCTGTAATTGCTTTTGTTAT 
tbtA V(-3)A R CAGCTTGCACCAGCTTCGGTCATACCATGACCTGCGGTCA 
tbtA C12A F TTTGTTGTAGCGCCAGCAGCGCCTAACTCGAGCACCACCAC 
tbtA C12A R TAGGCGCTGCTGGCGCTACAACAAATATAACAAAAGCAATTAC 
tbtA C12A, C10A F GTTATATTTGTGCGAGCGCCAGCAGCGCCTAACTCGAGCAC 
tbtA C12A, C10A R CTGCTGGCGCTCGCACAAATATAACAAAAGCAATTACAGCTTG 
tbtA C12A, C10A, C9A F TTTGTTATATTGCGGCGAGCGCCAGCAGCGCCTAACTCGAG 
tbtA C12A, C10A, C9A R CTGGCGCTCGCCGCAATATAACAAAAGCAATTACAGCTTGC 
tbtA C12A, C10A, C9A, 
C6A F 
GTAATTGCTTTGCGTATATTGCGGCGAGCGCCAGCAGCGCC 
tbtA C12A, C10A, C9A, 
C6A R 
GCCGCAATATACGCAAAGCAATTACAGCTTGCACCAACTTC 
tbtA C12A, C10A, C9A, 
C6A F 
CTGCGTTTCATGCCGAACTGGAAAGCCGTCCGGAATGGGCAC 
tbtA C12A, C10A, C9A, 
C6A R 
CTTTCCAGTTCGGCATGAAACGCAGAAACTTCAGCCAGGCTC 
tbtA C12A, C10A, C9A, 
C6A, C4A F 
CAAGCTGTAATGCGTTTGCGTATATTGCGGCGAGCGCCAGC 
tbtA C12A, C10A, C9A, 
C6A, C4A R 
ATATACGCAAACGCATTACAGCTTGCACCAACTTCGGTCATAC 
 
 
 
117 
Table 3.2 (cont.) 
tbtA C12A, C10A, 
C9A, C6A, C4A, 
C2A F 
TTGGTGCAAGCGCGAATGCGTTTGCGTATATTGCGGCGAGC 
tbtA C12A, C10A, 
C9A, C6A, C4A, 
C2A R 
GCAAACGCATTCGCGCTTGCACCAACTTCGGTCATACCATG 
tbtA pan-Cys to 
Ala A4C F 
CAAGCGCGAATTGTTTTGCGTATATTGCGGCGAGCGCCAGC 
tbtA pan-Cys to 
Ala A4C R 
ATATACGCAAAACAATTCGCGCTTGCACCAACTTCGGTCATAC 
tbtA pan-Cys to 
Ala A6C F 
CGAATGCGTTTTGTTATATTGCGGCGAGCGCCAGCAGCGCC 
tbtA pan-Cys to 
Ala A6C R 
GCCGCAATATAACAAAACGCATTCGCGCTTGCACCAACTTC 
tbtA pan-Cys to 
Ala A9C F 
TTGCGTATATTTGTGCGAGCGCCAGCAGCGCCTAACTCGAG 
tbtA pan-Cys to 
Ala A9C R 
CTGGCGCTCGCACAAATATACGCAAACGCATTCGCGCTTGC 
tbtA pan-Cys to 
Ala A10C F 
CGTATATTGCGTGTAGCGCCAGCAGCGCCTAACTCGAGCAC 
tbtA pan-Cys to 
Ala A10C R 
CTGCTGGCGCTACACGCAATATACGCAAACGCATTCGCGCTTG 
tbtA pan-Cys to 
Ala A12C F 
TTGCGGCGAGCTGCAGCAGCGCCTAACTCGAGCACCACCAC 
tbtA pan-Cys to 
Ala A12C R 
TAGGCGCTGCTGCAGCTCGCCGCAATATACGCAAACGCATTC 
tbtA S1A F GGTGCAGCGTGTAATTGCTTTTGTTATATTTGTTGTAGC 
tbtA S1A R CAAAAGCAATTACACGCTGCACCAACTTCGGTCATAC 
tbtA S11A F GTTATATTTGTTGTGCTTGCAGCAGCGCCTAATG 
tbtA S11A R CTGCTGCAAGCACAACAAATATAACAAAAGCAATTACAGCTTG 
MBP-tbtB F GAGAACCTGTACTTCCAATCCATGCGTCTGGTGGAAC 
MBP-tbtB R GGTGCTCGAGTGCGGCCGCATTATTCACCCAGTTCAACCAG 
tbtC R60A F CATCTGCGTTTCGCTGTTCGTCTGCTGCCG 
tbtC R60A R CAGACGAACAGCGAAACGCAGATGCGGAC 
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Table 3.2 (cont.) 
tbtA S13A F GTTGTAGCTGCGCAAGCGCCTAATGCGGC 
tbtA S13A R CATTAGGCGCTTGCGCAGCTACAACAAATATAACAAAAGCAATTAC 
tbtA S14A F GTAGCTGCAGCGCTGCCTAATGCGGCCGC 
tbtA S14A R GCATTAGGCAGCGCTGCAGCTACAACAAATATAACAAAAGC 
tbtA C2A F GTGCAAGCGCGAATTGCTTTTGTTATATTTGTTGTAGC 
tbtA C2A R CAAAAGCAATTCGCGCTTGCACCAACTTCG 
tbtA C2A, 
C4A F 
GCGCGAATGCATTTTGTTATATTTGTTGTAGCTGCAG 
tbtA C2A, 
C4A R 
CAAATATAACAAAATGCATTCGCGCTTGCACC 
tbtA C2A, 
C4A, C6A F 
GAATGCATTTGCGTATATTTGTTGTAGCTGCAGCAG 
tbtA C2A, 
C4A, C6A R 
CAAATATACGCAAATGCATTCGCGCTTGCACC 
tbtA C2A, 
C4A, C6A, 
C9A F 
ATCGAAGGTCTCATGCGTATATTGCATGTAGCTGCAGCAGCG 
tbtA C2A, 
C4A, C6A, 
C9A R 
TTAGCTGGTCTCACGCAAATGCATTCGCGCTTGCACCAAC 
tbtA C2A, 
C4A, C6A, 
C9A, C10A F 
ATCGAAGGTCTCATGCGTATATTGCAGCTAGCTGCAGCAGCGC 
tbtA C2A, 
C4A, C6A, 
C9A, C10A R 
TTAGCTGGTCTCACGCAAATGCATTCGCGCTTGCACCAAC 
mbp F GAGGAAGAGTTGGCGAAAGATCCACGTA 
T7 F TAATACGACTCACTATAGGG 
T7 R  GCTAGTTATTGCTCAGCGG 
MBP-TbtF F GAGCGGATAACAATTTCACACAGGAGACAGACCATGAAAATCGAAGAAGGTAAAC 
MBP-TbtF R GATTTTCATGGTATATCTCCTTGAATCTTACACATGTGCAGATTC 
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Table 3.2 (cont.) 
RBS MBP-TbtG F 
GATAACAATTTCACACAGGAAACAGACCATGGATTCAAGGAGATATACCATG 
AAAATCGAAGAAGGTAAAC 
RBS MBP-TbtG R GGAATGGTCATGGATTATCTCCTTATTAATTACGGAAACGGGTG 
RBS TbtE F GTTTCCGTAATTAATAAGGAGATAATCCATGACCATTCCGCCGG 
RBS TbtE R CAGCCAAGCTTGCATGCCTGCAGGTCGACTTACGATTCTTCAACCGTG 
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Table 3.3 Expected and observed masses for diagnostic ions in ESI-MS/MS spectra.  
TbtA monoazole (Figure 3.2)    TbtA diazole (Figure 3.2) 
 
Species 
Predicted 
mass 
Observed 
mass 
Error (ppm) 
 
Species 
Predicted 
mass 
Observed 
mass 
Error (ppm) 
[M+H]+ 2085.7050 2085.7109 2.8  [M+H]+ 2008.6573 2008.6851 13.8 
[M+2H]2+ 1043.3561 1043.3565 0.4  [M+2H]2+ 1004.8323 1004.7927 39.4 
b5 475.1969 475.1931 8.0  b8 742.2436 742.2444 1.1 
b8 819.2913 819.2860 6.5  y4 424.1500 424.1604 24.5 
y4 424.1497 424.1539 9.9  y6 671.2123 671.2158 5.2 
y6 671.2123 671.2072 7.6  y7 831.2430 831.2410 2.4 
y7 831.2430 831.2474 5.3      
 
 
TbtA triazole (Figure 3.2)    Monoglutamylated TbtA hexazole (Figure 3.3) 
 
Species 
Predicted 
mass 
Observed 
mass 
Error (ppm) 
 
Species 
Predicted 
mass 
Observed 
mass 
Error (ppm) 
[M+H]+ 1931.6096 1931.6620 27.1  [M+H]+ 1829.5098 1829.5093 0.3 
[M+2H]2+ 966.3085 966.3063 2.3  b2 157.0977 157.0991 8.9 
b8 742.2441 742.2440 0.1  b3 228.1348 228.1369 9.2 
y5 434.1340 434.1354 3.2  b10 988.2904 988.2845 6.0 
y6 594.1647 594.1636 1.9  b15 1437.3554 1437.3598 3.1 
y7 754.1953 754.1954 0.1  y2 306.1301 306.1308 2.3 
     y8 842.2272 842.2268 0.5 
     y15 1602.3828 1602.4041 13.3 
     y16 1673.4199 1673.3906 17.5 
     y17 1730.4414 1730.4592 10.3 
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Table 3.3 (cont.) 
Monodehydrated TbtA hexazole (Figure 3.17A)              Didehydrated TbtA hexazole (Figure 3.17B)             
Species 
Predicted 
mass 
Observed 
mass 
Error (ppm) 
 
Species 
Predicted 
mass 
Observed 
mass 
Error (ppm) 
[M+H]+ 1682.4566 1682.4335 13.7  [M+H]+ 1664.4460 1664.4596 8.2 
b2 157.0977 157.0996 12.1  b3 228.1348 228.1382 14.9 
b3 228.1348 228.1382 14.9  b10 988.2904 988.3035 13.3 
b10 988.2904 988.2952 4.9  b15 1437.3554 1437.3519 2.4 
b16 1524.3875 1524.3881 0.4  b16 1506.3769 1506.3826 3.8 
b16-H2O 1506.3769 1506.3583 12.3  b16-b10 519.0943 519.1047 20.0 
b16-b10 537.1049 537.1086 6.9  c15 1454.3820 1454.3657 11.2 
y8 695.1740 695.1746 0.9  y8 677.1634 677.1667 4.9 
 
Monoglutamylated and tridehydrated TbtA hexazole (Figure 3.18B) 
Species Predicted mass 
Observed 
mass 
Error (ppm) 
[M+H]+ 1775.4781 1775.4564 12.2 
b10 1117.3330 1117.3466 12.2 
b16 1617.4089 1617.3906 11.3 
b16-b10 501.0837 501.0931 18.7 
c15 1565.4140 1565.4050 5.7 
c15-b10 449.0888 449.0941 11.8 
y8 659.1529 659.1412 17.7 
 
Didehydrated TbtA S13A hexazole (Figure 3.20A)           Didehydrated TbtA S14A hexazole (Figure 3.20B)           
 
 Species 
Predicted 
mass 
Observed 
mass 
Error (ppm) 
 
Species 
Predicted 
mass 
Observed 
mass 
Error (ppm) 
a16 1462.3871 1462.3906 2.4  [M+H]+ 1648.4511 1648.4489 1.3 
a16-b3 1235.2601 1235.2703 8.3  b3 228.1348 228.1386 16.0 
b3 228.1348 228.1369 9.2  b10 970.2799 970.2800 0.1 
b10 970.2799 970.2899 10.3  b16 1488.3663 1488.3749 5.8 
b16 1490.3820 1490.3979 10.7  b17 1559.4034 1559.3975 3.8 
b16-b3 1263.2550 1263.2523 2.1  b16-b3 1261.2393 1261.2450 4.5 
b16-b10 521.1099 521.1188 17.1  b16-b10 519.0943 519.1021 15.0 
y8 679.1791 679.1857 9.7  y8 679.1791 679.1805 2.1 
y15 1421.3241 1421.3389 10.4      
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Table 3.3 (cont.) 
Tridehydrated TbtA C2A/C4A tetrazole (Figure 3.25A) Didehydrated TbtA C12A pentazole  
(Figure 3.25A) 
Species 
Predicted 
mass 
Observed 
mass 
Error (ppm) 
 
Species 
Predicted 
mass 
Observed 
mass 
Error (ppm) 
[M+H]+ 1622.5438 1622.5620 11.2  [M+H]+ 1652.5002 1652.4898 6.3 
b5 386.2040 386.2053 3.4  b2 157.0977 157.0987 6.4 
b7 571.2840 571.2892 9.1  b3 228.1348 228.1358 4.4 
b10 964.3987 964.3935 5.4  b10 988.2904 988.2957 5.36 
b16-b10 501.0837 501.0865 5.6  b16 1494.4310 1494.4511 13.4 
y8 659.1529 659.1580 7.7  b17 1563.4525 1563.4701 11.2 
y16 1466.4539 1466.4525 1.0 
 
b16-b10 507.1484 507.1515 6.1 
y8 665.2176 665.2115 9.2 
 y15-H2O 1407.3626 1407.3808 12.9 
     
Didehydrated TbtA C2A/C4A/C6A triazole (Figure 3.26A)  
Species 
Predicted 
mass 
Observed 
mass 
Error (ppm) 
[M+H]+ 1628.6085 1628.6061 1.5 
b5 386.2040 386.2084 11.4 
b10 952.4529 952.4545 1.7 
b16 1470.5393 1470.5495 6.9 
c15 1418.5444 1418.5331 8.0 
c15-b10 467.0994 467.1024 6.4 
y8 677.1634 677.1617 2.5 
y9 840.2268 840.2358 10.7 
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Table 3.3 (cont.) 
Didehydrated TbtA C2A/C4A/C6A/C9A/C10A monoazole (Figure 3.26B)   
Species 
Predicted 
mass 
Observed 
mass 
Error (ppm) 
[M+H]+ 1604.7168 1604.7129 2.4 
b7 571.2840 571.2892 9.1 
b8 718.3524 718.3522 0.3 
b10 952.4529 952.4555 2.7 
b11 1065.5369 1065.5264 9.9 
b12 1136.5740 1136.5811 6.2 
b13 1207.6111 1207.6029 6.8 
b16 1446.6476 1446.6616 9.7 
b16-b13 240.0443 240.0462 7.9 
c15 1394.6527 1394.6523 0.3 
y5 398.1134 398.1151 4.3 
y6 469.1505 469.1570 13.9 
y7 540.1877 540.1877 0.0 
y8 653.2717 653.2711 0.9 
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Chapter 4: Bioinformatic Expansion and Discovery of Thiopeptide Antibiotics4
 
4.1 Introduction  
With the advent of modern genome sequencing technology and powerful bioinformatics tools to 
aid in their analysis, it is apparent that ribosomally synthesized and posttranslationally modified peptide 
(RiPP) natural products are underexplored and pervasive in all domains of life.1 Many bioactive RiPPs are 
antibiotics, making them potential leads for future drug development. One therapeutically promising class 
of RiPP are the thiopeptides, which routinely display nanomolar growth suppression activity towards 
clinically problematic Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus, 
vancomycin-resistant enterococci, and Clostridium difficile.2,3 Thiostrepton has been employed in topical 
veterinary applications while LFF571, a semi-synthetic analog of GE2270A, displayed efficacy in treating 
C. difficile commensurate with vancomycin.4 Nosiheptide also has a long history of use in animal feed 
where it acts as a growth promoter at sub-therapeutic concentrations. Thiopeptides predominantly exert 
their antibiotic activity by inhibiting protein synthesis with two notable exceptions: the cyclothiazomycins 
are reported to inhibit RNA polymerase5 while lactazole is reported to lack antibiotic activity.6 The 
mechanism of action for thiopeptides acting as protein synthesis inhibitors correlates with the size of the 
primary macrocycle: 29-atom macrocycles (e.g. thiomuracin and GE2270A) bind elongation factor thermo 
unstable (EF-Tu)7 while 26- and 32-atom macrocycles (e.g. thiostrepton and berninamycin, respectively) 
bind to the interface of protein L11 and the 23S rRNA within the 50S ribosomal subunit8 (Figure 4.1).  
The complex scaffolds that compose thiopeptide structures all adhere to a common biosynthetic logic. As 
RiPPs, thiopeptide biosynthesis begins with the ribosomal production of a precursor peptide. RiPP 
precursor peptides are bipartite and typically consist of an N-terminal leader region that contains a 
recognition sequence that is directly engaged by the maturation proteins. The C-terminal core region 
receives the posttranslational modifications to become the mature RiPP.9-11 Recent work has shown that 
thiopeptide precursor peptides are first acted upon by a trimeric heterocycle synthetase (Ocin-ThiF-
dependent YcaO) which cyclodehydrates Cys and select Ser/Thr residues to azoline heterocycles, often 
with subsequent dehydrogenation to the corresponding azole.12,13 The azol(in)e-bearing intermediate is then 
dehydrated at other unmodified Ser and Thr residues in a tRNA-dependent manner by a split LanB-like 
dehydratase, giving rise to dehydroalanine (Dha) and dehydrobutyrine (Dhb) moieties, respectively. The 
last step that is common to all thiopeptide biosynthetic pathways involves a formal [4+2] cycloaddition 
between two Dha residues and the amide backbone, giving rise to a six-membered, central N-heterocycle. 
                                                     
4 This chapter has been reproduced with permission from Schwalen, C.J.; Hudson, G.A.; Kille, B.; Mitchell, D.A. Bioinformatic 
expansion and discovery of thiopeptide antibiotics. J. Am. Chem. Soc. 2018, 140, 9494-9501. Copyright 2018 American Chemical 
Society. G.A.H and C.J.S designed and performed experiments. K.B performed bioinformatic analyses. All authors wrote and 
edited the manuscript. G.A.H and C.J.S are co-first authors.  
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This cycloaddition forms the primary macrocycle found in all thiopeptides. Most frequently, this central 
heterocycle appears in mature thiopeptides as pyridine, but other oxidation states are known, such as 
hydroxypyridine, dehydropiperidine, and piperidine (Figure 4.1).10  
Despite proven industrial and promising clinical applications, only a handful of truly distinct 
thiopeptide scaffolds have been characterized. Approximately 150 thiopeptides are known; however, the 
majority of these molecules are close analogs of each other (including naturally-occurring congeners) and 
fall within seven classes: nosiheptide/nocathiacin-like, thiocillin-like, thiostrepton-like, cyclothiazomycin-
like, lactazole-like, thiomuracin/GE2270A-like, and berninamycin-like (Figure 4.1). All known 
thiopeptides are variations on these scaffolds by means of amino acid substitutions and/or ancillary 
modifications such as oxidation, methylation, glycosylation, amidation, and thioamidation.3 
Based on our previous bioinformatic work on the pyridine-forming [4+2]-cycloaddition enzyme 
involved in thiomuracin biosynthesis14, we suspected that the thiopeptide genomic space was far greater 
than currently appreciated. Due to the recent magnitude of microbial genome sequencing that has taken 
place, multiple classes of natural products have been significantly expanded through genome-mining.15,16 
Therefore, we endeavored to comprehensively catalog and classify all identifiable thiopeptide biosynthetic 
gene clusters in GenBank. This would allow us to identify biosynthetic gene clusters for thiopeptides of 
previous unknown genetic origin and the dataset could guide the discovery of new thiopeptides while also 
shedding light on currently enigmatic biosynthetic reactions. 
 
4.2 Results and Discussion 
4.2.1 Thiopeptide genome-mining 
The bioinformatics algorithm RODEO (Rapid ORF Description and Evaluation Online) has 
previously been leveraged to define the genomic landscape of the lasso peptide class of RiPPs.17,18 Given 
that all thiopeptides share a core set of biosynthetic genes (i.e. Ocin-ThiF-like protein, azoline-forming 
YcaO cyclodehydratase, azoline dehydrogenase, split LanB dehydratase, and [4+2]-cycloaddition enzyme), 
homologous gene clusters can be readily identifiable using position-specific iterative BLAST (PSI-
BLAST).19 As the presence of a [4+2]-cycloaddition enzyme discriminates thiopeptides from closely 
related goadsporin-type linear RiPPs,14,20 we chose the encoding gene from the thiomuracin, thiostrepton, 
nosiheptide, cyclothiazomycin, thiocillin, and berninamycin biosynthetic gene clusters as input for PSI-
BLASTP searches to generate a comprehensive, non-redundant list of all [4+2]-cycloaddition enzymes in 
GenBank. 
One difficulty in analyzing thiopeptide [4+2]-cycloaddition enzymes is they bear the initially 
misleading annotation as members of the “Lant_Dehydr_C” protein superfamily (PF14028).21 Indeed, 
members of PF14028 carry out the elimination reaction required for Dha/Dhb formation as exemplified by 
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the C-terminal domain of NisB from nisin biosynthesis.22 During the evolution of thiopeptide biosynthesis, 
it is likely that this domain evolved to catalyze the non-spontaneous [4+2]-cycloaddition reaction 
characteristic of thiopeptides, as best-evidenced by substantial primary sequence and tertiary structural 
similarity between the two enzyme types.14  
To aid in the differentiation of bona fide [4+2]-cycloaddition enzymes from other members of 
PF14028, we generated custom profile Hidden Markov Models (pHMMs) for each of the four major 
subclasses of enzyme found in mature thiopeptides (Figure 4.2A). Using these models as classification 
standards, we identified 508 thiopeptide [4+2] enzymes in GenBank with 372 being unique at an amino 
acid identity cutoff of 95%. This represents a nearly 4-fold expansion of the thiopeptide class of natural 
products compared to previous estimates.14 This aggregated list of [4+2]-cycloaddition enzymes was used 
as input for RODEO, in conjunction with the custom pHMMs for the remaining proteins minimally required 
for thiopeptide biosynthesis: Ocin-ThiF-like protein, azoline-forming YcaO cyclodehydratase,23 and split 
LanB enzymes involved in Dha/Dhb formation.12 Clusters bearing the majority of core modifying enzymes 
were included for further analyses. 
Most characterized thiopeptides bear a central pyridine heterocycle and the [4+2]-cycloaddition 
enzyme responsible for its synthesis falls into the thiomuracin-like class of pyridine synthases. 
Unexpectedly, nearly half of all [4+2]-cycloaddition enzymes matched most closely with the pHMM for 
lactazole-like pyridine synthases, despite the only known member being lactazole itself (Figure 4.2).6 
Thiopeptide biosynthetic gene clusters containing a lactazole-like [4+2]-cycloaddition enzyme span several 
large clades that do not contain any characterized members (Figure 4.2B). These data suggest that there 
exists a great number of undiscovered thiopeptides that will contain a lactazole-like central pyridine but are 
otherwise structurally divergent. The remaining three classes of [4+2]-cycloaddition enzymes, thiomuracin-
, thiostrepton-, and berninamycin-like, tend to form groupings that correlate with central heterocycle 
oxidation/substitution status. Analysis of our dataset suggests there is less structural diversity yet to be 
discovered within these clades compared to thiopeptides biosynthetic gene clusters that harbor a lactazole-
like [4+2]-cycloaddition enzyme.  
The vast majority (95.1%) of organisms that encode thiopeptide biosynthetic gene clusters belong 
to either the Actinobacteria or Bacilli bacterial classes (Figure 4.7). The remaining 4.9% of thiopeptides in 
our dataset are encoded by a limited number of bacterial phyla not yet reported to naturally produce 
thiopeptides, including Bacteroidetes, Chloroflexi, Deinococcus-Thermus, and Proteobacteria. 
Examination of a maximum likelihood tree based on the [4+2]-cycloaddition protein sequence suggests that 
lactazole-like thiopeptides diverged early from other members of this family (Figures 4.8-4.9). Parametric 
G+C content comparison of the gene encoding the [4+2]-cycloaddition enzyme versus the genome suggests 
that most identified clusters were vertically acquired with a few exceptions within both Firmicutes and 
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Actinomyces. This analysis highlights the dominance of Actinobacteria and Firmicutes with their 
characteristic high and low G+C contents, respectively (Figure 4.10).  
 
4.2.2 Analysis of precursor peptide diversity and co-occurrence of biosynthetic genes in identified 
clusters 
Thiopeptide precursor peptides were identified and scored using our previously described RODEO 
algorithm.18 Upon scoring potential thiopeptide precursors, we noticed there was more variability in the 
leader peptide cleavage site compared to lasso peptides. Therefore, to develop a robust model for predicting 
the site of thiopeptide leader peptide cleavage, we scanned all potential thiopeptide precursors and identified 
three distinct motifs that were located at the junction of known leader/core sequences. These three motifs 
were implemented into the RODEO thiopeptide scoring algorithm (Figure 4.11).24 In total, 614 sequences 
were identified as probable thiopeptide precursor peptides, which is greater than the number of [4+2] 
enzymes owing to some gene clusters encoding more than one precursor peptide. Upon removal of 
precursor peptides with identical core sequences, 246 unique peptides remained. When the full-length 
precursor peptides were visualized in the form of a sequence similarity network (SSN), where sequences 
are displayed as nodes and similarity to another sequence by an edge, two trends emerged: (i) certain 
thiopeptide precursor subclasses are driven together by sequence similarity in the leader region, despite 
having highly variable core sequences and, (ii) the majority of predicted thiopeptide precursors are sequence 
divergent from currently known thiopeptides (Figure 4.3A). Aligned sequence logos of the core region of 
the major thiopeptide subclasses highlight the dominant trends in these groups (Figure 4.12). These trends 
support the hypothesis that like other RiPPs, thiopeptide structure is diversified mainly through variation 
of the core sequence while preserving the leader region which is critical for recognition by the biosynthetic 
proteins. 
The sequences of the thiopeptide core region show a wide distribution in Cys content, ranging from 
1-10 with a mean of 4.6 ± 2.1 Cys. Ser/Thr content also varies widely, appearing bimodal with most core 
sequences containing 7 or 13 Ser+Thr residues (Figure 4.3). Correlating Cys and Ser/Thr counts to 
determine the maximum number of (cyclo)dehydrations yields a nearly normal distribution around 10-11 
residues, although there is an enrichment of sequences that contain 15 dehydratable (i.e. Cys+Ser+Thr) 
residues. Lastly, the lengths of the thiopeptide core regions is highly variable (range: 10-45 residues); 
however, the majority contain 17-25 residues (Figure 4.13). Based on the fact that the majority of groups 
on both the [4+2]-cycloaddition enzyme and precursor peptide SSNs lack a characterized member, we 
predict that many unusual thiopeptides remain to be discovered. The data presented here provide a starting 
point for pursuing such compounds (Figure 4.12).  
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To further validate our thiopeptide dataset, we assigned biosynthetic gene clusters for several 
known thiopeptides previously of unknown genetic origin based on their deduced precursor peptide 
sequence and tailoring genes. Examples include  sulfomycin,25 geninthiocin,26 A10255,27 and Sch 40832 
(Figure 4.14).28 The latter thiopeptide is distinctive in that it bears the only 6-membered N-heterocycle fused 
to an imidazoyl-like moiety. Contrary to the previously reported precursor peptide for Sch 40832, our 
genomic data show that the fused imidazoyl ring derives from Cys instead of Ser.29 
Thiopeptide structural diversity is not solely determined by core sequence, but also from additional 
modification by ancillary tailoring enzymes. Many thiopeptide gene clusters feature ancillary tailoring 
enzymes, but, with the exception of methyltransferases, no particular class appears in >25% of analyzed 
gene clusters. This observation is in accord with the known breadth of modification to thiopeptide scaffolds 
(Table 4.2). Besides methylation, modification by cytochrome P450 enzymes appears to be the next most 
common ancillary tailoring step. Another prevalent protein family of interest to thiopeptide biosynthesis 
are members of the radical S-adenosylmethionine (SAM) superfamily. Genes encoding P450 or radical 
SAM enzymes are present in ~20% of thiopeptide biosynthetic clusters.30,31   
When superimposed on the [4+2]-cycloaddition enzyme SSN (Figures 4.2 and 4.9), it becomes 
apparent that thiopeptide biosynthetic gene clusters encoding P450 or radical SAM enzymes are not 
constrained to any particular group. Presumably, acquisition of these and other additional modification 
enzymes provided a gain-of-function, as it is pervasive amongst thiopeptide biosynthetic gene clusters 
(Figure 4.9). The modular nature of RiPP biosynthesis allows for a few dominating modifications, but also 
a magnitude of diverse modifications that are less frequently encountered. 
Among these infrequently co-occurring genes, we found that 2% of thiopeptide biosynthetic 
clusters feature a gene encoding a TfuA-like protein (PF07812, Table 4.2). Previous work has shown that 
~10% of all YcaO proteins are encoded next to TfuA.32 Recently, the TfuA-YcaO pair from 
Methanosarcina acetivorans, a methanogenic archaeon, was found to be responsible for a posttranslational 
thioamidation modification. Conversion of a key glycine residue to thioglycine within methyl-coenzyme 
M reductase has been shown to be ubiquitous amongst methanogens.33,34 Nature employs several distinct 
strategies to form carbon-sulfur bonds.35 In contrast to methanobactins, whose thioamides are formed in a 
YcaO-independent fashion36,37, thioviridamide biosynthetic gene clusters encode uncharacterized TfuA-
YcaO pairs,38-41 and hence we reasoned that thiopeptides encoding these two proteins may also feature a 
thioamide modification. Two known thiopeptides have been reported that feature a single thioamide 
modification at equivalent positions in Sch 18640 and thiopeptin.42,43 Although the genome sequences for 
the producing organisms were not available, our bioinformatics survey detected a thiostrepton-like 
biosynthetic gene cluster in Amycolatopsis saalfeldensis NRRL B-24474 that contained a tfuA-ycaO gene 
pair. Subsequently, this strain was screened for the production of a new thiopeptide.  
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4.2.3 Isolation and characterization of a new thiopeptide 
Reactivity-based screening augments typical media/growth condition testing for the production of 
compound of interest by exploiting selective chemical reactivity of functional groups.44 With few 
exceptions, all known thiopeptides contain Dha or Dhb residues that are susceptible to 1,4-nucleophilic 
addition by reaction with a soft nucleophile. The predicted A. saalfeldensis precursor peptide contains 10 
Ser+Thr residues. Based on the structure of thiostrepton, we predicted the following: two Ser residues 
would be employed for the [4+2]-cycloaddition, one Thr would be used for linking to the quinaldic acid 
moiety, and one Thr would be left unmodified as in thiostrepton. This analysis thus predicted the presence 
of 6 Michael acceptors in the final structure (5 Dha, 1 Dhb). Upon reacting the methanolic extract of A. 
saalfeldensis cultures with dithiothreitol, we identified by mass spectrometry (MS) a species that contained 
upwards of six DTT adducts (ions with 4-5 labels were the most intense), consistent with the prediction 
(Figure 4.15).  
Further inspection of the A. saalfeldensis biosynthetic gene cluster revealed significant similarity 
to other (dehydro)piperidine-containing thiopeptides. In particular, genes for the biosynthesis of the 
hallmark quinaldic acid moiety are present and conservation of Thr12 in the precursor peptide suggested a 
secondary, ester-linked macrocycle similar to that seen in thiostrepton. Missing from the A. saalfeldensis 
gene cluster was the asparagine synthetase responsible for C-terminal amidation45, implying the compound 
would display a carboxylate terminus (Figure 4.4). High-resolution electrospray ionization tandem MS 
(HR-ESI-MS/MS) confirmed the predicted chemical formula (C69H77N18O18S6+). This formula is consistent 
with: (i) the 6 Dha/Dhb groups identified by reactivity towards dithiothreitol, (ii) the bioinformatically 
predicted C-terminal carboxylate, and (iii) the bioinformatically predicted thioamidation (replacement of 
an oxygen atom with sulfur) akin to Sch 18640 and thiopeptin. Tandem MS fragmentation of the quinaldic 
acid linkage involving residue Ala1 and Thr12 resembled that of known thiopeptides (Table 4.3, Figure 
4.16). Notably, the best alternative chemical formula, which involves oxidation (addition of oxygen) was 
inconsistent with our observed mass.  
To confirm the presence of the thioamide, we purified a larger quantity the A. saalfeldensis 
thiopeptide, now termed saalfelduracin, and subjected the compound to 1H, 1H-1H TOCSY, and 1H-1H 
NOESY NMR experiments. Analysis of the spectra confirmed the predicted structure. Spin systems 
consistent with all modifications, including the quinaldic acid, dehydrated amino acids, and side chains 
were identified (Table 4.4, Figures 4.17-4.20). In contrast to other members of the (dehydro)piperidine 
thiopeptides, we only observed the formation of a central piperidine central heterocycle. Assignment of the 
thioamide at position Cys11-Thr12 was determined through analysis of amide protons. The amide NH of 
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Thr12 was downshifted significantly (9.83 ppm), as well as the CαH (6.67 ppm), due to the electronic 
effects of the thiocarbonyl (Figure 4.4C). These chemical shift values are consistent with reported thioamide 
chemical shifts from Sch 18640 and thiopeptin.43,46,47 A commercial standard of thiostrepton was obtained 
and the NMR spectrum showed that the Thr12 NH and CαH protons were significantly shielded (~1 ppm) 
relative to the corresponding nuclei of saalfelduracin (Figure 4.4C).  
To evaluate the antibacterial activity of saalfelduracin, we measured the minimum inhibitory 
concentration (MIC) against a panel of human pathogenic bacteria. Saalfelduracin was not active against 
any Gram-negative bacterium tested, but the compound was strongly growth inhibitory towards against 
Gram-positive bacteria, including vancomycin-resistant Enterococcus and methicillin-resistant 
Staphylococcus aureus (Table 4.1). The potency and spectrum of activity of saalfelduracin is approximately 
equivalent to thiostrepton. 
 
4.2.4 Characterization of thiopeptide thioamidation 
Intrigued by the rarity of thioamides as a posttranslational modification, we sought to determine if 
the TfuA-YcaO pair was responsible for installing thioamides in thiopeptide natural products. The TfuA 
and YcaO proteins encoded by A. saalfeldensis belong to protein families PF07812 and PF02624, 
respectively. Unlike the YcaOs responsible for azoline formation via the ATP-dependent cyclodehydration 
of Cys/Ser/Thr residues, TfuA-associated YcaO proteins are shorter and do not contain the highly conserved 
Pro-rich C-terminal sequence.48,49 We reasoned that the other thiopeptides reported to contain thioamides 
(i.e. Sch 18640 and thiopeptin) would have biosynthetic gene clusters that also contain tfuA-ycaO genes; 
however, the genomes of the producing organisms were not available. Therefore, we obtained the natural 
producers of Sch 18640 and thiopeptin (Micromonospora arborensis NRRL 8041 and Streptomyces 
tateyamensis ATCC 21389, respectively), sequenced the genomes, and assembled the reads into ~200 
contigs for each organism. Homologs of the TfuA-like protein from A. saalfeldensis and the thioviridamide 
producer Streptomyces olivoviridis were used to query the sequenced genomes using translated BLAST 
(TBLASTN). A single matching sequence was identified adjacent to a YcaO homolog in both organisms 
(Figure 4.5). Further analysis of the local region confirmed these appear to be valid thiopeptide biosynthetic 
gene clusters given that the requisite genes for an azoline-forming cyclodehydratase, split LanB enzymes, 
and [4+2]-cycloaddition enzyme were identified. Short genes encoding the precursor peptides were found 
as well that perfectly matched the inferred core sequences of Sch 18640 and thiopeptin.  
In general, a high level of conservation was seen for the gene clusters of thioamide-containing 
(dehydro)piperidine thiopeptides. Most protein homologs encoded by these gene clusters were >30% 
sequence identical across species, with the greatest sequence conservation values found for the enzymes 
involved in the modifications common to all thiopeptides (Table 4.5 and Figure 4.21). Concurrently, 
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synteny analysis of the biosynthetic gene clusters also indicated conservation of the relative gene order, 
with exceptions occurring near the precursor peptide gene and the presumed gene cluster boundaries (Figure 
4.22). Taken together, these data suggest that variation in the precursor sequence, as well as the genetic 
content of the gene cluster periphery, are the primary mechanisms by which thiopeptide structural diversity 
is introduced.  
With the finding that all thioamide-containing thiopeptides contain tfuA-ycaO genes in their 
respective biosynthetic gene clusters, there was a clear genetic link to the modification, but no direct 
biochemical evidence that either gene was responsible for thiopeptide thioamidation. To evaluate the role 
of these genes in thioamide installation, we sought to convert the thiopeptide thiostrepton (naturally 
produced by Streptomyces laurentii, as well as a limited number of other strains) to its known thioamidated 
analog, Sch 18640 (naturally produced by M. arborensis) through heterologous expression. We reasoned 
that the M. arborensis TfuA-YcaO pair might be able to process a non-cognate thiopeptide precursor if the 
sequence was sufficiently similar to its native substrate. Notably, mature thiostrepton and Sch 18640 only 
differ by thioamidation, although there are a number of amino acid substitutions in the leader regions of the 
precursor peptides (the same is true for siomycin and thiopeptin, Figure 4.5). As indicated, the 
saalfelduracin precursor sequence is more divergent, however, the location of the thioamide (Cys11-Thr12) 
is unchanged.  
To determine whether genetic introduction of a TfuA-YcaO pair into a thiostrepton-only producer 
would result in a thioamidated analog, a bacteriophage integrase system was employed to mediate 
chromosomal insertion of tfuA and ycaO. Via a phage integrase protein, plasmids bearing the attP locus 
will insert the vector as long as the host chromosome contains an attB locus.50-52 The bacteriophage ΦC31 
integrase targets attB sequences found in many Streptomyces species, including S. laurentii NRRL B-
24298, which strictly produces thiostrepton.53 Our integrative plasmid also included an engineered, strong, 
constitutive promoter (ermE*p) for driving the expression of the non-cognate tfuA-ycaO genes (Figure 4.23 
and Tables 4.6-4.7).  
Conjugation and subsequent integration of S. laurentii with the integrative plasmid containing tfuA 
and ycaO were subsequently screened by MS to monitor thioamide congener formation. Upon introduction 
of the M. arborensis tfuA/ycaO, a metabolite 16 Da heavier than thiostrepton was observed (Figure 4.6). 
This +16 Da metabolite was also observed after introduction of either the S. tateyamensis or A. saalfeldensis 
tfuA/ycaO gene pairs. Both tfuA and ycaO were necessary for the +16 Da metabolite to be observed, given 
that omission of either tfuA or ycaO only yielded a mass consistent with thiostrepton (Figure 4.24). HR-
ESI-MS confirmed the +16 Da species to be chemically identical to Sch 18640 (m/z calculated: 1680.4768 
Da; observed: 1680.4781 Da; error: 0.8 ppm). These data suggest that all three tested TfuA-YcaO pairs 
were flexible enough to act upon a non-cognate substrate. Future work will be necessary to delineate at 
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which point in the biosynthetic pathway thioamidation takes place. The precise role of this modification, if 
any, also awaits further exploration.  
 
4.3 Conclusion 
Thiopeptides are among the most posttranslationally modified RiPP natural products identified, 
originally being misidentified as non-ribosomal peptides. The remarkable structural complexity of 
thiopeptides is due to a modular “plug and play” logic to the modifications displayed by thiopeptides. 
Indeed, the core modifications of thiopeptides appear to be a natural hybrid of two progenitor classes of 
RiPPs: linear azole-containing peptides and lanthipeptides, with an additional [4+2]-cycloaddition reaction 
giving rise to a central N-heterocycle. Mutations to the precursor peptide genes further amplify the diversity 
of thiopeptides.  
Despite their intrinsic potential for structural divergence, most known thiopeptides are close 
structural homologs of one another. To enable a more rational exploration of the thiopeptide chemical-
genomic space, we cataloged and classified all observable biosynthetic gene clusters in GenBank. 
Leveraging this dataset, we connected a protein modification universally present in methanogenic archaea 
to a comparatively rare and understudied modification in peptidic natural products. From this, we used a 
genomics-driven approach to isolate a new thiopeptide and reconcile the enigmatic biosynthetic pathways 
of several previously known thiopeptides. Lastly, we demonstrated the activity of the genes responsible for 
thiopeptide thioamidation, which adds yet another characterized modification to the growing list of 
reactions seen in these complex natural products. 
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4.5 Methods 
4.5.1 General materials and methods 
Reagents used for molecular biology experiments were purchased from New England Biolabs 
(NEB, Ipswich, MA), Thermo Fisher Scientific (Waltham, MA) or Gold Biotechnology Inc. (St. Louis, 
MO). Other chemicals were purchased from Sigma-Aldrich (St. Louis, MO). Escherichia coli DH5α strain 
was used for plasmid maintenance. Competent E. coli conjugation strains WM6026 (dam+/dcm+) and 
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WM6029 (dam-/dcm-) and integrative plasmid pAE4 were gifts from Prof. William Metcalf (University of 
Illinois at Urbana–Champaign). Plasmid inserts were sequenced at the University of Illinois Core 
Sequencing Facility (Urbana, IL). Matrix-assisted laser desorption ionization time-of-flight mass 
spectrometry (MALDI-TOF-MS) analysis was performed using a Bruker UltrafleXtreme MALDI-TOF-
TOF mass spectrometer (Bruker Daltonics) in reflector positive mode at the University of Illinois School 
of Chemical Sciences Mass Spectrometry Laboratory. Electrospray ionization (ESI)-MS/MS analyses were 
performed using a ThermoFisher Scientific Orbitrap Fusion ESI-MS using an Advion TriVersa Nanomate 
100. 
 
4.5.2 Molecular biology techniques 
Oligonucleotides were purchased from Integrated DNA Technologies Inc. (Coralville, IA). 
Genomic DNA isolation from Actinobacteria was performed using UltraClean Microbial DNA Isolation 
Kit (MO BIO Laboratories) per the manufacturer’s instructions, and cloning was performed using Platinum 
Taq (Thermo Fisher), Q5 High-Fidelity Polymerase (New England Biolabs) or PfuTurbo (Agilent) DNA 
polymerase.  
 
4.5.3 Bioinformatic analysis of thiopeptide biosynthetic gene clusters 
Position-iterative BLAST (PSI-BLAST) was performed using the sequences of known thiopeptide 
[4+2] enzymes: TbtD, from thiomuracin (WP_050760415.1), NosO, from nosiheptide (ACR48344.1), 
BerD, from berninamycin (AGN11669.1), TsrD, from thiostrepton (ACN52295.1), LazD, from lactazole 
(BAO57436.1), TclM, from thiocillin (WP_000438834.1), and CtmG from cyclothiazomycin 
(ACS50127.1) for three iterations with a cut-off expectation value of 0.05 in March 2018 using GenBank. 
A non-redundant list of [4+2]-cycloaddition enzyme homologs was generated and used as input for the 
bioinformatics program RODEO (www.ripprodeo.org). Custom profile Hidden Markov Models (pHMMs) 
were generated for each class of thiopeptide [4+2]-cycloaddition enzyme (thiomuracin-like, 
dehydropiperidine, berninamycin-like, and lactazole-like) by aggregating a list of [4+2]-cycloaddition 
enzymes for verified or closely related gene clusters, aligning these sequencing using CLUSTALW, and 
finally converting into pHMMs using the HMMER3 software package.54 Similar pHMMs were made for 
the Ocin-ThiF-like protein as well as the glutamylation and elimination subunits of the lanthipeptide 
dehydratase. These pHMMs were used in conjunction with RODEO to analyze open reading frames (ORFs) 
near each encoded [4+2]-cycloaddition enzyme and those that featured most/all of the thiopeptide 
biosynthetic genes were included for subsequent analysis. The RODEO algorithm was modified to score 
thiopeptide precursors using the same scoring scheme implemented in AntiSMASH4.0.55 Leader peptide 
cleavage sites were scored using three distinct motifs by the MEME bioinformatics application (see Figure 
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4.11 for motif logos).56 The top scoring motif is used to predict the site of leader peptide cleavage. All 
sequence similarity networks were constructed using the Enzyme Function Initiative Enzyme Similarity 
Tool (EFI-EST) (https://efi.igb.illinois.edu/). All maximum likelihood tree analyses were performed on a 
computer running Debian 3.2.54-2 i686 GNU/Linux by aligning sequences using MAFFT 7.39457 with the 
L-INS-i alignment option and subsequently transformed into a maximum likelihood tree using FastTree 
2.158 with the default Jones-Taylor-Thornton (JTT) model. Trees were visualized using the Interactive Tree 
of Life (iTOL) website (http://itol.embl.de/). 
 
4.5.4 Whole-genome sequencing 
Streptomyces tateyamensis ATCC 21389 and Micromonospora arborensis NRRL 8041 are the 
known producers of the thioamidated thiopeptides thiopeptin and Sch 18640, respectively.59,60 To elucidate 
the unknown origin of the thioamide moiety, these bacteria were grown in ATCC 172 liquid media 
supplemented with 0.8% glycine (w/v) at 30 °C with agitation ~7 d. A 30 mL portion of the cultures were 
harvested by centrifugation (4,000 × g, 10 min at 4 °C), and the supernatant was discarded. The cells were 
resuspended in 2 mL of TE25S buffer (25 mM Tris, 25 mM ethylenediaminetetraacetic acid (EDTA) 
disodium salt, 30% sucrose (w/v), pH 8). Cell clumping was disrupted with a glass rod. Lysozyme was 
added to a final concentration of 10 mg/mL and the suspension was equilibrated at 37 °C for 1 h with 
agitation. Afterwards, 6 mL of modified lysis buffer (569 mM 4-aminosalicylic acid sodium salt, 69 mM 
sodium dodecyl sulfate, 100 mM Tris, pH 8) and 40 µL of proteinase K (NEB, 30 U/mg at 20 mg/mL) were 
added. The suspension was then equilibrated at 75 °C for 30 min with the suspension being mixed by gentle 
inversion several times at the 15 min time point. An equal volume of phenol:chloroform:isoamyl alcohol 
(25:24:1, v/v) was then added and mixed by gentle inversion several times. The mixture was harvested by 
centrifugation (10,000 × g, 10 min, 4 °C) and the aqueous phase was transferred to a new container using a 
wide bore pipet. To the aqueous phase an equal volume of chloroform:isoamyl alcohol (24:1, v/v) was 
added and mixed by gentle inversion several times. The mixture was again harvested by centrifugation 
(10,000 × g, 10 min, 4 °C) and the aqueous phase was transferred to a new container using a wide bore 
pipet. Another round of chloroform:isoamyl alcohol extraction was performed if solid material was still 
present in the aqueous phase. The aqueous phase was then transferred to a 50 mL conical tube to which 0.1 
volume equivalents of 5 M NaCl was added. The tube was then filled to the top with isopropyl alcohol and 
the mixture was mixed by gentle inversion. A small glass hook fashioned from a melted Pasteur pipet was 
used to collect the precipitated DNA. The DNA was washed twice with 75% aq. EtOH followed by a single 
wash with 100% EtOH. The DNA was then allowed to air dry on the glass hook overnight. 
Genomic libraries were prepared with an Illumina-Compatible KAPA DNA Library Preparation Kit (Kapa 
Biosystems). Paired-end sequencing was performed on an Illumina MiSeq with 250 nt reads by the Roy J. 
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Carver Biotechnology Center (University of Illinois, Urbana, IL, USA). Genomic assembly was performed 
with CLC Genomics Workbench (CLC Bio). These genomes have been deposited into GenBank under the 
following identifying codes:  
 
 Bacterial Strain    BioProject  Accession   
Micromonospora arborensis NRRL 8041  PRJNA437756  PYBV00000000 
Streptomyces tateyamensis ATCC 21389 PRJNA437757  PYBW00000000 
 
4.5.5 Spore preparation of Streptomyces laurentii 
Spores of Streptomyces laurentii NRRL B-24298 were produced by growing cultures in 5 mL of 
medium ATCC 172 [10 g/L glucose, 20 g/L soluble starch, 5 g/L yeast extract, 5 g/L N-Z amine type A 
(Sigma, C0626), 1 g/L reagent grade calcium carbonate, pH 7.3] at 30 °C until high density was reached. 
Cell clusters were homogenized by vortexing, then plated onto 10 cm petri dishes of MS medium [10 g/L 
mannitol, 10 g/L soy flour (Kinako, Wel-Pac), 15 g/L agar] supplemented with 10 mM MgCl2 (sterile-
filtered, added after autoclaving). Bacteria were grown on plates at 30 °C for 7 d. Spores were harvested by 
the addition of 5 mL of sterile water and gently scraped with a cell spreader. The liquid suspension was 
filtered through sterile cotton in an autoclaved syringe and harvested by centrifugation (4000 × g, 10 min, 
4 °C). After centrifugation, the supernatant was discarded and the cell pellet was resuspended in 2 mL 
sterile water with 25% (v/v) glycerol. This mixture was then flash frozen in liquid nitrogen and stored at -
80 °C until use. 
 
4.5.6 Construction of integrative vector pAE4 for TfuA/YcaO complementation in Streptomcyes 
laurentii  
Integrative vector pAE4 was modified by Gibson Assembly61 to feature the strong constitutive 
promoter ermE*p62. Subsequent Gibson Assembly was used to insert the TfuA/YcaO, TfuA-only, or YcaO-
only downstream of this promoter (A. saalfeldensis accession numbers for TfuA and YcaO, 
WP_091614392.1 and WP_091614389.1, respectively). These vectors were then transformed into 
conjugative E. coli for insertion into S. laurentii spores (see Table 4.6 for sequences).  
 
4.5.7 E. coli conjugation to Streptomyces laurentii 
E. coli conjugation strains WM6026 and WM6029 were transformed with pAE4-ermE*p 
constructs and selected on lysogeny broth (LB) [10 g/L NaCl, 10 g/L tryptone, 5 g/L yeast extract, 15 g/L 
agar] plates containing 40 µg/mL 2,6-diaminopimelic acid (DAP) and 40 µg/mL apramycin sulfate. 
Colonies selected for conjugation were used to inoculate 5 mL of LB with 40 µg/mL DAP and 40 µg/mL 
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Apr and allowed to grow at 37 °C for 16 h. Fresh LB (10 mL) with 40 µg/mL DAP and 40 µg/mL Apr was 
inoculated with 200 µL of the dense cultures and incubated at 37 °C until OD600 = 0.6. Cells were then 
harvested by centrifugation (4000 × g for 5 min, 4 °C), supernatants discarded, and pellets were washed 
with 1 mL 2xYT (16 g/L tryptone, 10 g/L yeast extract, 5 g/L NaCl). Cells were washed an additional three 
times, resuspended in 1 mL of 2xYT with 40 µg/mL DAP, and placed on ice until conjugation. 
When conjugation strains reached mid-exponential optical density (OD600 = 0.6), a frozen suspension of S. 
laurentii spores was removed from -80 °C and heat shocked at 56 °C for 15 min. Afterwards, 500 µL of 
2xYT was added and mixed by pipetting. Conjugation reactions between E. coli and S. laurentii were 
initiated by aliquoting 200 µL of heat shocked spore suspension into three sterile 1.7 mL tubes and 4 µL 
(50:1 v/v), 40 µL (5:1 v/v), and 200 µL (1:1 v/v) of E. coli was added to each of the three tubes, respectively. 
Conjugation reactions were centrifuged (17,000 × g for 60 s, 25 °C) then incubated at 25 °C for 30 min. 
Cells were then resuspended and plated on individual medium MS plates, and incubated at 30 °C for 16 h. 
Plates were then flooded with 2 mL of a sterile-filtered 0.5 mg/mL aq. Apr solution and dried in a biosafety 
cabinet, then incubated at 30 °C until colonies appeared (typically 48 h). 
 
4.5.8 Screening of Amycolatopsis saalfeldensis NRRL B-24474 for thiopeptide production 
A. saalfeldensis was grown on ATCC medium 172, ISP medium 4 [10 g/L soluble starch 
(Amresco), 1 g/L K2HPO4, 1 g/L Mg2SO4∙7H2O, 1 g/L NaCl, 2 g/L (NH4)2SO4, 2 g/L CaCO3, 1 mg/L 
FeSO4∙7H2O, 1 mg/L ZnSO4∙7H2O, 1 mg/L MnCl2∙2H2O sterile filter, pH to 7.2], R2A medium [0.5 g/L 
yeast extract, 0.5 g/L peptone, 0.5 g/L casamino acids, 0.5 g/L D-glucose, 0.5 g/L soluble starch (Amresco), 
0.3 g/L sodium pyruvate (Sigma), 0.3 g/L K2HPO4, 0.05 g/L Mg2SO4∙7H2O], modified AltMS medium [20 
g/L mannitol (Sigma), 10 g/L malt extract (Sigma), 10 g/L soya flour], GUBC medium [5 mL glycerol, 10 
g sucrose, 5 g beef extract (Amresco), 5 g casamino acids (Sigma), 5 mL solution A (1 M Na2HPO4, 1 M 
KH2PO4), 5 mL solution B (to 1 L: 59.3 g MgSO4∙7H2O, 6.67 g CaCl2∙2H2O, 0.0185 g (NH4)6Mo7O24∙4H2O, 
0.198 g FeSO4∙7H2O, 100 mL of Hutner’s metals (vide infra), pH to 6.8) and 10 mL Balch’s vitamins (see 
below) added after autoclaving], MS medium, ISP medium 2 [4 g/L yeast extract, 10 g/L malt extract, 4 
g/L D-glucose], AGS medium [1 g/L arginine HCl, 12.5 g/L glycerol, 1 g/L K2HPO4, 1 g/L NaCl, 0.5 g/L 
Mg2SO4∙7H2O, 0.01 g/L FeSO4∙7H2O, 1 mg/L CuSO4∙5H2O, 1 mg/L MnSO4∙H2O, 1 mg/L ZnSO4∙7H2O, 
pH to 7.0], tryptic soy broth [17 g/L tryptone, 3 g/L soytone, 2.5 g/L D-glucose, 5 g/L NaCl, 2.5 g/L 
K2HPO4, pH to 7.3], nutrient broth [3 g/L beef extract, 5 g/L peptone, pH to 6.8], V8® medium (200 mL/L 
V8® vegetable juice mix, 3 g/L CaCO3]. and Staib’s medium [70 g/L crushed niger seed, 1 g/L D-glucose, 
1 g/L yeast extract, 1 g/L KH2PO4] were prepared as solid media with the addition of 1.5% agar on 10 cm 
sterilized petri dishes.  
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Hunter’s metals [2.5 g/L EDTA∙2Na, 10.95 g/L ZnSO4∙7H2O, 5 g/L FeSO4∙7H2O, 1.54 g/L 
MnSO4∙H2O, 0.392 g/L CuSO4∙5H2O, 0.250 g/L Co(NO3)2∙6H2O, 0.177 g/L Na2B4O7∙10H2O, pH with 5 
drops H2SO4] and Balch’s vitamins (2 mg/L biotin, 2 mg/L folic acid, 10 mg/L pyridoxine hydrochloride, 
5 mg/L thiamine hydrochloride, 5 mg/L riboflavin, 5 mg/L nicotinic acid, 0.5 mg/L calcium pantothenate, 
0.1 mg/L vitamin B12, 5 mg/L p-aminobenzoic acid, 5 mg/L lipoic acid) were sterile-filtered and used as 
additives for GUBC. 
Cultures were allowed to grow at 30 °C for 14 d prior to whole-cell mass spectrometry. A portion 
of cell mass (pinhead-sized, including aerial hyphae) was picked from the plate and placed in 2 µL of sat. 
50% aq. MeCN solution of α-cyano-4-hydroxycinnamic acid (CHCA) with 0.1% trifluoroacetic acid (v/v) 
on a stainless steel MALDI target. Additional aliquots of matrix (2 µL) were spotted and allowed to dry on 
the cell mass three times to extract metabolites onto the plate. Samples were analyzed using a Bruker 
UltrafleXtreme MALDI-TOF MS using manufacturer methods for reflector positive mode. 
 
4.5.9 Thiol labeling of A. saalfeldensis thiopeptide 
Colonies of A. saalfeldensis NRRL B-24474 grown on ISP2 medium for 7 d then extracted with 
0.5 mL methanol for 3 h. Extract was reacted with 100 mM dithiothreitol (DTT) and 10 mM N,N-
diisopropylethylamine (DIPEA) for 6 h at 25 °C. Cell debris was removed by centrifugation (17,000 × g, 
10 min, 4 °C) and the soluble fraction was dried under vacuum. Extract was dissolved in 100 µL of 10 mM 
aq. NH4HCO3 and desalted using C18 ZipTips (EMD Millipore), eluted into 2 µL of 75% aq. MeCN 
saturated with sinapinic acid and spotted on a stainless steel MALDI target. Samples were analyzed by a 
Bruker UltrafleXtreme MALDI-TOF MS using manufacturer methods for reflective positive mode. 
 
4.5.10 Isolation of saalfelduracin 
A. saalfeldensis NRRL B-24474 was grown on ISP2 medium with 1.5% agar (w/v) on 15 cm 
sterilized petri dishes (n = 100) at 30 °C for 21 d. Cells were harvested by scraping cell mass from the plates 
with a sterile razor blade and collectively extracted with 600 mL MeOH with shaking at room temperature 
overnight. The methanolic extract was vacuum-filtered and dried under reduced pressure onto 10 g of Celite 
545 adsorbent.  
Spent agar was frozen at ˗20 °C overnight and then allowed to thaw. The agar was squeezed and 
filtered through cheesecloth to harvest the aqueous portion, which was vacuum-filtered with Whatman filter 
paper and loaded onto a HyperSep C18 10 g SPE column (Thermo Scientific) pre-equilibrated with H2O. 
The loaded column was washed with 200 mL of H2O, and bound material was eluted with successive 50 
mL portions of 5%, 10%, 25%, 50% and 75% aq. MeCN, followed by 100 mL of MeCN. Fractions were 
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analyzed via MALDI-TOF MS. Fractions containing saalfelduracin (monoisotopic m/z = 1637) were pooled 
with the methanolic extract and dried under reduced pressure onto 5 g of Celite 545 adsorbent. 
Saalfelduracin adsorbed onto Celite was purified by medium pressure liquid chromatography (MPLC) 
using a Teledyne Isco Combiflash EZprep equipped with a RediSep Rf C18 cartridge (130 g media, 60 Å 
pore size, 40–63 µm particle size, 230–400 mesh) using a mobile phase of 10 mM aq. NH4HCO3/MeCN at 
85 mL min-1 over a gradient from 20–60% MeCN (10 column volumes), then 60–95% MeCN (5 column 
volumes). Fractions were analyzed via MALDI-TOF and dried under reduced pressure.  
Saalfelduracin was dissolved in 7 mL of water each and filtered with a 0.22 µm syringe filter (BD 
Technologies) prior to injection. HPLC was performed using a Teledyne Isco Combiflash EZprep equipped 
with a RediSep Prep C18Aq column (100 Å pore size, 150 × 20 mm, 5 µM particle size) with a mobile 
phase of 10 mM aq. NH4HCO3/MeCN (gradient from 10 to 95% MeCN) at 19 mL min-1. Fractions 
containing saalfelduracin were dried under reduced pressure, resuspended in H2O, flash-frozen, and 
lyophilized overnight to dryness.  
Preparative HPLC was performed with a Perkin Elmer Flexar HPLC equipped with a Betasil C18 
(Thermo Scientific) reverse phase column (250 × 10 mm, 5 µm particle size). Saalfelduracin was dissolved 
separately in 1.5 mL of water, subjected to centrifugation (17,000 × g for 10 min, 25 °C)to remove 
precipitate, and injected with a mobile phase of water/MeCN + 0.1% formic acid (v/v) with a gradient from 
10–95% over 30 min. The sample absorbance was monitored at 220 and 280 nm and appropriate fractions 
were dried under reduced pressure, dissolved in water (2 mL), flash-frozen, and lyophilized overnight to 
dryness. Saalfelduracin was collected as colorless powders (1.3 mg). The isolated, post-purification yield 
for saalfelduracin was 6.7 µg/15 cm dish. 
 
4.5.11 Mass spectrometric characterization of saalfelduracin 
Saalfelduracin was desalted using a ZipTip were eluted into 75% aq. MeCN. Samples were directly 
infused into a ThermoFisher Scientific Orbitrap Fusion ESI-MS using an Advion TriVersa Nanomate 100. 
The MS was calibrated and tuned with Pierce LTQ Velos ESI Positive Ion Calibration Solution 
(ThermoFisher). The MS was operated using the following parameters: resolution, 100,000; isolation width 
(MS/MS), 2 m/z; normalized collision energy (MS/MS), 70; activation q value (MS/MS), 0.4; activation 
time (MS/MS), 30 ms. Fragmentation was performing using collision-induced dissociation (CID) at 70%. 
Data analysis was conducted using the Qualbrowser application of Xcalibur software (Thermo-Fisher 
Scientific). 
 
4.5.12 NMR characterization of thiostrepton and saalfelduracin 
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HPLC-purified saalfelduracin (1.3 mg) was dissolved in 250 μL of 1:1 CDCl3:CD3OH (CDCl3: 
Cambridge Isotope Labs, >99.8% atom %D, CD3OH: Acros Organics, >99.40% atom % D). The sample 
containing thiostrepton (8 mg, Calbiochem product #598226 Lot D00115085) was similarly prepared. 
NMR spectra were recorded on an Agilent VNMRS 750 MHz narrow bore magnet spectrometer equipped 
with a 5 mm triple resonance (1 H-13C-15N) triaxial gradient probe and pulse-shaping capabilities. Samples 
were held at 25 °C during acquisition. Standard Varian pulse sequences were used for each of the following 
experiments: 1H-NMR, 1H-1H Total correlation spectroscopy (TOCSY) (80 ms mixing time), and 1H-1H 
Nuclear Overhauser effect spectroscopy (NOESY) (400 ms mixing time). Solvent suppression by 
presaturation (PRESAT) was employed for 1H, 1H-1H NOESY, and 1H-1H TOCSY. Spectra were 
recorded with VNMRJ 3.2A. Spectra were imported into MestReNova 8.1.1, reference to tetramethylsilane 
(TMS), phased and baseline corrected and zero-filled to 1024 points. Two-dimensional spectra were 
symmetrized across the diagonal and a 90° Sine Bell apodization with a first point correction of 0.5 were 
used. 
4.5.13 Microbroth dilution antibacterial assays 
A microbroth dilution assay was used to determine the minimum inhibitory concentration (MIC) 
of saalfelduracin and thiostrepton against the following strains: Staphylococcus aureus USA300 (MRSA), 
Enterococcus faecium U503 (VRE), Bacillus anthracis Sterne, Escherichia coli MC4100, Pseudomonas 
aeruginosa PA01, and Acinetobacter baumannii ATCC 19606. These bacteria were grown in brain heart 
infusion (BHI) broth (BD Biosciences). Bacteria were grown overnight in 5 mL of BHI at 37 °C to 
stationary phase. Cultures were diluted 50-fold into 5 mL of fresh BHI, allowed to grow back to mid-
exponential phase (OD600 = 0.5), and diluted to OD600 = 0.01. Saalfelduracin or thiostrepton was serially 
diluted (2-fold) in BHI in a 96-well microtiter plate and an equal volume of bacterial culture in BHI was 
added to each well. Cultures were allowed to grow at 37 °C with gentle shaking. The MIC reported was the 
concentration that resulted in no visible growth after 18 h.  
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4.6 Figures 
 
Figure 4.1 Representative structures of thiopeptides. The number of atoms in the primary macrocycle are 
given. All known thiopeptides are close structural analogs of these seven natural products. 
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Figure 4.2 Analysis of thiopeptide [4+2] enzymes found in GenBank. (A) Thiopeptide [4+2] enzymes 
constitute ~4% of the Lant_Dehydr_C enzyme superfamily. The majority of [4+2] enzymes closely match 
the lactazole- or thiomuracin-like pHMMs. (B) Sequence similarity network of thiopeptide [4+2] enzymes 
(100% identical sequences are conflated, alignment score 43, colored as in panel A). While thiomuracin-, 
thiostrepton-, and berninamycin-like [4+2] enzymes tend to cluster together, the lactazole-like [4+2] 
enzymes form numerous unexplored groups at this alignment value. Blue outline nodes co-occur with 
additional TfuA/YcaO-encoding genes. 
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Figure 4.3 Bioinformatic analysis of thiopeptide precursor peptides. (A) Sequence similarity network of 
precursor peptides (conflated at 100% identity, alignment score of 8). Sequence logos of the top 14 most 
populous clusters are in Figure 4.12. Nodes are colored based on Cys content as in panel B. (B) Histogram 
of Cys content in thiopeptide precursors. (C) Histogram of Ser+Thr content in thiopeptide precursors. (D) 
Histogram of maximum possible (cyclo)dehydrations excluding critical dehydrations incorporated into 
pyridine/(dehydro)piperidine. This value is calculated by Cys+Ser+Thr-2 (if the C-terminus is C/S/T, the 
residue is not counted given these are not known to undergo dehydration). 
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Figure 4.4 Discovery of saalfelduracin (A) Saalfelduracin biosynthetic gene cluster and predicted precursor 
peptide (B) Proposed structure of saalfelduracin with motifs distinct from thiostrepton in red (C) 1H shift 
of the Thr12 amide and Cα proton in saalfelduracin (red), compared to thiostrepton (black). 
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Figure 4.5 (A) Organization of thiopeptide biosynthetic gene clusters and precursor peptides with core 
sequences in bold. Whole-genome sequencing of S. tateyamensis and M. arborensis revealed analogous 
thiopeptide gene clusters with additional ycaO-tfuA genes, denoted by asterisks. (B) Structures of 
thiopeptides with thioamide analogs (red). 
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Figure 4.6 MALDI-TOF MS of S. laurentii integration mutants. Colonies of S. laurentii with chromosomal 
copies of ycaO-tfuA genes under strong constitutive promotion from M. arborensis (marTY), S. 
tateyamensis (staTY), and A. saalfeldensis (asaTY) were analyzed by MALDI-TOF MS. Conjugants 
produced a thioamidated species (m/z 1680), 16 Da greater than unmodified thiostrepton (m/z 1664) and 
consistent with Sch 18640. High-resolution masses were obtained by Orbitrap HRMS. 
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Figure 4.7 Phylogenetic distribution of [4+2]-cycloaddition enzymes. Maximum likelihood tree of all 508 
identified thiopeptide [4+2]-cycloaddition enzymes (including redundant sequences) colored according to 
phylogenetic class of the encoding organism. Tree was visualized using Interactive Tree of Life (iTOL).63  
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Figure 4.8 Maximum likelihood tree of [4+2]-cycloaddition enzymes. Each member of the tree is colored 
according to the best-matching class of [4+2]-cycloaddition enzyme, as scored by custom generated 
pHMMs. All 508 identified [4+2]-cycloaddition enzymes are included, including redundant sequences. The 
tree was visualized using Interactive Tree of Life (iTOL).63  
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Figure 4.9 Sequence similarity networks of [4+2]-cycloaddition enzymes. The sequence similarity network 
(SSN) is colored by phylogenetic class (A) and on the presence of P450/radical SAM tailoring enzymes 
(B). Clusters that contain TfuA-like proteins are outlined in blue. While many thiopeptides, such as 
thiostrepton and thiomuracin, have multiple ancillary tailoring enzymes, an appreciable of thiopeptide 
biosynthetic gene clusters apparently lack ancillary tailoring enzymes, as exemplified by lactazole. The 
SSN was generated using the Enzyme Function Initiative Enzyme Similarity Tool (EFI-EST) and visualized 
with Cytoscape.64,65 Each node is conflated at the 100% identity level, resulting in 456 nodes. The cutoff 
value for node relatedness is visualized at an identity score of 43.  
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Figure 4.10 Analysis of G+C content in thiopeptide [4+2]-cycloaddition enzymes. The G+C content of 
thiopeptide [4+2]-cycloaddition enzymes identified through genome mining. The average difference and 
standard deviation between the G+C content of the genome and the [4+2]-cycloaddition gene was 1.8 ± 
2.3%. [4+2]-cycloaddition genes that differed from the genomic G+C content by three or more standard 
deviations are annotated on the plot.  
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Figure 4.11 Motifs used in thiopeptide leader peptide cleavage site prediction. The following three motifs 
are used to predict the cut site between the leader and core peptides in analyzed thiopeptide precursor 
peptides using RODEO in conjunction with the MEME suite of bioinformatics tools.56 The occurrence of 
each cut site within our dataset of 614 precursor peptides is given.  
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Figure 4.12 Sequence analysis of RODEO-identified thiopeptides. The top 14 most populous clusters on 
the SSN (Figure 4.3) were analyzed for core sequence content using WebLogo and divided into four 
categories based on [4+2]-cycloaddition enzyme class: (A) lactazole-like, (B) thiomuracin-like, (C) 
berninamycin-like, and (D) thiostrepton-like. Groups with at least one characterized member (groups 3, 4, 
10-13) feature an annotation indicating which Ser residues are incorporated into the central 6-membered 
N-heterocycle, as well as the number of atoms comprising the primary macrocycle. Many of the groups 
lacking a known member are among the most populated (see Figure 4.3).  
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Figure 4.13 Thiopeptide precursor length variability. Histogram of thiopeptide core sequence length. 
Sequences were identified/scored by RODEO and the putative leader peptide cleavage site predicted by 
motif analysis. The group centered >20 represent a large number of currently uncharacterized thiopeptide 
families while the grouping <20 includes all characterized thiopeptides to date. 
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Figure 4.14 RODEO-identified “deorphaned” thiopeptides. Thiopeptide biosynthetic gene clusters 
identified by RODEO were cross-referenced with previously characterized thiopeptides of unknown 
genetic origin. (A) Gene clusters containing precursor peptides with core sequences corresponding to 
orphan thiopeptides. (B) Precursor peptide sequences aligned with inferred thiopeptide core sequences from 
unsequenced organisms (blue). The red Cys (Sch 40832) corrects a previous prediction regarding this 
thiopeptide core sequence which suggested that the unique imidazolyl-fusion was a result of Ser, not Cys, 
modification. 
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Figure 4.15 Thiol labeling of saalfelduracin dehydrated amino acids. A. saalfeldensis extracts were 
alkylated with 10 mM N,N-diisopropylethylamine (DIPEA) and 100 mM dithiothreitol (DTT). A mass with 
consistent with the addition of 6 DTT equivalents was seen, suggestive of 6 Michael acceptor groups in the 
mature natural product. Side products with 5, 4, 3 and 2 DTT adducts were also identified. The core 
sequence of the A. saalfeldensis thiopeptide precursors is as follows: ASSSSCTTCICTCSCSS. 
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Figure 4.16 Tandem MS fragmentation of saalfelduracin. (A) Shown is the numbering convention for 
saalfelduracin fragments seen in MS/MS. (B) CID spectrum of saalfeduracin with assigned fragments. 
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Figure 4.17 NMR assignments of saalfelduracin. Saalfelduracin purified from A. saalfeldensis was 
analyzed by NMR 1H-1H TOCSY and 1H-1H NOESY (sample held at 25 °C in 1:1 CDCl3:CD3OH and 
recorded using a 750 MHz magnet, see Section 4.5.12). (A) Numbering convention for residues in 
saalfelduracin. (B) 1H-1H TOCSY correlations are indicated in bold black while NOESY correlations are 
shown in purple. 
  
159 
 
Figure 4.18 1H spectrum of saalfelduracin. 
  
160 
 
Figure 4.19 1H-1H TOCSY spectrum of saalfelduracin. Red trace indicates the Thr12 spin system 
containing the thioamide nitrogen.  
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Figure 4.20 1H-1H NOESY spectrum of saalfelduracin. 
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Figure 4.21 Identity plot of thioamide-containing thiopeptides with thiostrepton. Genes in common 
between thiostrepton and the three identified (dehydro)piperidine- and thioamide-containing thiopeptides 
were analyzed to evaluate which gene sequences were under the strictest conservation. Average percent 
identity was plotted against relative gene position relative to the biosynthetic gene cluster for thiostrepton. 
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Figure 4.22 Gene synteny plots of thioamide-containing thiopeptides. Synteny plots between thiostrepton 
and the three identified (dehydro)piperidine- and thioamide-containing thiopeptides were generated by 
r2cat.66 BGC, biosynthetic gene cluster. 
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Figure 4.23 Constructs used for conjugation with Streptomyces laurentii. pAE4 integrative plasmid was 
used as the backbone to create heterologous expression constructs under strong constitutive promotion. An 
engineered version of ermE*p promoter with tfuA-ycaO genes was cloned into the vector adjacent to the 
ΦC31-attP integrase site via Gibson assembly. Figure was creating using ApE 2.0.50 
(http://biologylabs.utah.edu/jorgensen/wayned/ape/).  
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Figure 4.24 tfuA and ycaO are both required for thioamide formation. Streptomyces laurentii conjugants 
with constructs containing either the tfuA (marT), ycaO (marY) or both (marTY) were analyzed by MALDI-
TOF MS for the presence of thioamide formation converting thiostrepton to Sch 18640. 
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4.7 Tables 
Table 4.1 Antibiotic activity of saalfelduracin and thiostrepton as determined by microbroth dilution assay. 
MIC, minimum inhibitory concentration. 
Strain 
MIC (μg/mL) 
saalfelduracin thiostrepton 
Staphylococcus aureus USA300 0.25 0.12 
Enterococcus faecium U503 0.12 0.12 
Bacillus anthracis str. Sterne 0.25 0.25 
Escherichia coli MC4100 >64 >64 
Pseudomonas aeruginosa  
PAO1 
>64 >64 
Acinetobacter baumannii  
ATCC 19606 
>64 >64 
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Table 4.2 Co-occurring genes in thiopeptide BGCs. The most abundant genes that co-occur with the gene 
encoding the [4+2]-cycloaddition enzyme are listed in descending order. Percent co-occurrence indicates 
the percentage of clusters that contain at least one gene matching the indicated protein family (PFAM). 
Custom pHMMs created for this study are highlighted in yellow. Co-occurrence statistics were obtained 
from the RODEO dataset (instructions at www.ripprodeo.org). Note that although certain protein families 
appear on this list, they are not necessarily involved in thiopeptide biosynthesis. However, very low co-
occurring entries, such as the TfuA-like domain (PF07812), are now known to be involved in the 
biosynthesis of certain thiopeptides. 
 
PFAM 
ID/pHMM 
PFAM/pHMM 
Name                         PFAM/pHMM Description Count 
% co-
occurrence 
PF02624 YcaO YcaO cyclodehydratase, ATP-ad Mg2+-binding 546 106 
ThiF ThiF Ocin-ThiF (required for many YcaO enzymes)  504 98 
Glutamylator Glutamylator Glutamylator (tRNA-dep., for Dha/Dhb formation) 502 97 
PF00881 Nitroreductase Nitroreductase family 468 91 
PF04738 Lant_dehydr_N Lantibiotic dehydratase, C terminus 448 87 
Eliminator Eliminator Eliminator (for Dha/Dhb formation) 446 87 
PF14028 Lant_dehydr_C Lantibiotic biosynthesis dehydratase C-term 446 87 
PF00005 ABC_tran ABC transporter 420 82 
PF13304 AAA_21 AAA domain, putative AbiEii toxin, Type IV TA system 378 73 
PF02463 SMC_N RecF/RecN/SMC N terminal domain 272 53 
PF01061 ABC2_membrane ABC-2 type transporter 227 44 
PF12698 ABC2_membrane_3 ABC-2 family transporter protein 218 42 
PF00196 GerE Bacterial regulatory proteins, luxR family 177 34 
PF00072 Response_reg Response regulator receiver domain 170 33 
PF13649 Methyltransf_25 Methyltransferase domain 148 29 
PF13191 AAA_16 AAA ATPase domain 137 27 
PF07690 MFS_1 Major Facilitator Superfamily 135 26 
PF08241 Methyltransf_11 Methyltransferase domain 135 26 
PF00440 TetR_N Bacterial regulatory proteins, tetR family 124 24 
PF00106 adh_short short chain dehydrogenase 123 24 
PF08281 Sigma70_r4_2 Sigma-70, region 4 123 24 
PF00501 AMP-binding AMP-binding enzyme 119 23 
PF08242 Methyltransf_12 Methyltransferase domain 115 22 
PF01494 FAD_binding_3 FAD binding domain 113 22 
PF13489 Methyltransf_23 Methyltransferase domain 111 22 
PF13555 AAA_29 P-loop containing region of AAA domain 111 22 
PF13561 adh_short_C2 Enoyl-(Acyl carrier protein) reductase 110 21 
PF13847 Methyltransf_31 Methyltransferase domain 108 21 
PF00067 p450 Cytochrome P450 105 20 
PF00528 BPD_transp_1 
Binding-protein-dependent transport system inner 
membrane component 105 20 
PF04545 Sigma70_r4 Sigma-70, region 4 104 20 
PF00561 Abhydrolase_1 alpha/beta hydrolase fold 99 19 
PF13175 AAA_15 AAA ATPase domain 96 19 
PF08659 KR KR domain 95 18 
PF12802 MarR_2 MarR family 92 18 
PF13401 AAA_22 AAA domain 90 17 
PF04055 Radical_SAM Radical SAM superfamily 89 17 
PF00583 Acetyltransf_1 Acetyltransferase (GNAT) family 88 17 
PF02518 HATPase_c 
Histidine kinase-, DNA gyrase B-, and HSP90-like 
ATPase 87 17 
PF12697 Abhydrolase_6 Alpha/beta hydrolase family 84 16 
PF13193 AMP-binding_C AMP-binding enzyme C-terminal domain 82 16 
PF01370 Epimerase NAD dependent epimerase/dehydratase family 81 16 
PF07992 Pyr_redox_2 Pyridine nucleotide-disulphide oxidoreductase 78 15 
PF13450 NAD_binding_8 NAD(P)-binding Rossmann-like domain 75 15 
PF12146 Hydrolase_4 Serine aminopeptidase, S33 73 14 
PF00155 Aminotran_1_2 Aminotransferase class I and II 71 14 
 
168 
Table 4.2 (cont.) 
PF01381 HTH_3 Helix-turn-helix 71 14 
PF13384 HTH_23 Homeodomain-like domain 71 14 
PF00486 Trans_reg_C Transcriptional regulatory protein, C terminal 63 12 
PF13424 TPR_12 Tetratricopeptide repeat 61 12 
PF13560 HTH_31 Helix-turn-helix domain 61 12 
PF01266 DAO FAD dependent oxidoreductase 60 12 
PF03704 BTAD Bacterial transcriptional activator domain 58 11 
PF12840 HTH_20 Helix-turn-helix domain 58 11 
PF07730 HisKA_3 Histidine kinase 56 11 
PF00069 Pkinase Protein kinase domain 54 10 
PF01546 Peptidase_M20 Peptidase family M20/M25/M40 52 10 
PF07719 TPR_2 Tetratricopeptide repeat 52 10 
PF13508 Acetyltransf_7 Acetyltransferase (GNAT) domain 52 10 
PF00266 Aminotran_5 Aminotransferase class-V 51 10 
PF13412 HTH_24 Winged helix-turn-helix DNA-binding 51 10 
PF00441 Acyl-CoA_dh_1 Acyl-CoA dehydrogenase, C-terminal domain 50 10 
PF00664 ABC_membrane ABC transporter transmembrane region 50 10 
PF02771 Acyl-CoA_dh_N Acyl-CoA dehydrogenase, N-terminal domain 50 10 
PF05977 MFS_3 Transmembrane secretion effector 50 10 
PF01041 DegT_DnrJ_EryC1 DegT/DnrJ/EryC1/StrS aminotransferase family 49 10 
PF13673 Acetyltransf_10 Acetyltransferase (GNAT) domain 49 10 
PF01791 DeoC DeoC/LacD family aldolase 48 9 
PF08279 HTH_11 HTH domain 47 9 
PF13302 Acetyltransf_3 Acetyltransferase (GNAT) domain 47 9 
PF00070 Pyr_redox Pyridine nucleotide-disulphide oxidoreductase 44 9 
PF00083 Sugar_tr Sugar (and other) transporter 44 9 
PF01047 MarR MarR family 44 9 
PF12679 ABC2_membrane_2 ABC-2 family transporter protein 44 9 
PF13545 HTH_Crp_2 Crp-like helix-turn-helix domain 44 9 
PF01959 DHQS 3-dehydroquinate synthase (EC 4.6.1.3) 43 8 
PF13476 AAA_23 AAA domain 43 8 
PF04397 LytTR LytTr DNA-binding domain 42 8 
PF12844 HTH_19 Helix-turn-helix domain 42 8 
PF13581 HATPase_c_2 Histidine kinase-like ATPase domain 42 8 
PF07714 Pkinase_Tyr Protein tyrosine kinase 41 8 
PF13460 NAD_binding_10 NAD(P)H-binding 41 8 
PF01636 APH Phosphotransferase enzyme family 40 8 
PF02770 Acyl-CoA_dh_M Acyl-CoA dehydrogenase, middle domain 40 8 
PF00004 AAA 
ATPase family associated with various cellular activities 
(AAA) 38 7 
PF00009 GTP_EFTU Elongation factor Tu GTP binding domain 38 7 
PF03144 GTP_EFTU_D2 Elongation factor Tu domain 2 38 7 
PF14501 HATPase_c_5 GHKL domain 38 7 
PF00296 Bac_luciferase Luciferase-like monooxygenase 37 7 
PF00392 GntR Bacterial regulatory proteins, gntR family 37 7 
PF00903 Glyoxalase 
Glyoxalase/Bleomycin resistance protein/Dioxygenase 
superfamily 37 7 
PF07883 Cupin_2 Cupin domain 37 7 
PF08028 Acyl-CoA_dh_2 Acyl-CoA dehydrogenase, C-terminal domain 37 7 
PF00512 HisKA His Kinase A (phospho-acceptor) domain 36 7 
PF01073 3Beta_HSD 3-beta hydroxysteroid dehydrogenase/isomerase family 36 7 
PF02310 B12-binding B12 binding domain 36 7 
PF00326 Peptidase_S9 Prolyl oligopeptidase family 35 7 
PF13463 HTH_27 Winged helix DNA-binding domain 35 7 
PF00515 TPR_1 Tetratricopeptide repeat 34 7 
PF03466 LysR_substrate LysR substrate binding domain 34 7 
PF00702 Hydrolase haloacid dehalogenase-like hydrolase 33 6 
PF01022 HTH_5 Bacterial regulatory protein, arsR family 33 6 
PF12832 MFS_1_like MFS_1 like family 33 6 
PF12680 SnoaL_2 SnoaL-like domain 32 6 
PF01547 SBP_bac_1 Bacterial extracellular solute-binding protein 31 6 
PF02082 Rrf2 Transcriptional regulator 31 6 
PF13604 AAA_30 AAA domain 31 6 
PF00126 HTH_1 Bacterial regulatory helix-turn-helix protein, lysR family 30 6 
PF00890 FAD_binding_2 FAD binding domain 30 6 
PF01638 HxlR HxlR-like helix-turn-helix 30 6 
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Table 4.2 (cont.) 
PF04542 Sigma70_r2 Sigma-70 region 2 30 6 
PF00532 Peripla_BP_1 
Periplasmic binding proteins and sugar binding domain 
of LacI family 29 6 
PF00550 PP-binding Phosphopantetheine attachment site 29 6 
PF04321 RmlD_sub_bind RmlD substrate binding domain 29 6 
PF13377 Peripla_BP_3 Periplasmic binding protein-like domain 29 6 
PF13558 SbcCD_C Putative exonuclease SbcCD, C subunit 29 6 
PF00107 ADH_zinc_N Zinc-binding dehydrogenase 28 5 
PF00202 Aminotran_3 Aminotransferase class-III 28 5 
PF00672 HAMP HAMP domain 28 5 
PF08240 ADH_N Alcohol dehydrogenase GroES-like domain 28 5 
PF13374 TPR_10 Tetratricopeptide repeat 28 5 
PF13407 Peripla_BP_4 Periplasmic binding protein domain 28 5 
PF13420 Acetyltransf_4 Acetyltransferase (GNAT) domain 28 5 
PF16363 GDP_Man_Dehyd GDP-mannose 4,6 dehydratase 28 5 
PF00356 LacI Bacterial regulatory proteins, lacI family 27 5 
PF00376 MerR MerR family regulatory protein 27 5 
PF13411 MerR_1 MerR HTH family regulatory protein 27 5 
PF13481 AAA_25 AAA domain 27 5 
PF00165 HTH_AraC Bacterial regulatory helix-turn-helix proteins, AraC family 26 5 
PF00171 Aldedh Aldehyde dehydrogenase family 26 5 
PF00553 CBM_2 Cellulose binding domain 26 5 
PF00589 Phage_integrase Phage integrase family 26 5 
PF00899 ThiF ThiF family 26 5 
PF01408 GFO_IDH_MocA Oxidoreductase family, NAD-binding Rossmann fold 26 5 
PF07731 Cu-oxidase_2 Multicopper oxidase 26 5 
PF07732 Cu-oxidase_3 Multicopper oxidase 26 5 
PF12833 HTH_18 Helix-turn-helix domain 26 5 
PF13531 SBP_bac_11 Bacterial extracellular solute-binding protein 26 5 
PF13602 ADH_zinc_N_2 Zinc-binding dehydrogenase 26 5 
PF01243 Putative_PNPOx Pyridoxamine 5'-phosphate oxidase 25 5 
PF04647 AgrB Accessory gene regulator B 25 5 
PF06722 DUF1205 Protein of unknown function (DUF1205) 25 5 
PF07366 SnoaL SnoaL-like polyketide cyclase 25 5 
PF07728 AAA_5 AAA domain (dynein-related subfamily) 25 5 
PF13732 DUF4162 Domain of unknown function (DUF4162) 25 5 
PF00394 Cu-oxidase Multicopper oxidase 24 5 
PF00588 SpoU_methylase SpoU rRNA Methylase family 24 5 
PF01053 Cys_Met_Meta_PP Cys/Met metabolism PLP-dependent enzyme 24 5 
PF07228 SpoIIE Stage II sporulation protein E (SpoIIE) 24 5 
PF08386 Abhydrolase_4 TAP-like protein 24 5 
PF12804 NTP_transf_3 MobA-like NTP transferase domain 24 5 
PF13280 WYL WYL domain 24 5 
PF00248 Aldo_ket_red Aldo/keto reductase family 23 4 
PF00271 Helicase_C Helicase conserved C-terminal domain 23 4 
PF00668 Condensation Condensation domain 23 4 
PF03446 NAD_binding_2 
NAD binding domain of 6-phosphogluconate 
dehydrogenase 23 4 
PF04072 LCM Leucine carboxyl methyltransferase 23 4 
PF05368 NmrA NmrA-like family 23 4 
PF06779 MFS_4 Uncharacterised MFS-type transporter YbfB 23 4 
PF08352 oligo_HPY Oligopeptide/dipeptide transporter, C-terminal region 23 4 
PF13347 MFS_2 MFS/sugar transport protein 23 4 
PF16859 TetR_C_11 Bacterial transcriptional repressor C-terminal 23 4 
PF00201 UDPGT UDP-glucoronosyl and UDP-glucosyl transferase 22 4 
PF01609 DDE_Tnp_1 Transposase DDE domain 22 4 
PF01978 TrmB Sugar-specific transcriptional regulator TrmB 22 4 
PF02687 FtsX FtsX-like permease family 22 4 
PF02719 Polysacc_synt_2 Polysaccharide biosynthesis protein 22 4 
PF02826 2-Hacid_dh_C 
D-isomer specific 2-hydroxyacid dehydrogenase, NAD 
binding domain 22 4 
PF03372 Exo_endo_phos Endonuclease/Exonuclease/phosphatase family 22 4 
PF13360 PQQ_2 PQQ-like domain 22 4 
PF00111 Fer2 2Fe-2S iron-sulfur cluster binding domain 21 4 
PF00270 DEAD DEAD/DEAH box helicase 21 4 
PF01926 MMR_HSR1 50S ribosome-binding GTPase 21 4 
PF04705 TSNR_N Thiostrepton-resistance methylase, N terminus 21 4 
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PF00324 AA_permease Amino acid permease 20 4 
PF00679 EFG_C Elongation factor G C-terminus 20 4 
PF01979 Amidohydro_1 Amidohydrolase family 20 4 
PF03193 RsgA_GTPase RsgA GTPase 20 4 
PF03764 EFG_IV Elongation factor G, domain IV 20 4 
PF03807 F420_oxidored NADP oxidoreductase coenzyme F420-dependent 20 4 
PF08220 HTH_DeoR DeoR-like helix-turn-helix domain 20 4 
PF09339 HTH_IclR IclR helix-turn-helix domain 20 4 
PF13343 SBP_bac_6 Bacterial extracellular solute-binding protein 20 4 
PF13353 Fer4_12 4Fe-4S single cluster domain 20 4 
PF14492 EFG_II Elongation Factor G, domain II 20 4 
PF00931 NB-ARC NB-ARC domain 19 4 
PF01212 Beta_elim_lyase Beta-eliminating lyase 19 4 
PF01695 IstB_IS21 IstB-like ATP binding protein 19 4 
PF01965 DJ-1_PfpI DJ-1/PfpI family 19 4 
PF03143 GTP_EFTU_D3 Elongation factor Tu C-terminal domain 19 4 
PF07676 PD40 WD40-like Beta Propeller Repeat 19 4 
PF07969 Amidohydro_3 Amidohydrolase family 19 4 
PF12710 HAD haloacid dehalogenase-like hydrolase 19 4 
PF12867 DinB_2 DinB superfamily 19 4 
PF13416 SBP_bac_8 Bacterial extracellular solute-binding protein 19 4 
PF13520 AA_permease_2 Amino acid permease 19 4 
PF13551 HTH_29 Winged helix-turn helix 19 4 
PF13738 Pyr_redox_3 Pyridine nucleotide-disulphide oxidoreductase 19 4 
PF14200 RicinB_lectin_2 Ricin-type beta-trefoil lectin domain-like 19 4 
PF00082 Peptidase_S8 Subtilase family 18 3 
PF00144 Beta-lactamase Beta-lactamase 18 3 
PF00483 NTP_transferase Nucleotidyl transferase 18 3 
PF00542 Ribosomal_L12 Ribosomal protein L7/L12 C-terminal domain 18 3 
PF00623 RNA_pol_Rpb1_2 RNA polymerase Rpb1, domain 2 18 3 
PF01575 MaoC_dehydratas MaoC like domain 18 3 
PF04983 RNA_pol_Rpb1_3 RNA polymerase Rpb1, domain 3 18 3 
PF04997 RNA_pol_Rpb1_1 RNA polymerase Rpb1, domain 1 18 3 
PF04998 RNA_pol_Rpb1_5 RNA polymerase Rpb1, domain 5 18 3 
PF05000 RNA_pol_Rpb1_4 RNA polymerase Rpb1, domain 4 18 3 
PF05175 MTS Methyltransferase small domain 18 3 
PF10604 Polyketide_cyc2 Polyketide cyclase / dehydrase and lipid transport 18 3 
PF12730 ABC2_membrane_4 ABC-2 family transporter protein 18 3 
PF13394 Fer4_14 4Fe-4S single cluster domain 18 3 
PF13419 HAD_2 haloacid dehalogenase-like hydrolase 18 3 
PF13518 HTH_28 Helix-turn-helix domain 18 3 
PF13527 Acetyltransf_9 Acetyltransferase (GNAT) domain 18 3 
PF13579 Glyco_trans_4_4 Glycosyl transferase 4-like domain 18 3 
PF13671 AAA_33 AAA domain 18 3 
PF00132 Hexapep Bacterial transferase hexapeptide (six repeats) 17 3 
PF00164 Ribosom_S12_S23 Ribosomal protein S12/S23 17 3 
PF00562 RNA_pol_Rpb2_6 RNA polymerase Rpb2, domain 6 17 3 
PF00733 Asn_synthase Asparagine synthase 17 3 
PF01209 Ubie_methyltran ubiE/COQ5 methyltransferase family 17 3 
PF01565 FAD_binding_4 FAD binding domain 17 3 
PF03795 YCII YCII-related domain 17 3 
PF04101 Glyco_tran_28_C Glycosyltransferase family 28 C-terminal domain 17 3 
PF04560 RNA_pol_Rpb2_7 RNA polymerase Rpb2, domain 7 17 3 
PF04561 RNA_pol_Rpb2_2 RNA polymerase Rpb2, domain 2 17 3 
PF04565 RNA_pol_Rpb2_3 RNA polymerase Rpb2, domain 3 17 3 
PF07859 Abhydrolase_3 alpha/beta hydrolase fold 17 3 
PF07959 Fucokinase L-fucokinase 17 3 
PF10385 RNA_pol_Rpb2_45 RNA polymerase beta subunit external 1 domain 17 3 
PF13185 GAF_2 GAF domain 17 3 
PF13242 Hydrolase_like HAD-hyrolase-like 17 3 
PF13646 HEAT_2 HEAT repeats 17 3 
PF00109 ketoacyl-synt Beta-ketoacyl synthase, N-terminal domain 16 3 
PF00177 Ribosomal_S7 Ribosomal protein S7p/S5e 16 3 
PF00298 Ribosomal_L11 Ribosomal protein L11, RNA binding domain 16 3 
PF00466 Ribosomal_L10 Ribosomal protein L10 16 3 
PF00753 Lactamase_B Metallo-beta-lactamase superfamily 16 3 
PF01551 Peptidase_M23 Peptidase family M23 16 3 
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PF03559 Hexose_dehydrat NDP-hexose 2,3-dehydratase 16 3 
PF03946 Ribosomal_L11_N Ribosomal protein L11, N-terminal domain 16 3 
PF05401 NodS Nodulation protein S (NodS) 16 3 
PF08803 ydhR Putative mono-oxygenase ydhR 16 3 
PF13176 TPR_7 Tetratricopeptide repeat 16 3 
PF13522 GATase_6 Glutamine amidotransferase domain 16 3 
PF13537 GATase_7 Glutamine amidotransferase domain 16 3 
PF13556 HTH_30 PucR C-terminal helix-turn-helix domain 16 3 
PF13977 TetR_C_6 BetI-type transcriptional repressor, C-terminal 16 3 
PF16320 Ribosomal_L12_N Ribosomal protein L7/L12 dimerisation domain 16 3 
PF00465 Fe-ADH Iron-containing alcohol dehydrogenase 15 3 
PF00582 Usp Universal stress protein family 15 3 
PF00652 Ricin_B_lectin Ricin-type beta-trefoil lectin domain 15 3 
PF00665 rve Integrase core domain 15 3 
PF01738 DLH Dienelactone hydrolase family 15 3 
PF02311 AraC_binding AraC-like ligand binding domain 15 3 
PF02525 Flavodoxin_2 Flavodoxin-like fold 15 3 
PF02558 ApbA Ketopantoate reductase PanE/ApbA 15 3 
PF02801 Ketoacyl-synt_C Beta-ketoacyl synthase, C-terminal domain 15 3 
PF03358 FMN_red NADPH-dependent FMN reductase 15 3 
PF03486 HI0933_like HI0933-like protein 15 3 
PF04264 YceI YceI-like domain 15 3 
PF05724 TPMT Thiopurine S-methyltransferase (TPMT) 15 3 
PF05729 NACHT NACHT domain 15 3 
PF07687 M20_dimer Peptidase dimerisation domain 15 3 
PF07729 FCD FCD domain 15 3 
PF08282 Hydrolase_3 haloacid dehalogenase-like hydrolase 15 3 
PF11716 MDMPI_N Mycothiol maleylpyruvate isomerase N-terminal domain 15 3 
PF13181 TPR_8 Tetratricopeptide repeat 15 3 
PF13685 Fe-ADH_2 Iron-containing alcohol dehydrogenase 15 3 
PF00122 E1-E2_ATPase E1-E2 ATPase 14 3 
PF00127 Copper-bind Copper binding proteins, plastocyanin/azurin family 14 3 
PF00657 Lipase_GDSL GDSL-like Lipase/Acylhydrolase 14 3 
PF00933 Glyco_hydro_3 Glycosyl hydrolase family 3 N terminal domain 14 3 
PF00989 PAS PAS fold 14 3 
PF01569 PAP2 PAP2 superfamily 14 3 
PF01610 DDE_Tnp_ISL3 Transposase 14 3 
PF01656 CbiA CobQ/CobB/MinD/ParA nucleotide binding domain 14 3 
PF01915 Glyco_hydro_3_C Glycosyl hydrolase family 3 C-terminal domain 14 3 
PF02909 TetR_C Tetracyclin repressor, C-terminal all-alpha domain 14 3 
PF13245 AAA_19 AAA domain 14 3 
PF13472 Lipase_GDSL_2 GDSL-like Lipase/Acylhydrolase family 14 3 
PF00037 Fer4 4Fe-4S binding domain 13 3 
PF00149 Metallophos Calcineurin-like phosphoesterase 13 3 
PF00367 PTS_EIIB phosphotransferase system, EIIB 13 3 
PF00687 Ribosomal_L1 Ribosomal protein L1p/L10e family 13 3 
PF00975 Thioesterase Thioesterase domain 13 3 
PF02378 PTS_EIIC Phosphotransferase system, EIIC 13 3 
PF04978 DUF664 Protein of unknown function (DUF664) 13 3 
PF08327 AHSA1 Activator of Hsp90 ATPase homolog 1-like protein 13 3 
PF08445 FR47 FR47-like protein 13 3 
PF11066 DUF2867 Protein of unknown function (DUF2867) 13 3 
PF12704 MacB_PCD MacB-like periplasmic core domain 13 3 
PF13238 AAA_18 AAA domain 13 3 
PF13426 PAS_9 PAS domain 13 3 
PF13452 MaoC_dehydrat_N N-terminal half of MaoC dehydratase 13 3 
PF14310 Fn3-like Fibronectin type III-like domain 13 3 
PF00027 cNMP_binding Cyclic nucleotide-binding domain 12 2 
PF00190 Cupin_1 Cupin 12 2 
PF00384 Molybdopterin Molybdopterin oxidoreductase 12 2 
PF00497 SBP_bac_3 Bacterial extracellular solute-binding proteins, family 3 12 2 
PF00892 EamA EamA-like transporter family 12 2 
PF00990 GGDEF Diguanylate cyclase, GGDEF domain 12 2 
PF01042 Ribonuc_L-PSP Endoribonuclease L-PSP 12 2 
PF01145 Band_7 SPFH domain / Band 7 family 12 2 
PF01257 2Fe-2S_thioredx Thioredoxin-like [2Fe-2S] ferredoxin 12 2 
PF01522 Polysacc_deac_1 Polysaccharide deacetylase 12 2 
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PF01568 Molydop_binding Molydopterin dinucleotide binding domain 12 2 
PF01872 RibD_C RibD C-terminal domain 12 2 
PF02129 Peptidase_S15 X-Pro dipeptidyl-peptidase (S15 family) 12 2 
PF02254 TrkA_N TrkA-N domain 12 2 
PF03459 TOBE TOBE domain 12 2 
PF03992 ABM Antibiotic biosynthesis monooxygenase 12 2 
PF04851 ResIII Type III restriction enzyme, res subunit 12 2 
PF04879 Molybdop_Fe4S4 Molybdopterin oxidoreductase Fe4S4 domain 12 2 
PF07993 NAD_binding_4 Male sterility protein 12 2 
PF08448 PAS_4 PAS fold 12 2 
PF09084 NMT1 NMT1/THI5 like 12 2 
PF12418 AcylCoA_DH_N Acyl-CoA dehydrogenase N terminal 12 2 
PF12706 Lactamase_B_2 Beta-lactamase superfamily domain 12 2 
PF12727 PBP_like PBP superfamily domain 12 2 
PF12806 Acyl-CoA_dh_C Acetyl-CoA dehydrogenase C-terminal like 12 2 
PF12857 TOBE_3 TOBE-like domain 12 2 
PF13241 NAD_binding_7 Putative NAD(P)-binding 12 2 
PF13340 DUF4096 Putative transposase of IS4/5 family (DUF4096) 12 2 
PF13541 ChlI Subunit ChlI of Mg-chelatase 12 2 
PF13614 AAA_31 AAA domain 12 2 
PF13683 rve_3 Integrase core domain 12 2 
PF13828 DUF4190 Domain of unknown function (DUF4190) 12 2 
PF14534 DUF4440 Domain of unknown function (DUF4440) 12 2 
PF00015 MCPsignal 
Methyl-accepting chemotaxis protein (MCP) signalling 
domain 11 2 
PF00535 Glycos_transf_2 Glycosyl transferase family 2 11 2 
PF00696 AA_kinase Amino acid kinase family 11 2 
PF00756 Esterase Putative esterase 11 2 
PF00941 FAD_binding_5 FAD binding domain in molybdopterin dehydrogenase 11 2 
PF01512 Complex1_51K Respiratory-chain NADH dehydrogenase 51 Kd subunit 11 2 
PF01557 FAA_hydrolase Fumarylacetoacetate (FAA) hydrolase family 11 2 
PF01590 GAF GAF domain 11 2 
PF01699 Na_Ca_ex Sodium/calcium exchanger protein 11 2 
PF03551 PadR Transcriptional regulator PadR-like family 11 2 
PF04616 Glyco_hydro_43 Glycosyl hydrolases family 43 11 2 
PF05931 AgrD Staphylococcal AgrD protein 11 2 
PF06325 PrmA Ribosomal protein L11 methyltransferase (PrmA) 11 2 
PF06968 BATS Biotin and Thiamin Synthesis associated domain 11 2 
PF07638 Sigma70_ECF ECF sigma factor 11 2 
PF07739 TipAS TipAS antibiotic-recognition domain 11 2 
PF07812 TfuA TfuA-like protein (for thioamide formation) 11 2 
PF10531 SLBB SLBB domain 11 2 
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Table 4.3 MS fragment assignments. Mass values assigned to the fragmentation products with calculated 
and observed values and associated error. Thioamide predicted mass (thioamidation) is compared with a 
theoretical oxidation mass resulting from an additional oxygen atom (oxidized) in red. 
 
Species Predicted mass Observed mass Error (ppm) 
[M+H]+ (thioamidated, OS) 1637.3982 1637.3996 0.8 
[M+H]+ (oxidized, +O) 1637.4160 1637.3996 10.0 
[M+H-H2O]+ 1619.3876 1619.3845 1.9 
[M+H-2H2O]+ 1601.3771 1601.3743 1.7 
[M+H-Qui]+ 1404.3294 1404.3268 1.9 
[M+H-Qui-Ala1]+ 1333.2923 1333.2903 1.5 
[M+H-Qui-Ala1-Dha2]+ 1264.2708 1264.2686 1.8 
[M+H-Qui-Ala1-Dha2-Dha3]+ 1195.2494 1195.2468 2.1 
[M+H-Qui-Ala1-Dha2-Dha4]+ 1126.2279 1126.2255 2.2 
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Table 4.4 1H NMR assignments for saalfelduracin. Resonances are labeled based on position within the 
thiopeptide as depicted in Figure 4.17. Highlighted red value (NH, Thr12) corresponds to shifted thioamide 
backbone proton (spin system shown in Figure 4.19). 
 
Residue Group 
1H δ m 
  
Residue Group 
1H δ m 
(ppm) (J, Hz) (ppm) (J, Hz) 
Ala1 CH3 2.03 d (4.0)   Tzn9 CH 4.94 m 
  CH 1.34 m     CH2 
  
3.12 m 
  NH 3.08 m     3.53 m 
Dha2 NH 9.41 s   Ile10 NH 7.55 d (7.8) 
  CH2 5.21 s     CH (1) 5.73 obsc 
    6.33 br d (2.2)     CH3 (3) 1.10 dd (3.78, 7.8) 
Dha3 NH 8.10 obsc     CH (4) 3.81 obsc 
  CH2 5.46 br d (2.5)     CH3 (5) 1.21 d (6.2) 
    5.69 br d (2.6)   Thz11 CH 
8.49 
(ambig) 
s 
Dha4 NH 7.98 s   Thr12 NH 9.83 d (8.63) 
  CH2 5.75 s     CH (1) 6.67 br d (8.3) 
    6.00 br s     CH (2) 6.45 dq (6.56) 
Pip NH (1) 2.29 dd (obsc)     CH3 1.47 d (6.69) 
  CH (2) 4.42 m   Thz13 CH 
8.47 
(ambig) 
s 
  
CH2 (3) 
2.24 m     CH (3) 7.31 s 
  2.77 m     CH (11) 5.25 q (7.1) 
  
CH2 (4) 
2.15 m     CH3 (12) 1.28 d (6.6) 
  3.81 m   Qui CH (5) 6.86 d (9.9) 
  CH (6) 4.40 d (4.3)     CH (6) 6.36 dd 
  NH (5) 10.33 s     CH (7) 3.64 br dd 
Thz6 CH 7.36 s     CH (8) 4.30 br d 
Thr7 NH 6.78 d (7.8)   Thz15 CH 
8.12 
(ambig) 
s 
  CH (1) 4.33 dd (3.78, 7.8)   Dha16 NH 8.07 s 
  CH (2) 1.46 obsc     CH2 5.57 br s 
  CH3 (4) 0.83 d (6.2)       6.53 br d (2.0) 
Dhb8 NH 8.50 s   Dha17 NH 9.36 s 
  CH 6.15 q (6.8)     CH2 
  
5.74 br d (4.9) 
  CH3 1.53 d (5.7)     6.22 br s 
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Table 4.5 Sequence similarity/identity comparison of thioamide-containing thiopeptides. NCBI accession 
numbers of relevant sequences were analyzed for sequence similarity using MatGAT 2.0 with a 
BLOSUM62 scoring matrix.67 Percent similarity values are yellow while percent identity values are blue. 
 
aminotransferase 1 2 3 4 
1. ACN52311.1 TsrV Streptomyces laurentii   18 21 36 
2. Micromonospora arborensis 29   28 20 
3. Streptomyces tateyamensis 32 35   21 
4. WP_091614342.1 hypothetical protein Amycolatopsis saalfeldensis 49 29 30   
 
hydrolase 1 2 3 4 
1. ACN52310.1 TsrU Streptomyces laurentii   49 17 21 
2. Micromonospora arborensis 63   16 17 
3. Streptomyces tateyamensis 25 24   15 
4. WP_091614355.1 alpha/beta hydrolase Amycolatopsis saalfeldensis 31 28 22   
 
asparagine synthetase 1 2 
1. ACN52309.1 TsrT Streptomyces laurentii   68 
2. Micromonospora arborensis 77   
 
quinaldic acid cyclase 1 2 3 4 
1. ACN52308.1 TsrS Streptomyces laurentii   16 18 59 
2. Micromonospora arborensis 22   20 19 
3. Streptomyces tateyamensis 33 25   18 
4. WP_091614345.1 hypothetical protein Amycolatopsis saalfeldensis 68 25 33   
 
dehydrogenase 1 2 3 4 
1. ACN52307.1 TsrQ Streptomyces laurentii   60 20 55 
2. Micromonospora arborensis 76   20 59 
3. Streptomyces tateyamensis 32 32   20 
4. WP_091614348.1 acyl-CoA dehydrogenase Amycolatopsis saalfeldensis 68 70 29   
 
methyltransferase 1 2 3 4 
1. ACN52306.1 TsrP Streptomyces laurentii   56 19 45 
2. Micromonospora arborensis 65   20 45 
3. Streptomyces tateyamensis 24 26   18 
4. WP_091614350.1 SAM methyltransferase Amycolatopsis saalfeldensis 56 57 24   
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DUF2867 1 2 3 4 
1. ACN52305.1 TsrO Streptomyces laurentii   37 18 32 
2. Micromonospora arborensis 55   18 42 
3. Streptomyces tateyamensis 30 32   20 
4. WP_091614353.1 DUF2867 Amycolatopsis saalfeldensis 51 62 34   
 
LanB tRNA-dependent glutamylating domain 1 2 3 4 
1. ACN52293.1 TsrC Streptomyces laurentii   49 52 51 
2. Micromonospora arborensis 61   54 53 
3. Streptomyces tateyamensis 64 66   66 
4. WP_091614364.1 hypothetical protein Amycolatopsis saalfeldensis 64 66 76   
 
LanB elimination domain 1 2 3 4 
1. ACN52294.1 TsrD Streptomyces laurentii   56 58 55 
2. Micromonospora arborensis 68   55 56 
3. Streptomyces tateyamensis 70 68   71 
4. WP_091614367.1 hypothetical protein Amycolatopsis saalfeldensis 69 71 82   
 
[4+2]-cycloaddition 1 2 3 4 
1. ACN52295.1 TsrE Streptomyces laurentii   69 74 73 
2. Micromonospora arborensis 82   70 71 
3. Streptomyces tateyamensis 86 81   83 
4. WP_091614370.1 hypothetical protein Amycolatopsis saalfeldensis 84 84 91   
 
azoline dehydrogenase 1 2 3 4 
1. ACN52296.1 TsrF Streptomyces laurentii   55 57 57 
2. Micromonospora arborensis 63   59 58 
3. Streptomyces tateyamensis 64 71   70 
4. WP_091614372.1 hypothetical protein Amycolatopsis saalfeldensis 65 69 77   
 
Ocin-ThiF 1 2 3 4 
1. ACN52297.1 TsrG Streptomyces laurentii   48 46 47 
2. Micromonospora arborensis 56   47 48 
3. Streptomyces tateyamensis 54 59   68 
4. WP_091614375.1 hypothetical protein Amycolatopsis saalfeldensis 56 60 76   
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Azoline-forming cyclodehydratase 1 2 3 4 
1. ACN52298.1 TsrH Streptomyces laurentii   58 59 44 
2. Micromonospora arborensis 67   61 47 
3. Streptomyces tateyamensis 67 69   56 
4. WP_091614694.1 hypothetical protein Amycolatopsis saalfeldensis 50 54 60   
 
P450 oxygenase 1 2 3 4 
1. ACN52299.1 TsrI Streptomyces laurentii   54 61 57 
2. Micromonospora arborensis 66   62 61 
3. Streptomyces tateyamensis 70 72   70 
4. WP_091614379.1 cytochrome P450 Amycolatopsis saalfeldensis 66 73 79   
 
Acyl CoA synthase (adenylation) 1 2 3 4 
1. ACN52300.1 TsrJ Streptomyces laurentii   60 64 64 
2. Micromonospora arborensis 72   62 62 
3. Streptomyces tateyamensis 73 73   79 
4. WP_091614382.1 long-chain fatty acid--CoA ligase Amycolatopsis saalfeldensis 71 72 87   
 
P450 oxygenase 1 2 3 4 
1. ACN52301.1 TsrK Streptomyces laurentii   54 53 56 
2. Micromonospora arborensis 68   56 61 
3. Streptomyces tateyamensis 64 69   71 
4. WP_091614385.1 cytochrome P450 Amycolatopsis saalfeldensis 66 72 79   
 
LanB tRNA-dependent glutamylating domain 1 2 3 4 
1. ACN52302.1 TsrL Streptomyces laurentii   45 45 47 
2. Micromonospora arborensis 56   48 52 
3. Streptomyces tateyamensis 55 59   59 
4. WP_091614387.1 hypothetical protein Amycolatopsis saalfeldensis 58 63 68   
 
radical SAM 1 2 3 4 
1. ACN52303.1 TsrM Streptomyces laurentii   62 64 64 
2. Micromonospora arborensis 74   66 64 
3. Streptomyces tateyamensis 73 75   85 
4. WP_091614395.1 tryptophan 2-C-methyltransferase 
Amycolatopsis saalfeldensis 73 76 91   
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short chain dehydrogenase 1 2 3 
1. ACN52304.1 TsrN Streptomyces laurentii   48 52 
3. Streptomyces tateyamensis 59   73 
3. WP_091614398.1 KR domain-containing protein Amycolatopsis saalfeldensis 66 82   
 
TfuA-like protein 1 2 3 
2. Micromonospora arborensis   58 56 
3. Streptomyces tateyamensis 67   72 
3. WP_091614392.1 hypothetical protein Amycolatopsis saalfeldensis 67 80   
 
TfuA-associated YcaO (thioamide-forming) 1 2 3 
2. Micromonospora arborensis   67 71 
3. Streptomyces tateyamensis 75   77 
3. WP_091614389.1 hypothetical protein Amycolatopsis saalfeldensis 78 84   
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Table 4.6 Sequences used for construction of tfuA-ycaO conjugation vectors. All sequences are provided 
5’ to 3’. Promoter sequence ermE*p was derived from engineered Streptomyces variant.68 
ermE*p: 
ACGCGGTCGATCTTGACGGCTGGCGAGAGGTGCGGGGAGGATCTGACCGACGCGGTCCACACGTGGCACCGCGATGCTGTTGTGGG
CACAATCGTGCCGGTTGGTAGGATCCAGCGGAGCAACGGAGGTACGGACATG 
Amycolatopsis saalfeldensis asaTY: 
ATGGTCACCGCGCAGCAGGAGGCGGTGAAGCGGTACTTCACCGGCACCCACCGCACCCGCGCCCCGGAGCAGACCTGGGCGCTGGC
GACCGGGCTGTTCGACCGCTGCGGGATCAGCCGGGTCGCCGACGTCACCGGCCTCGACGTGCTCGGCATCCCCACGTGGGTCGCGG
TCCGCCCGCTGGCCAGCACGCTGAGCGTGAGCCAGGGCAAGGGCGCGACCGACACGGCGGCGAAGGTCTCCGCGTGCATGGAGGCG
ATCGAACTCTGGTACGCGGAGAACCTGCCGGCCGCCGGCGAACCGGTCACCGCGAACGCGGCCGAGCTCGCGCTGCCGTACGACTT
CACCGGCCTCCAGCGTGCCGCCCGCAGCCTGGTGACGGACCGCACCCCGTTGGAATGGCTGCCCGCCGGGGTCATCGGGGAGCCGC
GGACGACGCTGGTGCCGCGGCCCTGCGTCGGGATCTCCTCCCTCGCGTCGCCGGCCTGGTCACCGCCACTGCTGCGGGTGTCGAGC
AACGGCCTGGCCAGTGGCAACTGCATCGAAGAGGCCACGCTCCACGCCTTGTTCGAGCTGGTCGAGCGGGACGCCACCGCCGACCT
GATCGACCGTCCCACCACGGTCCGCGACCACATCGCGCCGGAGACCGTCGACGATCCCGGGTGCGCCGACCTGATCGCGCGCATCG
CGGACGCCGGTGCCTGGCTGGAGCTGGTCGACAACACCCGCGACCCGCACTTCCCTTGTTACGTCGCCTATCTCTGGTCCCCGGAG
GACCCGTCGATCTACTCCGGCTCCGGCTGCCACACCGACCCGGCCGTCGCGCTGTCGCGGGCCATCACGGAGGCGGCCCAGAGCCG
GCTCACCGTCATCAACGGCACCCGCGACGACGTGCACGGCTCGCTGTACCGCTCGCACCGATGGGACGCCGAGCAGCCCGAGACGC
CCGCGGACCGGACCGGCAGCTGGGCCCGCGCGCTCGAGCGCGTCGACCGGGTCGAATGCGACTCGATGGACGAGGAGCTGGTCCGG
TGCGCCCGGCTCGTCGGCGCCCGGACCGGCCAGCCGGTGCTGGCCGTGCCGCTGACCACTGTGGACGAACCGCTGGCCGTGGTCCG
GGTCGTCGCGCCCGGATTGCGGTTCGGCGCGGGCGACGAGTGTCCCCGCCCGGTCCAGCCGAACAGGAGTTGAACCGCCATGACCG
TGCACGTCTTCGCCGGGCCGACCGTCACCCCCGAGCGGATCACCGGCCTGCTGCCCGGCGCCGAGGTGCACCCGCCGGTGCAACAC
GGTGACCTGCTGCGGCTGCCGGCCTGCGGCGGGGACACGGTGCTGCTCGTGGACGGGTTCTTCCTCCAGGCACCCGCCGTGCGGCA
CAAGGAGATCCTGCACCTGATCCACTCCGGGGTCCGGGTGGCCGGGACCAGCAGCATGGGTGCGCTGCGCGCGGCCGAACTGCACC
GCTTCGGCATGATCGGTCTCGGCCAGGTGTTCCGCTGGTACGCCGAGGGCACCGTGACCGCCGACGACGAGGTCGCGGTTTCGCAC
CTGACCGAGGAGGACGGCTACCGCCAGCTCTCCGACGCGCTGGTCGCCCTGCGCTACGGCCTGGAGCGCGCCACCGGCACCGCGAT
CACCGCCGCCGAGCGGGACGCGTTGCTCGCGGAGGTCGCCGCGCTGCCGTTCGCGCGGCGCAGCTGGCGGACGCTGTGGCGGATCA
CCGGGCACACTCCCCTCGCCGACGCCGCCGCCCGGGTCCGCGCGTACCTCGCCGACCACCCGCAGGACGCCGACGTCAAACTGCTG
GACGCCGAGCTGGCCCTGCGCTGGGTGCTCGACAACCCCGTGCCACCAGCGTCCGCGGGCGAACGGCCGTCCACTTTGGACACGGT
GTACCTCGCCGACTGGCGATGGGAGCACACCCCCGTGCCGGCCGGTGACCGCCGGACCAGCGATCACCTCGCGCTCGGCTTCCTGC
AGCTGTTCCTGCCGGCCTACCCCCGGCTGAACCGGTACACCGCCCTCGCCCGCATCGGCGGCGACGCCGACGGCGCGCTCGCTGCG
GCCCGGGCGGCCGGGCTGATCGGCGAAGAGGACGAGCCCAGCCCCGGTATGCGCGAGTGGCTGACCGACGAGGAATTGGCCACGAC
ATCCGGCCGCGAGCTGGTGCTCACGGCGCTCGTGCGGTCGTTCCGCACCGAACCGGGTGTGCGGACCACCCACACGCTGCCGGACC
TGGTCTCCTCCGCGGAGCCACTGCTGCGGCTGGCGAGGAAGTGCGCCGCCACCGCGGGGGCGATGAACGACGCCCGCCGGCAGCGG
CACCCGGAGTTCCAGGTCGAGCACGTCCGGACGGATCTGGTCGAGCAGTTCTTCTCCGCGCGCTGGCAGTGCGCCGATCTGGAGAC
CGCCTGCTGGGACCGGGGACTGACCGGACTCGGGCAGCTGCACGAGCTCGGCCGGTACTACCTGTTGTTCGGGCGGTCGGGCCGGG
CCCCGGAACAAGCACTCGCGGCGGTGACCGTCGGCGCCGCGACCGACCACGGCGAGGAGTCCCGATGA 
Streptomyces tateyamensis staTY: 
ATGGCCACGGCCCAACAGGACCTCACCAAAAGGTACTTCACCGGCACCCAGCGGACCCGGGCGCCGGAGCGGACCTGGCAGTTGGC
GCAGCGTCAGTTCGAGCGGTGCGGGATCAGCCGGGTGGCCGACGTCACCGGACTGGACGTACTGGGCATCCCGACCTGGGTCGCGG
TCCGCCCGCTGGCCGCCACGCTGAGCGTCAGTCAGGGCAAGGGCGCCACCCACACCGCCGCGAAGGTCTCCGCGAGCATGGAGGCG
ATCGAGCTCTGGTACGCCGAGAACCTGCCGCACGCCGGCCCCGCGGTCACCGCGCCGGCTGCCGAACTCGCCCTGCCCTACGACTT
CGCCGGCCTGCAGCGGGCCGCGGGCAGCCTGCTGACCGAGCACACCCCGCTGCCGTGGCTGCCGGCCGAGGTGATCGGCCAGGCGG
CCACCAGCTGGGTGCCCCGGCCCTGCGTGGCGATCTCCTCGCTGGCCGCCCCGGACTGGTCGCCGCCGCTGCTGCGGGTCTCCAGC
AACGGCCTGGCCAGCGGGAACTGTGTCGAGGAGGCGGCCCTGCACGCGCTGTTCGAACTGGTCGAGCGGGACAGCACCGCCGACCT
GCGGGAGCGCCCGGTGGACCGGCGCCGGCACATCGAGCCGCACAGCGTCACCGACCCCGGCTGCGCCGAGCTGATCGACCGGATCG
ACCGGGCCGGGGCCTGGCTGGAGCTGGTGGACAACACCCGCGACCCGCACTTCCCCTGCTACGTCGCCTACCTGTGGTCCCCGGAG
GACCCGACCGTCTACTCGGGCTCCGGCTGCCACACCGACCCGGCGGTGGCGCTCTCCCGGGCGATCACCGAGGCCGCGCAGAGCCG
GCTCACGGTGATCAACGGCACCCGCGACGACGTGCGCGGCGGCCTCTACCGCGGCCACCGCTGGGACGCCGCGCAGCCCGTCACAC
CCCCGGACACGCAGGGCAGTTGGGCGCAGGCGGTGCGGCGGATCGAGCCCGCCGGGCGGGCCGCGGTCGACACTGAACTGCTGCAC
TGCGCCGAGCTGGTGCGGGCCCGGACCGGCCGACCGGTGCTGAGCGTGCCGCTGACCGCCCCCGGGGAGGAGCTCGCGGTGGTCCG
GGTGATCGCCCCCGGCCTGCGCTTCGGCGTCGGCGACGAGTGCCCGCGCCCGCTCCGCCAACTGCCCGAGGAGGGCCGATGACCAC
GCACGTGTTCGCCGGGCCGACCATCGGCCCGGACCGGGTGGCCGAGCTACTGCCCGGCGCCGTGCTGCACCCGCCGGTGCAGCACG
GCGACCTGCTGCGGCTGCCGGTGGCCGCCGGGGACACCGTGCTGATCGTGGACGGGCTGTTCCAACAGGCCCCCGCGGTGCGGCAC
AAGGAGATCCTGCACCTGGTGCACGAGGGCGTCCGGGTGGCCGGCGCGAGCAGCATGGGCGCGCTGCGCGCGGCCGAGCTGCACCG
GTTCGGGATGCTCGGGCTGGGCCAGGTGTTCCGCTGGTACGCCGACGGCACGGTGACCGCCGACGACGAGGTGGCAGTGGCCCACC
TGGGCGAGGAGGACGGCTACCGCCAGCTCTCCGACGCCCTGGTCTCGGTGCGCTACGGGCTGGGCCGGGCAGTCGAGGCTGGCGTG
CTGAACGCCGCCGAGCAGGCCGGGCTGCTTGCCGCACTGGCCGAGCTGCCGTTCCCGCAGCGCAGTTGGCGCAACCTGTGGCGGAT
CACCGGGCAGACCGACCTGGCGGCGGCGGCCGCCCGGGTCCGCGCCCACCTGGCGGTGCGCCCCGCGGACGCCGACGTGAAGCGCC
TGGACGCCGAGACCGCGCTGCGGGCGCTGCGCCGGGAGGCCGCTCCCGCGGCGGCCCCCGGGCCCCGCCCGGCCACCCTGGACACC 
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Table 4.6 (cont.) 
 
GTCTACCTGGCCGACTGGCGGTTCGAGCACTCCGCCACCGACCCGGTGAGCGACTTCCACACCCTCGGCTTCCTCCAGCTGTTCCT
GCCGGCTTACCCGCAGCTGAACCGCCATCAGGCACTGGCCCGGATCGGCGGCGGCGAGGCGGGAGCCCTCGCGGCGGCCCGGGCCG
CGGGCCTGCTGGGCGCCGGCGACGAGCCGGGGAGCGGGATGCGGGCCTGGCTCACCGAGCGGGAACTGGCCGAGCTGCCCGGCCGC
GAGCTGGCGCTCACCGCCCTGGTGCGGTCCTTCCGCACCGCGCCCGGGGTGCGCACCGGCCACCGGCTGCCCGAGCCGCTCCTGGC
CGCCGGGCCGCTGCTGCGCATGGCCCGCAGCTGCGCCGCGGCCGCGGCCGCACTGAACGCGGCCCGCCGGGCCAGGCACCCGGAGT
TCCAGGTCGAGCACGTCCGCACCGACCTGGTGGAGGAGTTCTTCGCCGCCCGCTGGCAGTGCGCCGACCTGGTCACCGCCTGCTGG
GACCGCGGGCTCACGGGCCTTGGCCAACTGCACGAGCTGGGCCAGTACTTCCTGTTGCTCGGCCGGTCCGGCCGACTGCCGGAACC
GCAACTCGCGGCGGTCAGCTTCGCCGCCGCCGAAGGGGAGCCGTCATGA 
Micromonospora arborensis marTY: 
ATGAGTGAGTCATCCACCCTCGACGCGGGCCCGGTCACTGCCGACCGGAACGCGAAGCGGTATTTCGCCGGTACCCACCGCACCCG
CCATCCCGGGGAGACCTGGCGGCTCGCCGAGCGGCTCTTCGGACGCTGCGGGCTGACCCGGGTGGCCGACGTGACGGGCCTCGACG
TTCTCGGCATCCCGGTGTGGGTCGCCGTCCGGCCGATGGCAAGCACGCTGAGCGTCAGCCAGGGCAAGGGCGCCACGGACGTCGCC
GCCAAGGTCTCGGCGGCGATGGAGGCCATCGAGCTGTGGTACGCCGAGGAGCTTCCGGCGACACCGCCGGGGCCGGTGGGCGTGGC
CGCCTCGTCCCTGCGCCTGCCGTACGACGTCATGTCCCTGCAGCGCGCCGCCCGGAGCCTGCTCACGCCGGACACCCCGCTGGACT
GGGTGCCGGCCCTGGTGGCCGGTGAGGACCGGAGGACGCTGGTGCCGCGTACCGCCGTGGCCATCTCCTCGCTCGCCGCACCGGTC
TGGTCCGTACCGCTGTTGCGGGTCTCCAGCAACGGCCTGGCCAGTGGGAACTGCCCGGCGGAGGCAGCCCTGCACGGACTGTTCGA
ACTCATCGAGCGGGACTGCACGTTCGACCTCGGCGACCGGCCGGTGTCCACCCGGACCCACATCGCACCCGACACGGTCACGGACC
CGGGCTGCCGCAACCTGATCGCGCAGATCACCTCCGCCGGGGCATGGCTGGAGCTGGTCGACAACACCCGCGACCCCGCGTTCCCC
TGCTTCGTCGCCTACCTCTGGTCCCCCGAGGATCCGTCGATCTATTCGGGGTCTGGCTGCCACACCGACCCGGCGACGGCCCTCTC
CCGCGCCATCACCGAGGCCGCGCAGAGCCGGTTGACGGTCATCAACGGCACGCGGGACGACGTTCGAGGCACCCTCTACCGCTCCC
ACCGCTGGGACACCCAACGGCCGGTCACCCCACCCGACCGGCTCCGCTCGTGGGACCAGATCCTGGCCACGTTGCGGACCGCGCGG
TTCGACTCCGTCGACGAGGAGTACCGGTGGTGCCTGCGACAGGTCCGCCGGCAGACCGGCCAACCGGTGCTGGAGGTGCCGTTGTC
CACGGACGACGAGCCGCTGTCCGTGGTCCGGGTGATCGCCCCTGGGCTGCGCTTCGGCACCGGCGACGAATGCCCGAGGCCCGTTC
GAGCGGAGGAGTCCTGATCAGCATGGTGATCCACATCTTCGCCGGCCCGACCATCGGCGCCGACGACATCCGCCAGATCGTCCCCG
ACGCGGTGCTGCACCCGCCGGTGCGCCACGGCGACCTACTGCGGCTCCGGCCCGACCCGGCAAGCACCGTCCTGATCCTGGACGGG
CTCTTCTTCCAGGCGCCCGCCGTCCGGCACAAGGAGATCCTGCATCTGGTCCGCAACGGGGTCCGGGTCGTCGGGGCCAGCAGCAT
GGGCGCGCTGCGCGCCGCCGAACTGCACCCCTACGGTGTCATCGGCGTCGGCCAGGTCTTCGAGTGGTACGCGGACGGCACGGTCA
CCGCGGACGACGAGGTCGCCGTCGCCCACCTCGACGCCGACGACGGCCACACGCAGCTCTCCGACGCCCTGGTCTCGATCCGGTAC
GGCCTCCATGCGGCCACCGGCGAGGCGATCGACCCGGATGAGGCCGGCGGCCTGCTCGCGCTGGTCCGCGAGCTGCCGTTCCCCCG
CCGAAGCTGGTCGGCCCTGTGGCGGGTGGCTGAGCGGGGCGACCTGGCGGCTGCCGCCCGCCGGATGCGCGAGTGGCTCGACGCTC
GCCCGGACCAGGGCGACGTCAAGCGGCTCGACGCGCTGCGGGCGCTGCGCCTGGTGCGCGATGCGGGGCCGGCGGACGCGGCACCG
GTCGACGACCCCCGCTTCGCCAACCTCGACACGGTGTATCTCGCGGACTGGCGTTGGGAGAACGAGGGCGCCGAACTCGGCGGCCG
GGTGGTGACCGACCACCACGCACTGGCGTTTCTCCAGCTCTTCCTGCCGACGTACCCGTCGTTGCACCGCCGGGCGACGCTCGACG
CGATCGCGCGGGGCAGCGCGCCGGAGGGCGACGCCGCCGCCACGCTCGTCGAGCGGGCACTGGGCGCGGCCCGGGCCCGCAAGATA
CTCGGCCCCGACGACGCGCCGACGACCGGCTTGCGTGACTGGTTGTCGGCAGCGGAACAGGCCACCCTTCCCGACCGGGAACTCGT
CGTCCGGGCTCTGGTGCGTTCCTTCCGGACCGAACCCGGTGTCCGTACCGGGCACCGCATCCCGCCGTTGCTGGCCGGGCAGCGGG
CCCTGCTGCGGCTGGCCCGGACCTGTGCCGCGGCTGCCGGCGCACTCAACGAGATGACGATGCGCCGCAACGGCGAGTTCCGGGTC
GAGCACATCCGTCACGACCTGGTCGAGACCCTCTTCCGGGACCGCTGGGGCGGCGCCGATCTGGAGATCGCCTGCTGGGACCGAGG
ACTGACCGGGTTGGGGCAGTTGCACGAGCTCGGCCGGTACTTCCTGCTCCTGGCACGCTCCGGCAAGGTGCCGGAGGAGACGCTGA
ACGGGGTGCCGAGCTGGCCGGACGGCTCGGCCGGCGATTCCGTCTCCGATCCCGACACGGCCGCCCTCCTCAAACCCGCCACGAAT
GGACGCTGA 
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Table 4.7 Oligonucleotide primers used in this study. All sequences provided 5’ to 3’. 
Primer Oligonucleotide Sequence 
pAE4_Upstream_Sequencing GCTCTAGCGATTCCAGAC 
pAE4_ErmE*p_Insert_F GGCAACCCTCAGCGGATGCCACGCGGTCGATCTTGACGGCTG 
pAE4_ErmE*p_Insert_R CCTGGGAAAACGTGAAGCCCCGGCATGTCCGTACCTCCGTTGCTCCGC 
pAE4_ErmE*p_Vector_F GCGGAGCAACGGAGGTACGGACATGCCGGGGCTTCACGTTTTCCCAGG 
pAE4_ErmE*p_Vector_R CAGCCGTCAAGATCGACCGCGTGGCATCCGCTGAGGGTTGCC 
pAE4_MarbTfuAYcaO_Insert_F GCGGAGCAACGGAGGTACGGACATGAGTGAGTCATCCACCCTCGACGCGG 
pAE4_MarbTfuAYcaO_Insert_R GACCTGGGAAAACGTGAAGCCCCGGTCAGCGTCCATTCGTGGCGGGTTTG 
pAE4_MarbTfuAYcaO_Vector_F CAAACCCGCCACGAATGGACGCTGACCGGGGCTTCACGTTTTCCCAGGTC 
pAE4_MarbTfuAYcaO_Vector_R CCGCGTCGAGGGTGGATGACTCACTCATGTCCGTACCTCCGTTGCTCCGC 
pAE4_StateTfuAYcaO_Insert_F GCGGAGCAACGGAGGTACGGACATGGCCACGGCCCAACAGGACCTCACC 
pAE4_StateTfuAYcaO_Insert_R GACCTGGGAAAACGTGAAGCCCCGGTCATGACGGCTCCCCTTCGGCGGCG 
pAE4_StateTfuAYcaO_Vector_F CGCCGCCGAAGGGGAGCCGTCATGACCGGGGCTTCACGTTTTCCCAGGTC 
pAE4_StateTfuAYcaO_Vector_R GGTGAGGTCCTGTTGGGCCGTGGCCATGTCCGTACCTCCGTTGCTCCGC 
pAE4_AsaaTfuAYcaO_Insert_F AGCGGAGCAACGGAGGTACGGACATGGTCACCGCGCAGCAGGAGGCGGTG 
pAE4_AsaaTfuAYcaO_Insert_R GACCTGGGAAAACGTGAAGCCCCGGTCATCGGGACTCCTCGCCGTGGTCG 
pAE4_AsaaTfuAYcaO_Vector_F GACCTGGGAAAACGTGAAGCCCCGGTCATCGGGACTCCTCGCCGTGGTCG 
pAE4_AsaaTfuAYcaO_Vector_R AGCGGAGCAACGGAGGTACGGACATGGTCACCGCGCAGCAGGAGGCGGTG 
pAE4_MarbTfuA_Insert_F GCGGAGCAACGGAGGTACGGACATGGTGATCCACATCTTCGCCGGC 
pAE4_MarbTfuA_Insert_R CCTGGGAAAACGTGAAGCCCCGGTCAGCGTCCATTCGTGGCGGG 
pAE4_MarbTfuA_Vector_F CCCGCCACGAATGGACGCTGACCGGGGCTTCACGTTTTCCCAGG 
pAE4_MarbTfuA_Vector_R GCCGGCGAAGATGTGGATCACCATGTCCGTACCTCCGTTGCTCCGC 
pAE4_MarbYcaO_Insert_F CGGAGCAACGGAGGTACGGACATGAGTGAGTCATCCACCCTCGACGCG 
pAE4_MarbYcaO_Insert_R CCTGGGAAAACGTGAAGCCCCGGTCAGGACTCCTCCGCTCGAACGG 
pAE4_MarbYcaO_Vector_F CCGTTCGAGCGGAGGAGTCCTGACCGGGGCTTCACGTTTTCCCAGG 
pAE4_MarbYcaO_Vector_R CGCGTCGAGGGTGGATGACTCACTCATGTCCGTACCTCCGTTGCTCCG 
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Chapter 5: Bioinformatic Mapping of Radical SAM-dependent RiPPs Identifies new Cα, Cβ, and  
Cγ-linked Thioether-containing Peptides5
 
5.1 Introduction 
With the growing availability of genome sequences, bioinformatics has become an increasingly 
popular and powerful technique for natural product discovery.1,2 The biosynthetic gene clusters (BGCs) of 
known natural product classes are readily identified by the presence of conserved genes and the structure 
of their products can be predicted to varying degrees of accuracy based on the number and type of enzymes 
locally encoded.3 This approach has been particularly useful in the discovery of ribosomally synthesized 
and posttranslationally modified peptides (RiPPs).4 RiPPs have no universally conserved gene but instead 
are united by a common biosynthetic logic: with rare exceptions, the biosynthetic enzymes bind their 
respective precursor peptides through a recognition sequence in the N-terminal region of the peptide, 
referred to as the leader peptide,5 and the posttranslational modifications are installed on the C-terminal 
region, referred to as the core peptide. During biosynthetic maturation, the leader peptide is eventually 
removed, and frequently additional enzymatic tailoring of the peptide occurs to yield the final RiPP product. 
Several posttranslational chemistries are known and are used to categorize RiPPs into their respective 
classes.4,6 
Despite the utility of genome mining to discover new natural products, the identification of RiPP 
BGCs remains challenging. First, RiPPs require analysis of a local genomic context for the presence of 
encoded regulators and transporters, or better yet, clear supporting genetic markers of RiPP biosynthetic 
pathways because RiPP enzymes are often members of larger protein superfamilies that bear homology to 
proteins not associated with natural product biosynthesis. Second, RiPP precursor peptides are often short 
and hypervariable, which means their coding sequences are often unannotated when deposited into public 
databases and they are rarely identifiable by sequence homology search tools (e.g., BLAST7). To address 
these challenges, we developed a bioinformatics program, Rapid ORF Description & Evaluation Online 
(RODEO), which automates the genome mining process.8 A typical RODEO input will be a list of NCBI 
gene accession identifiers for a biosynthetic protein of interest. The program then fetches genomic records 
from GenBank and uses the PFAM9 and/or TIGRFAM10 databases to predict the function of neighboring 
genes. Next, RODEO identifies all possible precursor peptides and scores their likelihood of being a true 
RiPP precursor by a scoring function based on motif analysis and supervised machine learning. Given the 
disparate nature of RiPP precursor peptides, the scoring function is optimized for each distinct class. In our 
initial report, RODEO was leveraged to identify and classify lasso peptides which led to an order of 
                                                     
5 This work is currently in peer review for publication to the Journal of the American Chemical Society.  
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magnitude expansion of the RiPP class. RODEO was also been reconfigured to aid in the discovery of 
thiopeptides11 and was incorporated into antiSMASH (version 4.0),12 a tool which mines single genome 
inputs for natural products. Once the requisite sequence attributes and machine learning classifications are 
established, performing updates for a RiPP class via RODEO is straightforward, as demonstrated very 
recently with the lasso peptides.13 
Given the success of RODEO in defining other RiPP classes, we sought to expand its capabilities 
to aid in the discovery of new sactipeptides. Sactipeptides have garnered interest due to their unique hairpin 
structures and potent, narrow-spectrum activity towards several human pathogenic bacteria.14-16 They are 
defined by a radical SAM (rSAM) enzyme that forms “sactionine” crosslinks which are formed upon the 
linkage of a donor Cys sulfur to the alpha carbon of an acceptor amino acid (Figure 5.1).15,17,18 rSAM 
enzymes are a versatile family and prevalent in RiPP pathways that employ a [4Fe-4S] cluster to catalyze 
the reductive cleavage of SAM to yield a 5′-deoxyadenosyl radical.19-23 This reactive intermediate then most 
often abstracts a hydrogen atom from the substrate, which leads to a variety of different outcomes based on 
the specifics of a given biosynthetic pathway. The precise mechanistic details of sactipeptide crosslink 
formation remains poorly characterized, although several groups are taking on this challenge.24,25 Studies 
of the sactipeptide rSAM enzyme itself have revealed that sactisynthases contain three [4Fe-4S] clusters: 
one which reductively cleaves SAM and two auxiliary clusters in what has been called dubbed a SPASM 
domain.26-29 Only five peptides with the hallmark S–Cα crosslinks have been isolated thus far: subtilosin 
A,30, 31 thurincin H,30 thuricin CD (two peptide products),16 and sporulation killing factor.31,32 A sixth 
sactipeptide, hyicin 4244, was recently reported but was not isolated for detailed characterization.33 All 
structurally characterized sactipeptides contain ring-within-a-ring topologies and thus form rigid, hairpin-
like structures (Figure 5.1). However, in 2011, Haft reported the bioinformatic discovery of a related class 
of putative thioether-crosslinked peptides, which he referred to as the six Cys in forty-five residue peptides 
(SCIFFs).34 No bona fide SCIFFs have been isolated, but in vitro enzymatic reactions with the purified 
rSAM and precursor peptide indicated that a crosslink is formed between a donor Cys and an acceptor Thr 
residue.24,25  
Similar to our earlier work that redefined the genomic landscape of the lasso peptides and 
thiopeptides, we herein conducted a comprehensive analysis of the sactipeptide RiPP class using a re-
written and improved version of RODEO, version 2.0. Although previous bioinformatic surveys have been 
conducted on the sactipeptide class,35-39 none have employed machine learning, which casts a wider net to 
identify candidate precursor peptides. In this study, we have conducted a comprehensive analysis and 
connected 3,156 rSAM enzymes to a RiPP precursor peptide and found new varieties of thioether-linked 
natural products. Guided by this dataset, we selected a new sactipeptide, huazacin, for characterization that 
contains a thioether ring architecture larger than any sactipeptide previously characterized. Additionally, 
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our bioinformatic analysis indicated that SCIFF-associated rSAM maturases were much more closely 
related to QhpD proteins than characterized sactisynthases. QhpD is a rSAM enzyme which is known to 
form β- and γ-linked thioethers,40 thus calling into question the linkage architecture within a SCIFF natural 
product. We pursued this line of inquiry resulting in the bioinformatic identification and structural 
characterization of two SCIFF natural products. The first, freyrasin, features six thioether linkages, all of 
which are S-Clinkages. The second, thermocellin, has previously been reported in the literature and 
characterized only after partial in vitro enzymatic reconstitution. We have confirmed thermocellin to feature 
a Cys-Thr thioether as reported, but rather than harboring a S–Cα linkage, the peptide contains a S–Cγ 
linkage. To distinguish this group from the structurally distinct sactipeptides, we propose the renaming of 
this RiPP class as the ranthipeptides, for radical non-alpha thioether peptides. 
 
5.2 Results and Discussion 
5.2.1 RODEO2.0-enabled sactipeptide discovery 
With >450,000 rSAM proteins listed in the InterPro 72.0 database (IPR007197),41 a focused 
bioinformatic search was necessary to winnow down candidates more likely to be involved in sactipeptide 
biosynthesis for our purposes. Therefore, four rounds of iterative PSI-BLAST (Position-Specific Iterated 
Basic Local Alignment Search Tool42) searches using rSAM sequences from four known sactipeptides 
(AlbA, SkfB, ThnB, and TrnC)15 and two partially characterized SCIFFs (CteB25 and Tte118624) was 
performed to identify candidate proteins. A stringent expectation value of 1e-70 was used as a cut-off to 
assist in keeping the retrieved candidate proteins more likely to be involved in RiPP biosynthesis in addition 
to filtering sequences <300 amino acids. This procedure yielded ~4,600 protein sequences, which were 
subsequently analyzed by RODEO2.0, a rewritten and more efficient version of our previously reported 
RODEO algorithm (see Section 5.5.2), to annotate the local genomic context and score potential 
sactipeptide precursor sequences. 
Sactipeptide precursor peptides were identified using a series of heuristics in conjunction with 
support vector machine classification as previously reported resulting in 504 candidate precursor 
sequences.12 The top scoring sequences were then manually inspected for similarity to known sactipeptides. 
In general, a peptide was considered to be a strong candidate sactipeptide if it had 3 or more Cys separated 
by equal spacing of 1 to 3 residues. Additionally, peptides were scored more favorably if the Cys residues 
were clustered within the N-terminal half of the core peptide, similar to that observed for other sactipeptides 
(i.e. the donor residues line one side of the hairpin while the receptor residues line the other side, Figure 
5.1). Precursor peptides were further analyzed by a sequence similarity network (SSN) generated using the 
Enzyme Function Initiative Enzyme Similarity Tool (EFT-EST)43 which revealed that clustering of 
precursors appears to be largely driven by conservation of donor Cys residues (Figure 5.7), which is 
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predicted to govern the location of crosslinks and thus the overall structure of the sactipeptide. This 
bioinformatic analysis identified four significantly populated groups of uncharacterized sactipeptides. Two 
groups, named hypervariable groups 1 and 2, possess precursor peptides that are more than double the 
length of any known sactipeptide. While the core sequences within these two groups are overall 
“hypervariable”, there are 6-8 locations that display highly conserved Cys residues. A third uncharacterized 
group of sactipeptides are concentrated in the Lachnospiraceae family, thus we have termed these predicted 
compounds the “lachnocins” (Figure 5.7).  
We elected, based on the above bioinformatics results, to pursue the fourth uncharacterized 
sactipeptide group. The target producer chosen was Bacillus thuringiensis serovar huazhongensis (Figure 
5.2), owing to strain availability from the Bacillus Genetic Stock Center (BGSC 4BD1) and the fact that 
the predicted structure contained a unique crosslinked structure (4 crosslinks separated by 3 residues each). 
Although bioinformatically predicted in a previous study,39 the mature natural product has never been 
reported. Upon screening various culture extracts by matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry (MALDI-TOF-MS), we observed a mass consistent with the predicted structure 
(Figure 5.8). The metabolite, hereafter huazacin, was then subjected to high-resolution and tandem MS 
(HR-MS/MS) analysis using an Orbitrap instrument. The observed m/z value ([M+3H]3+ = 1241.5396) 
agreed with the theoretical mass of the expected molecular formula of C160H241N43O50S53+ ([M+3H]3+ = 
1241.5393; error = 0.2 ppm, Figure 5.8). This formula contains four thioether linkages (8 Da lighter than 
the unmodified core peptide). Upon subjecting the parent ion to collision-induced dissociation (CID) 
conditions, we observed robust fragmentation of the amide and thioether linkages (Figure 5.9). This gas-
phase behavior was consistent with the thioether linkages of huazacin being S-C linked (i.e., sactionines), 
as bioinformatically predicted.  
Multidimensional NMR spectroscopy (1H-1H TOCSY and 1H-1H NOESY) were collected on 
HPLC-purified huazacin, which corroborated the sactionine (S-Cα) linkages of huazacin (Figures 5.10-
5.11, Table 5.3). We observed NOESY correlations for the Cys-CαH (and Cys-CH) to the recipient site 
backbone NH (Figure 5.12). Further, no TOCSY correlations were observed from NH to CH, which is 
consistent with a quaternary carbon at the alpha position as expected for a sactionine linkage (Figure 5.13). 
Ring topology was also established by NOESY analysis of the Cys12-Thr30 and Cys8-Tyr34 rings. 
We next assessed the antibacterial activity of huazacin by testing a small panel of bacteria for 
growth suppression using the microbroth dilution method. Reported sactipeptides typically have a narrow 
spectrum of activity towards Gram-positive organisms, most notably Clostridium difficile, Listeria 
monocytogenes, and Bacillus cereus.16,17,44-47 Consistent with previously characterized sactipeptides, 
huazacin inhibited the growth of L. monocytogenes 4b F2365 with a minimum inhibitory concentration 
(MIC) of 4 μM (Table 5.4). These results with huazacin reinforce the concept that RODEO is a useful tool 
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to accelerate RiPP discovery. While many additional, predicted sactipeptides are found in less populated 
clusters (with many being singletons, Figure 5.7), these data provide a roadmap to guide for future 
sactipeptide discovery efforts.  
 
5.2.2 Mining the rSAM-modified RiPP thioether genomic landscape 
Having shown the utility of RODEO for the discovery of a new sactipeptide, we sought to more 
broadly survey the genomic landscape of rSAM-modified RiPPs that were likely to contain thioether 
linkages. We began this effort by obtaining a list of rSAM sequences by PSI-BLAST with protein sequence 
similarity visualized in the form of a SSN (Figure 5.2). Sequences with >70% amino acid identity were 
conflated to a single node and connected by an edge if significant sequence similarity was shared between 
the two sequences (BLAST expectation value < 1e-50). Thus, only highly similar rSAM proteins form 
clusters during this type of analysis. Given that the similarly of a RiPP modifying enzyme strongly 
correlates with the similarity of the cognate precursor peptides (i.e. similar rSAM enzymes produce similar 
products),8 a properly annotated SSN provides a simplified but informative view of the peptide substrate 
diversity.  
To provide context for the rSAM SSN, the nodes were colored based on the sequence characteristics 
of the cognate precursor peptide identified by RODEO (Figure 5.3). Several of the clusters were readily 
annotated by similarity to known sactipeptide precursor peptides, such as subtilosin (SboA), thurincin H 
(ThnA), thuricin CD (TrnA), and sporulation killing factor (SkfA). The novel sactipeptide huazacin (HuaA) 
described above is also indicated on the network. Two outlier sequences, the thermocellins (CteA and 
Tte1186a), belong to the so-called SCIFF family and are contained within a separate, much larger group. 
Additionally, two large groupings of uncharacterized rSAM proteins with low-level similarity to TrnC were 
readily identified. The RODEO-identified precursor peptides encoded next to these rSAM proteins 
comprise the above-mentioned hypervariable groups 1 and 2 (Figure 5.7).  
Several trends for the number and position of Cys residues within the peptides were further 
analyzed to gain deeper insight into the RiPP thioether landscape (Figure 5.14). The positioning of the Cys 
residues indicated that nearly all groups had the potential to form the traditional sactipeptide hairpin-like 
topology wherein Cys residues are concentrated near the N-terminus and crosslink to acceptor residues 
concentrated near the C-terminus. Only the SkfA and SCIFF groups seemed capable of adopting an 
alternative structural topology based on their Cys residues being more evenly distributed (Figure 5.14). 
However, SKF is known to display a hairpin-like topology, which is attributable to an internal disulfide 
bond unique to the sactipeptides and an N-to-C macrocyclization and an internal disulfide bond. No mature 
SCIFFs have previously been reported in the literature, thus the topologies have remained undetermined. 
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The positioning of the Cys residues would suggest SCIFFs would be likely to display non-hairpin topologies 
(Figures 5.1 and 5.15).  
The majority of identified thioether-forming rSAM enzymes reside within the large SCIFF cluster. 
Despite their greater numbers, the cognate precursor peptides display low sequence diversity. The RiPP 
products of these BGCs have been termed the thermocellins, although the final structure of thermocellin 
has not been reported. We identified 1,634 SCIFF precursor peptides (1,023 unique sequences), which 
outnumber the RODEO-identified sactipeptides by three-fold (Figure 5.15). While the majority of these 
precursor peptides are virtually identical to thermocellin (CteA/Tte1186a), numerous smaller groupings 
display distinct core peptides (Figure 5.15). Several of these smaller groups display conserved Asp residues 
along with the putative Cys donors, indicating that the Asp residues may often serve as an acceptor for 
thioether formation. 
To uncover additional phylogenetic trends, we inspected the taxonomic distribution of all rSAMs 
predicted form thioether-containing RiPPs. The vast majority (~95%) are encoded by Firmicutes, consistent 
with Clostridium sequencing bias as well as the fact that all previously isolated sactipeptides originate from 
Bacillus (Figure 5.16). Nonetheless, divergent examples occur in numerous other phyla, including 
Proteobacteria, Actinobacteria, and Bacteroidetes, albeit with much lower frequency. We note that some of 
the genes encoding the rSAM enzyme from Clostridium showed significantly higher % GC content when 
compared to the entire genome, which may be indicative of horizontal gene transfer (Figure 5.17). 
Additionally, based on local genomic context (Table 5.1), many unusual gene cluster architectures were 
identified including cases where the RiPP may be further elaborated by locally encoded enzyme (Figure 
5.18). Co-occurrence with genes related to tRNA metabolism were also highly represented in the genomic 
context of SCIFFs, which may hint towards a function for these RiPPs, although this will require extensive 
investigation (Table 5.1 and Figure 5.18).  
Not every rSAM enzyme could be confidently assigned a substrate peptide. Therefore, the 
precursor peptides in such cases remain “unidentified” due to one of several possible reasons, such as (i) 
poor quality genome assembly, (ii) the precursor peptide is encoded elsewhere in the genome, (iii) the BGC 
has been deactivated (a relic) and there is no longer a coding sequence for the precursor peptide, or finally, 
(iv) the rSAM is not involved in RiPP biosynthesis. Indeed, some members within the unidentified group 
do not appear to RiPP-modifying rSAM proteins; however, our investigation found that only a few 
examples could be confidently placed in “non-RiPP” category based on local genomic context. A final 
group of rSAM enzymes were identified as orthologs of QhpD. These proteins are not involved in RiPP 
biosynthesis but rather they are involved in the posttranslational modification of a large protein.48-50 
Nonetheless, this indicates that our targeted BLAST searching was sufficient in identifying many thioether-
installing rSAM enzymes involved in RiPP biosynthesis. 
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5.2.3 Insights from relatedness to QhpD 
Given our targeted BLAST searching, it was initially surprising to retrieve such a large number of 
enzymes annotated as QhpD (n = 674). QhpD is not involved in RiPP biosynthesis but rather the 
posttranslational maturation of quinohemoprotein amine dehydrogenase (QHNDH) which catalyzes the 
oxidative deamination of aliphatic and aromatic amines.51-53 QHNDH is composed of three subunits and 
contains several unusual posttranslational modifications, including a cysteinyl tryptophylquinone cofactor 
as well as three catalytically essential thioether linkages. Two are between Cys-Asp (S-C) while the third 
thioether linkage is between Cys and Glu (S-C).48-50 As illustrated on the SSN, QhpD and orthologous 
rSAM enzymes share considerable sequence similarity to rSAM enzymes involved in SCIFF biosynthesis 
(Figure 5.3). This finding is significant because sactipeptides are defined based on a thioether crosslink to 
the alpha carbon (S-Cα) of an acceptor residue. Therefore, in addition to modifying a protein instead of a 
RiPP precursor peptide, the QhpD group should be carefully distinguished from rSAM enzymes that form 
sactipeptides. However, considering the stringency used during our bioinformatics survey and the similarity 
score threshold in the SSN, we predicted that any rSAM enzyme connected to the QhpD (i.e. the SCIFF 
cluster) would be more likely to catalyze S-C and/or S-C thioether linkges rather than a sactionine 
linkage. While an SSN provides a useful and simplified illustration of sequence similarity, the relatedness 
of the separate clusters is not depicted. Thus, the same set of rSAM enzymes were analyzed after 
constructing a maximum likelihood tree (Figure 5.19). Corroborating the previous analysis, rSAM enzymes 
implicated in SCIFF biosynthesis are more related to QhpD than those involved in sactionine formation 
(Table 5.7).  A subset of SCIFFs with precursor peptides distinct from those previously reported (Tte1186a 
and CteA) were also identified that are more similar to NxxcB, a rSAM enzyme recently described to form 
a S-C thioether linkage to an Asn acceptor in a RiPP that is neither a sactipeptide or a SCIFF.54 It should 
be noted that this target dataset was aggregated using BLAST queries of biosynthetic enzymes known to 
be involved in sactipeptide and SCIFF biosynthesis, rather than using all-inclusive list of rSAM proteins. 
This resulted in a more manageable dataset size but one that also lacks many proteins that may or may not 
be involved in peptidic thioether formation. Thus, the relationship of the rSAM proteins involved in 
sactipeptide versus SCIFF biosynthesis appear artificially more related to one another. To illustrate this, a 
BLAST query using AlbA (subtilosin, sacipeptide) will return nearly 40,000 protein sequences before 
retrieving the less-similar CteB (thermocellin, SCIFF).  
 
5.2.4 Freyrasin is a S–Cβ crosslinked peptide: MS evidence 
With bioinformatic evidence that rSAM proteins annotated as SCIFF maturases might not contain 
S-C thioether linkages, and that previous studies never confirmed the nature of the SCIFF crosslink in the 
SCIFFs,24,25 we next sought to determine the connectivity of the SCIFF thioether crosslink. To obtain the 
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milligram quantities of peptide that would be required for spectroscopic characterization, we first targeted 
the predicted SCIFF from Paenibacillus polymyxa ATCC 842 (Figure 5.4). This BGC was selected because 
it displayed a unique sequence variation of six CX3D repeats which suggested that each of the six Cys 
donors would be linked to an Asp acceptor (similar to QhpD, Figure 5.15). After MS-based screening of 
various culturing conditions, we did not detect any ions consistent with the expected natural product. 
Therefore, we heterologously coexpressed the precursor peptide (PapA) and rSAM enzyme (PapB) in 
Escherichia coli following a previously published method.55,56 After purification, the peptide product 
obtained was analyzed by MALDI-TOF-MS, which indicated that the precursor peptide had undergone 
processing with a mass loss of 12 Da (consistent with six thioether linkages, Figure 5.20). Controls where 
the precursor peptide was expressed in the absence of the rSAM enzyme resulted in a product with a mass 
loss of 6 Da from the starting material, consistent with the formation of three disulfide bonds). In contrast 
to the single crosslinks reported from in vitro studies on Tte1186a and CteA (thermocellin),24,25 we observed 
a single product where all of the six Cys were modified. We have termed this group the freyrasins.  
The structure of freyrasin obtained through heterologous expression was further examined by HR-MS/MS 
(Figure 5.21). The observed m/z value ([M+4H]4+ = 1397.6113) agreed with the molecular formula for the 
predicted structure (C233H262N66O80S74+; [M+4H]4+ = 1397.6094; error = 1.4 ppm). The tandem MS data 
were also consistent with the freyrasin precursor peptide, although the fragmentation pattern observed 
showed a limited number of ions for a peptide of this size. Significant ions were only detected for sites that 
dissociated either directly before or after non-overlapping CX3D motifs. Such fragmentation behavior was 
reminiscent of a lanthipeptide-like structure as opposed to a sactipeptide-like structure.57-59 Indeed, prior 
work from our lab and others have shown that the sactionine linkage itself (S-C thioether) readily 
dissociate under standard CID condition whereas S-C thioether linkages do not, as is well-documented for 
lanthipeptides.16,56,60 These observations are further consistent with the lack of inter-ring fragmentation data 
recently reported from in vitro work on SCIFF peptides that contain a single thioether.24,25 By virtue of not 
undergoing this characteristic fragmentation, we speculated that freyrasin might not contain S-Cα linkages.  
To better understand this difference in CID fragmentation behavior, we initiated quantum mechanical 
calculations of two model tripeptides (Gly-Cys-Gly and Gly-Asp-Gly) that were Cys-Asp thioether linked 
to the C or C of Asp (see Section 5.5.13). These calculations revealed that the difference in zero-point 
energy between the two model peptides was comparable to thermal energies (1 kcal/mol) and thus 
negligible. However, the electronic energy of the S-C linked model peptide was found to be 12 kcal/mol 
more stable than the corresponding S-C linked isomer (Figure 5.22). We attribute the weaker bond energy 
of the S-C linkage to the greater stability of the alpha-centered radical that arises after homolytic bond 
dissociation. Taken with the bioinformatic predictions, these calculations provide an explanation for the 
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differential CID behavior between the two linkage types and further suggests that SCIFF thioethers are not 
alpha linked.  
 
5.2.5 Freyrasin is a S–Cβ crosslinked peptide: NMR evidence 
To rigorously establish the atomic connectivity of the freyrasin thioether linkages, various 
multidimensional NMR experiments was performed. Proteolytic digestion yielded a peptide cleaved 
between Tyr/Gly that was employed for NMR analysis (Figure 5.23). Using the known precursor peptide 
sequence (Figure 5.4) and 1H-1H TOCSY spectrum, residues were assigned based on the cross-peak patterns 
observed in the amide region from 7.70–8.60 ppm (Figure 5.24). The 1H-1H NOESY spectrum was used to 
confirm the linear freyrasin sequence (Figure 5.25). All residues were confidently assigned with the 
exception of Cys17 (Table 5.2).  Through-space correlations were visible for all residues with the exception 
of Asn5 and Asn16. This is likely due to a flexible structure, as demonstrated by a narrow amide chemical 
shift dispersion.61 As revealed in the TOCSY spectrum, freyrasin displayed NH-CαH-CβH correlations for 
five of the six Asp residues believed to be thioether crosslinked, confirming a continuous spin system. This 
correlation would not be possible for a S-Cα thioether (i.e. sactionine). Additionally, each of the six Asp 
residues generated NH-CαH-CβH TOCSY correlations similar to that of Ser, with two deshielded 
resonances occurring in the CαH region (3.6–4.7 ppm), again supportive of a Cys-Asp (S-Cβ) linked 
thioether (Figure 5.26). To assign the ring topology of freyrasin, NOESY correlations between Cys-Asp 
were assigned based on the chemical shift values obtained by TOCSY (Figure 5.5). Two of the six thioether 
rings were assigned unambiguously. The redundancy of the freyrasin primary sequence unfortunately led 
to extensive chemical shift overlap compounded with line broadening, presumably arising from the 
flexibility of the peptide, so complete NOESY correlations were not evident for the remaining rings in 
freyrasin. Nonetheless, when coupled with the bioinformatics, MS data, and the definitive NMR 
assignments, freyrasin has been determined to contain exclusively Cys-Asp (S-Cβ) linkages. With the 
structure confirmed, we next tested for antibiotic activity of the heterologously obtained freyrasin, but it 
was not significantly active against any strain tested (MIC ≥ 32 μM). It is possible that additional 
modifications are present in the native product, but also possible are that freyrasin harbors very narrow-
spectrum activity towards an untested strain or instead functions in a capacity unrelated to growth 
suppression (Table 5.4). 
 
5.2.6 Thermocellin contains a Cys-Thr (S-Cγ) linked thioether 
Given that freyrasin contains exclusively S-Cβ linkages in agreement with our bioinformatic 
predictions, we sought to determine if other “SCIFFs” also lacked sactionine linkages. The only two 
(partially) characterized SCIFFs thus far reported (i.e. Tte1186a and thermocellin) were previously 
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investigated after in vitro enzymatic reconstitution, which resulted in the formation of only one Cys-Thr 
thioether.24,25 Despite these studies drawing on homology to sactionine-forming rSAM enzymes to predict 
function, the presumed thioether installed by these enzymes did not undergo the gas-phase dissociation 
reaction that is characteristic of sactionine linkages. When further considering (i) our tandem MS data that 
show huazacin, a Cys-Thr (S-Cα)-containing sactipeptide, behaved as expected under CID conditions 
(Figure 5.9) and (ii) the thermocellin-forming rSAM enzyme, CteB, is more related to QhpD than any 
known sactionine-forming rSAM enzyme (Figure 5.19), we questioned whether thermocellin actually 
contains S-Cα linkages, as previously reported.  
The possible thioethers for the Cys-Thr crosslink in thermocellin could theoretically include either 
the alpha, beta, or gamma carbon of Thr. We believed that in addition to an unlikely Cys-Thr (S-Cα) linkage 
for the above-mentioned reasons, a (S-Cβ) linkage would also be unlikely given the instability of resulting 
thiohemiacetal. To confirm or refute if thermocellin possessed a Cys-Thr (S-Cγ) crosslink, we prepared an 
isotopically labeled version of the thermocellin precursor peptide, CteA, that included 2H at the α and β 
positions of Thr while retaining 1H at the γ-methyl group. Isotopically labeled Thr was incorporated by 
overexpression of CteA in a Thr auxotroph (ΔthrC) of E. coli in defined minimal media where the only 
source of Thr was the supplied L-[4-13C,2,3-2H2]-Thr. Initial protein preparations led to scrambling of the 
13C and 2H labels into other amino acids, resulting in complex series of masses (Figure 5.27). Isotopic 
scrambling was readily suppressed by the addition of natural abundance Ile and Gly to the expression media, 
resulting in production of fully labeled CteA with no detectable under- or over-labeling (Figure 5.27).62 The 
location of the isotopic labels was verified to be confined to Thr residues by HR-MS/MS (Figure 5.28). 
Having devised a means to probe the chemical nature of the thioether linkage in thermocellin, we next 
coexpressed CteA with CteB (the rSAM enzyme) using the same conditions that led to exclusive Thr 
isotope labeling. Consistent with a Cys-Thr (S-Cγ) linkage, a two Da mass loss was observed relative to 
the starting material. This result is consistent only with the abstraction of 1H from Thr and the loss of the 
thiol hydrogen during thioether formation. Abstraction of 2H from either the α or β carbons of Thr would 
have yielded a three Da mass loss (Figure 5.29). HR-MS/MS analysis of the product confirmed a Cys-Thr 
(S-Cγ) thioether species that did not undergo gas-phase dissociation associated with S-Cα thioethers. 
Unexpectedly, the tandem MS data unequivocally showed that the Cys-Thr linkage is to the Thr that resides 
two positions away to the donor Cys, which is in contrast to previous reports that show localization to a Thr 
five residues away from the donor Cys (Figure 5.6). This localization was further corroborated by the 
observation of fragmentation within the new assignment of the macrocycle in unmodified peptide reacted 
with N-ethylmaleimidie (Figure 5.30). To evaluate if the incorporation of stable isotopes altered the in vivo 
activity of CteB, we analyzed the coexpression product with natural abundance Thr and verified the same 
location for the thioether linkage (Figure 5.31). While it cannot be ruled out that the difference in 
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localization is due to previous work being done in vitro with purified enzymes, our data conclusively show 
that 1H was abstracted from the γ-methyl group of Thr during thioether formation which is consistent only 
with a (S-Cγ) linkage.  
 
5.2.7 Proposal to alter nomenclature for thioether-containing natural products 
Both freyrasin and thermocellin belong to the “SCIFF” family owing to both containing six Cys 
residues in a span of ~45 total precursor residues. As we have shown that neither freyrasin nor thermocellin 
contain S-Cα thioethers but instead S-Cβ and S-Cγ, respectively, we propose to rename this class to 
ranthipeptides (radical non-alpha thioether peptides) to distinguish them both structurally and 
biosynthetically from other thioether containing RiPP classes, namely the sactipeptides and lanthipeptides. 
 
5.3 Conclusion 
In this work, we revealed that SCIFFs are not sactipeptides but instead feature rSAM-installed 
thioether crosslinks between Cys donor residues and the β- or γ-carbon of an acceptor residue. To better 
reflect their rSAM-dependent biosynthesis and to draw a correlation to lanthipeptides, which are S-C 
linked, we propose the name radical non-alpha thioether containing peptides (i.e. ranthipeptides) for this 
RiPP class. Our assignment of ranthipeptides as a RiPP class distinct from sactipeptides is supported by 
several independent lines of evidence including: (i) rSAM enzymes associated with ranthipeptide precursor 
peptides are considerably more sequence similar to QhpD, a known S-C and S-Cγ thioether-forming 
enzyme, than any sactipeptide-associated rSAM enzyme, (ii) unlike sactionines, ranthipeptide thioethers do 
not fragment under mild CID conditions, an observation now supported by quantum mechanical bond 
dissociation energy calculations, (iii) multidimensional NMR spectroscopy, including 1H-1H TOCSY and 
1H-1H NOESY that support a Cys-Asp S-C linkage for freyrasin, (iv) direct tandem MS and NMR 
comparison of freyrasin to the sactipeptide huazacin, which contains a Cys-Asp S-C linkage, and (v) CteB 
(thermocellin-forming rSAM enzyme) abstracting hydrogen from the γ-carbon of the acceptor Thr during 
thioether formation. Collectively, these data provide conclusive evidence that both freyrasin and 
thermocellin are not alpha-linked. With previously reported beta-linked thioether-containing RiPPs being 
restricted to the lanthipeptides and the recently reported NxxcA, the ranthipeptide linkage chemistry is now 
considerably much richer as it is theoretically compatible with any non-Gly acceptor residue. This feature 
renders ranthipeptides an attractive target for engineering conformationally restrained peptides.  
Over the past few years, several new peptide reaction chemistries catalyzed by RiPP rSAM 
enzymes23 have been discovered and include the proteusins,63 epipeptides,64 streptide,65 mycofactocin,66,67 
and alpha-keto beta-amino acid containing peptides.68 The discovery unanticipated S-Cβ or S-Cγ linked 
thioethers adds ranthipeptides to this growing list of unique chemistry found in RiPP biosynthetic pathways. 
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We propose that a combination of sequence similarity and tandem MS analysis will provide valuable insight 
in discerning the various linkage chemistries of these yet-uncharacterized rSAM products. Combined with 
the continuing improvement of bioinformatics tools like RODEO, we anticipate these findings will aid in 
the discovery and characterization of new natural product structures.  
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5.5 Methods 
5.5.1 General methods 
Materials and reagents were purchased from Gold Biotechnology, Fisher Scientific, or Sigma-
Aldrich unless otherwise noted. Molecular biology reagents for cloning (e.g. restriction enzymes, Q5 
polymerase, T4 DNA ligase, and deoxynucleotides) were purchased from New England Biolabs. DNA 
primers were obtained from Integrated DNA Technologies (Table 5.1). DNA spin columns were purchased 
from Epoch Life Sciences. Sanger DNA sequencing was performed by the Roy J. Carver Biotechnology 
Center (University of Illinois at Urbana-Champaign). Polymerase chain reactions were performed using a 
Bio-Rad S1000 thermal cycler. 
 
5.5.2 Bioinformatic mining of Cys-rich rSAM-modified peptides 
To identify potential radical SAM (rSAM)-modified, thioether-linked peptides, PSI-BLAST42 
searches were performed in late 2018 with the four known sactipeptide rSAM proteins (AlbA, 
WP_003242599.1; SkfB, NP_388073.2; ThnB, ACY56718.1; and TrnC, AED99784.1)15 and two partially 
characterized SCIFF rSAM proteins (CteB25, WP_003517268.1; and Tte118624, AAM24417.1) for four 
iterations with a stringent PSI-BLAST threshold of 1e-70 to populate a list of related enzymes. Truncated 
enzyme records were removed by eliminating sequences less than 300 amino acid yielding a final list of (n 
= 4,693). Cysteine-rich (≥3 Cys residues) precursor peptide candidates encoded near these rSAMs were 
found using our automated ribosomally synthesized post-translationally modified peptide (RiPP) genome 
mining platform, Rapid ORF Description & Evaluation Online (RODEO). While this procedure yielded an 
illustrative dataset for sactipeptide- and SCIFF-/ranthipeptide-related rSAMs, it does include the nearly 
40,000 unique sequences available in GenBank that occupy the sequence space between the two classes. 
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Therefore, caution is warranted in comparing the similarity of sactipeptide from ranthipeptide synthases 
(i.e. they appear more closely related owing to the omission of ~40,000 other sequences). 
 
New release of RODEO. RODEO 2.0 is a rewritten and more efficient version of the previous RODEO 
algorithm.8 The new version follows the same logic as the previous version by obtaining/analyzing the 
genomic region neighboring a gene(s) of interest while also prospecting for potential RiPP precursor 
peptides. RODEO 2.0 was written in Python and retrieves protein or DNA FASTA files from GenBank 
using the NCBI E-Utilities (Entrez Direct)69 embedded in Biopython.70 The source code and tutorials for 
local installation and use of RODEO are available at: http://www.ripprodeo.org. A web-based tool is also 
available for smaller jobs from infrequent users. The major functional improvement in RODEO 2.0 is that 
each step of the program has its own dedicated module which greatly increases the efficiency of altering 
specific steps within the program. This means that the peptide scoring algorithm for identifying additional 
classes of RiPP precursor peptides are more easily incorporated into the RODEO platform. Currently, 
RODEO 2.0 is capable of scoring RiPP precursor peptides for the following four classes: lanthipeptides, 
sactipeptides, lasso peptides, and thiopeptides.  
 
Precursor identification. Precursor peptide prioritization was based on the RODEO scoring module 
developed for sactipeptides (https://antismash.secondarymetabolites.org and http://www.ripprodeo.org).12 
While our efforts uncovered that the majority of Cys-rich peptides encoded adjacently the rSAM enzymes 
were not strictly sactipeptides, related classes of precursors could reliably be found using metrics developed 
for this class. To account for intrinsic differences between identified Cys-rich peptides and canonical 
sactipeptides for which the original scoring was originally optimized, a lower threshold of ≥10 was 
employed (instead of the ≥25 cutoff used to identify sactipeptides). This relaxed list of precursor peptides 
was then manually curated to afford a final list of non-redundant precursor sequences (n = 2,145; comprised 
of 504 sactipeptides and 1,634 members of the SCIFFs) which were used to seed the precursor peptide 
sequence similarity networks.  
 
5.5.3 Sequence-similarity network (SSN) generation 
The predicted precursor peptide SSNs (Figures 5.7 and 5.15) were generated using EFI-EST 
(http://efi.igb.illinois.edu/efi-est) using the “representative node 90” parameter to conflate sequences that 
are >90% identical to a single node. The resulting network was visualized in Cytoscape 3.4.0 using the 
organic layout and annotated with RODEO output.71,72 Sequence logos of the corresponding clusters of 
precursor peptides were generated using WebLogo 2.8.2 (http://weblogo.berkeley.edu/logo.cgi) for the 
major clusters present in the precursor SSNs. The SSN for the rSAM enzymes (Figure 5.2) was generated 
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using EFI-EST and the protein list acquired by PSI-BLAST of the known sactipeptide synthases and two 
partially characterized SCIFF rSAM enyzmes. An alignment score of 50 and “representative node 70” 
parameter were chosen to conflate sequences >70% identical. The resulting network was visualized in 
Cytoscape.72 Color-coding of nodes was based on identified precursor peptide or biosynthetic pathway 
identified. Sactipeptide and SCIFF precursors were identified by RODEO and manually curated. SCIFF 
precursor peptide mining was also aided by identifying matches to the SCIFF pfam (PF13165) using 
hmmr3.0 (http://hmmer.org).73 Accessions involved in quinohemoprotein amine dehydrogenase maturation 
were identified by the local presence of proteins matching pfam models PF08992, PF09098, PF09099, 
PF09100, or PF14930.9 
 
5.5.4 Preparation of huazacin 
Bacillus thuringiensis serovar huazhongensis was obtained from the Bacillus Genetic Stock Center 
(BGSC 4BD1). Initial production of the sactipeptide was assessed in BHI (Brain-Heart Infusion from 
Beckton Dickinson), LB, and TGY (5 g/L tryptone, 1 g/L glucose, and 3 g/L yeast extract), and a mass 
consistent with huazacin was observed by MALDI-TOF-MS with all three media (Figure 5.8). For 
production, bacteria were grown in LB at 37 °C with shaking at 200 rpm for 30 h. Cells were harvested at 
4,000  g for 15 min and the harvested cells were extracted with 35 mL MeOH/L culture for 3 h. The 
extracts were then clarified by centrifugation at 4,000  g for 10 min. Clarified extract was then dried on 
10 g Celite 545 Filter Aid (Fisher) by rotary evaporation at 25 °C.  
To purify huazacin, the dried extract was subjected to chromatographic separation using a 
CombiFlash EZ Prep MPLC fitted with a TeleDyne Isco 43 g C18 cartridge under the following conditions: 
solvent A (10mM NH4HCO3), solvent B (MeCN) and the following linear gradient combinations: 4 Column 
Volumes (CV) 5% B, 1 CV 50% B, 6 CV 100% B, 4 CV 100% B. Fractions containing huazacin (as 
assessed by MALDI-TOF-MS) were dried by rotary evaporation at 25 °C. After resuspension in 20% 
MeOH/80% 10mM NH4HCO3 and clarified by centrifugation (17,000  g, 10 min), semi-pure huazacin was 
further purified using an Agilent 1200 HPLC system fitted with a Thermo Betasil C18 5 μm particle size, 
10  250 mm operating at 4 mL/min under the following conditions: solvent A (10 mM NH4HCO3), solvent 
B (MeCN) and the following gradient: t=0 min, 20% B, t=3 min, 20% B, t=13 min, 40%B, t=16 min 95%B, 
t=21 min 95% B, t=24 min, 20% B, t=29 min, 20% B. The column was equilibrated at starting conditions 
for 10 min before each injection. Fractions containing huazacin (by MALDI-TOF-MS) were dried by rotary 
evaporation at 25 °C to dryness, resuspended in 20% MeOH/80% 10mM NH4HCO3 and clarified by 
centrifugation (17,000  g, 10 min). Huazacin was then purified using an Agilent 1200 HPLC system fitted 
with a Thermo Betasil C18 5 μm particle size, 4.6  250 mm operating at 1 mL/min under the following 
conditions: solvent A (10 mM NH4HCO3), solvent B (MeCN) and the following gradient: t=0 min, 20% B, 
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t=5 min, 20% B, t=8 min, 32%B, t=18 min 42%B, t=21 min 100% B, t=26 min, 100% B, t=29 min, 20% 
B. The column was equilibrated at starting conditions for 10 min before each injection. Pure huazacin was 
dried under rotary evaporation at 25 °C and then lyophilized to dryness. Mass of peptide was determined 
using a 5-digit analytical scale and indicated a final post-purification yield of 100 μg/L of culture. 
 
5.5.5 MALDI-TOF-MS 
Matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS) 
was used to identify peptide products based upon their characteristic mass changes upon posttranslational 
modification, protease digestion, or chemical modification. The huazacin peptides were detected using 20 
mg/mL sinapic acid in 75% MeCN with 0.1% formic acid. The samples were analyzed using a Bruker 
Daltonics UltrafleXtreme MALDI-TOF mass spectrometer in reflector/positive mode. The freyrasin 
precursor peptide and fragments gave the most intense peaks when mixed with a matrix consisting of 20 
mg/mL of α-cyano-4-hydroxycinnamic acid and 10 mg/mL 2,5-dihydroxybenzoic acid in 60% MeCN with 
0.1% formic acid.  
 
5.5.6 HR-ESI-MS/MS analysis 
Samples for high-resolution electrospray ionization (HR-ESI) MS were first HPLC-purified or 
desalted by ZipTip. Next, samples were diluted 1:1 into ESI mix (80% MeCN, 19% H2O, 1% formic acid). 
Samples were directly infused into a ThermoFisher Scientific Orbitrap Fusion ESI-MS using an Advion 
TriVersa Nanomate 100. The MS was calibrated and tuned with Pierce LTQ Velos ESI Positive Ion 
Calibration Solution (ThermoFisher). The MS was operated using the following parameters: resolution, 
100,000; isolation width (MS/MS), 2 m/z; normalized collision energy (MS/MS), 35; activation q value 
(MS/MS), 0.4; activation time (MS/MS), 30 ms. Fragmentation was performed using collision-induced 
dissociation (CID) at 35 to 70%. Data analysis was conducted using the Qualbrowser application of 
Xcalibur software (Thermo-Fisher Scientific). 
 
5.5.7 NMR of huazacin 
The sample was prepared by dissolving 1.5 mg (HPLC-purified and lyophilized) in 250 μL of 
CD3OH (Acros Organics, >99.40% atom % D). NMR spectra were recorded on an Agilent VNMRS 750 
MHz narrow bore magnet spectrometer equipped with a 5 mm triple resonance (1H-13C-15N) triaxial 
gradient probe and pulse-shaping capabilities. Samples were held at 25 °C during acquisition. Standard 
Varian pulse sequences were used for each of the following experiments: 1H-NMR, 1H-1H TOCSY (80 
ms mixing time), and 1H-1H NOESY (400 ms mixing time). Solvent suppression by presaturation 
(PRESAT) was employed for 1H, 1H-1H NOESY and 1H-1H TOCSY. Spectra were recorded with 
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VNMRJ 3.2A. Spectra were imported into MestReNova 8.1.1, phased and baseline corrected. Sine Bell 
apodization with a first point correction of 0.5 were used with a zero fill of 1024. Resonances were 
referenced internally to 4,4-dimethyl-4-silapentane-1-sulfonic acid (0.00 ppm). 
 
5.5.8 Microbiology assays 
Aerobic bacteria were grown in BHI with shaking (200 rpm) at 37 °C, but the media for Listeria 
was supplemented with 5 mM Cys. Cultures were initiated from glycerol backstocks, grown overnight, and 
then diluted into fresh media and regrown to OD600 = 0.5. Next, cultures were diluted 1000-fold with fresh 
media and used in growth-suppression assays. Anaerobic media was prepared for Clostridium by sparging 
the media with N2 for 15 minutes and then autoclaved for 30 mins. After autoclaving, media was again 
sparged with N2 for 15 minutes, transferred to an anaerobic growth chamber, and allowed to equilibrate 
overnight. Glycerol back stocks of C. sporogenes were inoculated and grown overnight without shaking. 
Minimum inhibitory concentrations (MICs) were determined using the microbroth dilution method. 
Lyophilized compounds (freyrasin/huazacin) in sterile-filtered DMSO were added at a starting 
concentration of 256 μM. Two-fold serial dilutions were performed into wells containing ~5.0  105 
CFU/mL. Wells were examined for turbidity after overnight incubation. 
 
5.5.9 Genomic DNA extraction 
Paenibacillus polymyxa ATCC 842 was grown overnight in Lysogeny Broth (LB). Genomic DNA 
was extracted from 5 mL of culture using the DNeasy UltraClean Microbial Kit (MOBIO) according to the 
manufacturer’s protocol. 
 
5.5.10 Cloning of freyrasin 
Based on previous expression of sactipeptides in E. coli,55,56 a pETDuet-1 vector was used for co-
expression of the freyrasin (SCIFF/ranthipeptide) precursor peptide, PapA, and the radical SAM enzyme 
(WP_019688962.1), PapB, from Paenibacillus polymyxa ATCC 842. The pETDuet vector was modified 
to encode a maltose-binding protein (MBP) tag with a tobacco etch virus (TEV) protease-cleavable linker 
at the N-terminus of the precursor peptide in the first multiple cloning site (MCS). The expression plasmid 
was constructed using restriction enzyme cloning (BamHI and NotI for the precursor peptide; AatII and 
XhoI for the radical SAM). The genes for papA and papB were amplified from genomic DNA using Q5 
polymerase and the primers in Table 5.1. The amplicons were purified with a QIAquick PCR purification 
kit, digested with the appropriate restriction enzymes, and then purified again using the QIAquick PCR 
purification kit. The peptide-encoding gene was then sequentially ligated into similarly prepared pETDuet 
plasmid to create pET-Duet-MCS1: MBP-PapA MCS2: PapB. 
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5.5.11 Preparation of freyrasin 
BL21-RIPL (DE3) cells were transformed with pET-Duet-MCS1: MBP-PapA MCS2: PapB 
containing the MBP-tagged freyrasin precursor peptide (MCS1) and tagless rSAM (MCS2) and streaked 
onto LB agar plates supplemented with 100 µg/mL ampicillin and 34 µg/mL chloramphenicol. A single 
colony was used to inoculate a 10 mL starter culture with the same antibiotics. After 5 h of growth at 37 
°C, 1 L of culture in a flat bottom 4 L flask was inoculated and grown to ~0.8 OD600. At this density, 
expression was induced with 0.6 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and the culture was 
shaken at 100 rpm for 16 h at room temperature. The cells were harvested by centrifugation at 4,000  g 
for 15 min. Cell pellets were frozen at -20 °C if not used immediately.  
To purify freyrasin, the harvested cells were resuspended in ice cold lysis buffer [50 mM Tris pH 
7.5, 500 mM NaCl, 2.5% (v/v) glycerol, 0.1% (v/v) Triton X-100] supplemented with 3 mg/mL lysozyme. 
The samples were subjected to three rounds of sonication for 30 s with 10 min equilibration periods at 4 °C 
between the sonication steps. The lysate was centrifuged for 60 min at 17,000  g to remove the cellular 
debris. The clarified lysate was loaded into a gravity flow column with amylose resin (pre-equilibrated in 
lysis buffer). The column was then washed with wash buffer [50 mM Tris pH 7.5, 500 mM NaCl, 2.5% 
(v/v) glycerol] and then eluted with elution buffer [50 mM Tris pH 7.5, 300 mM NaCl, 2.5% (v/v) glycerol, 
10 mM maltose]. The eluted protein was collected in Amicon Ultra 15 mL centrifugal filters [30 kDa 
NMWL (Nominal Molecular Weight Limit)]. The protein was concentrated and a 10-fold buffer exchange 
was performed into storage buffer [50 mM HEPES, 300 mM NaCl, 2.5% (v/v) glycerol]. 
MBP-tagged freyrasin (500 μL of 20 mg/mL solution) was digested with TEV protease (80 μg) at 
30 °C for 16 h to remove the MBP tag. Unexpectedly, TEV protease processed multiple sites within the 
freyrasin leader peptide, in addition to the intended site (Figure 5.23). However, one of the truncated 
peptides removed the entire predicted leader peptide, resulting in more ideal peptide for NMR analysis due 
to the reduction of amino acid multiplicity. Thus, this modified peptide was purified using an Agilent 1200 
series HPLC fitted with a 10  250 mm Betasil C18 column (Fisher Scientific). A gradient elution was used 
with solvent A (0.1% formic acid) and solvent B (MeCN + 0.1% formic acid) according to the following 
linear gradient combinations: at t=0 min, 10% B; t=2 min, 10% B; t=19 min, 35.5% B; t=22 min, 95% B; 
t=27 min, 95% B; t=31 min, 10% B; t=45 min, 1% B. Fractions containing pure freyrasin were dried under 
rotary evaporation at 25 °C and then lyophilized to dryness. Mass of peptide was determined using a 5-digit 
analytical scale and indicated a final yield after purification of 250 μg/L of culture. 
 
5.5.12 NMR of freyrasin 
The sample was prepared by dissolving 1.7 mg (HPLC-purified and lyophilized) in 350 μL of 9:1 
H2O:D2O (99.96 atom % D; Sigma-Aldrich) supplemented with 3 μL of 1M NaOH (aq). This sample was 
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then neutralized with 4 μL of 1M HCl (aq). The sample was then sonicated at room temperature for 15 min. 
NMR spectra were recorded on an Agilent VNMRS 750 MHz narrow bore magnet spectrometer equipped 
with a 5 mm triple resonance (1H-13C-15N) triaxial gradient probe and pulse-shaping capabilities. Samples 
were held at 25 °C during acquisition. Standard Varian pulse sequences were used for each of the following 
experiments: 1H, 1H-1H TOCSY (80 ms mixing time), and 1H-1H NOESY (400 ms mixing time). Solvent 
suppression by presaturation (PRESAT) was employed for 1H and 1H-1H NOESY experiments, while 1H-
1H TOCSY spectra were recorded using a z-filter and H2O flipback pulse.  was used as the solvent. Spectra 
were recorded with VNMRJ 3.2A. Spectra were imported into MestReNova 8.1.1, phased and baseline 
corrected. Sine Bell II apodization with a first point correction of 0.5 were used with a zero fill of 
1024.Resonances were referenced internally to the solvent peak (4.64 ppm, HOD). 
 
5.5.13 Quantum mechanical system preparation and calculations 
Two tripeptides, one being Gly-Cys-Gly and the other being Gly-Asp-Gly, were assembled using 
the Model Kit Peptide builder of Spartan 16 version 2.0.7 (Wavefunction, Inc. Irvine, CA, 
http://www.wavefun.com). The N-terminus of both peptides were capped as N-acetyl with the C-terminus 
being capped as the O-methyl ester to mitigate any charge effects. The initial peptide backbone dihedral 
angles were set as =180 and = -180. The tripeptides were further modified in Molecular Operating 
Environment MOE 2016.08 (Chemical Computing Group ULC) to match structures to model the natural 
product structures reported in this study, in which the Cys S atom is bonded either to the alpha- or beta-
carbon of the recipient Asp residue, termed S-Cα and S-Cβ, respectively (Figure 5.22). Finally, the two 
thioether-crosslinked peptides were imported to Avogadro 1.2.0, http://avogadro.cc),74 where the structures 
were subjected to a brief classical energy minimization with the steepest descent algorithm and the UFF 
force field,75 and input files for quantum calculations were prepared. Quantum mechanical geometry 
optimization followed by electronic and zero-point energy calculations were performed using Gaussian 
09,76 with density functional theory (DFT) methods using the B3LYP hybrid functional and 6-31G(d) basis 
sets.77,78 
 
5.5.14 Cloning of thermocellin 
E. coli optimized genes encoding for the thermocellin precursor peptide (cteA) and cognate rSAM 
(cteB) were ordered from Synbio Technologies (Monmouth Junction, NJ, USA) using sequences previously 
described by Grove et al.25 Similar to coexpression of freyrasin described above, cteA was inserted 
downstream of a MBP affinity tag to yield a construct for both overexpression of unmodified precursor as 
well as feedstock for subsequent insertion of tagless cteB in the second MCS of the pET-Duet vector via 
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Gibson assembly. Additionally, for overexpressions involving thermocellin, the AmpR resistance marker 
was swapped with KanR.  
 
5.5.15 Overexpression of unmodified, MBP-tagged thermocellin precursor CteA 
pET-Duet-MCS1: MBP-CteA was transformed into BL21(DE3) E. coli and plated on LB media 
containing 50 µg/mL kanamycin. A single colony was used to inoculate 10 mL of LB liquid media 
containing 50 µg/mL kanamycin as an overnight starter culture. This culture was then used to inoculate 1 
L of LB liquid media containing 50 µg/mL. The culture was allowed to grow at 37 °C with 250 rpm shaking 
until reaching an OD600 of 1.0. Upon reaching density, the culture was cooled in an ice bath for 15 min prior 
to the addition of 100 mg/L FeSO4 and IPTG to a final concentration of 0.4 mM. Induction was carried out 
for 16 h at 22 °C with shaking at 250 rpm.  
 
5.5.16 Isotopic labeling of CteA with L-[4-13C,2,3-2H2]-Thr.  
L-[4-13C,2,3-2H2]-Thr was purchased from Cambridge Isotope Laboratories (Tewksbury, MA, 
USA). pET-Duet-MCS1: MBP-CteA was transformed into RF2 E. coli, a threonine auxotroph owing a 
deletion of threonine synthetase (thrC), and plated on LB contianing 50 µg/mL kanamycin. A single colony 
was used to inoculate 5 mL of LB supplemented with 50 50 µg/mL kanamycin to create an overnight culture 
which was subsequently used to inoculate M9 media (22 mM KH2PO4, 43 mM Na2HPO4, 8.5 mM NaCl, 9 
mM (NH4)2SO4, 22.2 mM glucose) supplemented with 50 µg/mL kanamycin at a ratio of 1:100. 
Additionally, 1 mM L-[4-13C,2,3-2H2]-Thr and 2 mM L-Gly and L-Ile were added, the latter two to suppress 
isotopic scrambling by Thr-catabolizing pathways.62 Overexpression was otherwise carried out identically 
for natural-abundance MBP-tagged CteA, described immediately above. 
 
5.5.17 Coexpression of CteA with cognate rSAM CteB 
pET-Duet-MCS1: MBP-CteA-MCS2: CteB was transformed into E. coli RF2 cells harboring the 
pSUF accessory plasmid (chloramphenicol marked), which overexpresses the suf operon from E. coli and 
aids in Fe-S cluster formation,79 and plated on LB supplemented with 50 µg/mL kanamycin. A single colony 
was used to inoculate a starter culture of 5 mL LB containing 50 µg/mL kanamycin and 34 µg/mL 
chloramphenicol. This overnight culture was used to coexpress CteA and CteB using the same procedure 
described above for isotopically labeled CteA with the exception that shaking was done at 75 rpm to 
produce quasi-anaerobic conditions and prevent dissolved oxygen from poisoning Fe-S clusters. The 
threonine used was either L-[4-13C,2,3-2H2]-Thr (for labeled CteA) or L-Thr for natural abundance CteA.  
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5.5.18 Purification of MBP-tagged CteA 
For all variants of CteA expression (modified, unmodified, labeled, and natural abundance), MBP-
tagged CteA was purified by amylose resin as described above for freyrasin.  
 
5.5.19 N-ethylmaleimide labeling of CteA 
To assess the state of modification of CteA in coexpression assays, obviate convolution caused by 
disulfide formation, and facilitate separation of modified and unmodified peptide, unmodified Cys groups 
were labeled with N-ethylmaleimide (NEM) prior to HPLC and MS/MS analysis. Purified MBP-tagged 
CteA was cleaved with TEV protease at a ratio of 1:10 for 2 h at 25 °C. Free MBP and TEV protease were 
then removed by reverse Ni-NTA chromatography as previously described.80 The cleaved peptide was then 
reacted with a 10-fold molar excess of TCEP (relative to concentration of free thiol groups) at 37 °C for 10 
min. A 10-fold molar excess of NEM was added an incubated at 37 °C for 30 min. Lastly, a 15-fold molar 
excess of DTT was added to quench the reaction. 
 
5.5.20 Solid-phase extraction of NEM-labeled CteA 
A 500 g C18 solid-phase extraction (SPE) cartridge (ThermoFisher) was equilibrated with 10 
column volumes (CV) of MeCN followed by 10 CV of 0.1% formic acid prior to applying the bulk CteA 
NEM-labeling mixture. Salts were removed with 5 CV of 0.1% formic acid prior to elution with 80% MeCN 
+ 0.1% formic acid. The elution was then lyophilized to dryness prior to treatment with GluC 
endoproteinase. 
 
5.5.21 GluC endoproteinase treatment of CteA 
After SPE, the lyophilized peptide was resuspended in protein storage buffer (composition above) 
and treated with GluC endoproteinase (Worthingon Biochemical Corporation, Lakewood, NJ, USA) at a 
ratio of 1:20 (by mass) prior to HPLC and subsequent MS/MS analysis.  
 
5.5.22 HPLC purification and MS/MS analysis of GluC-treated, NEM-labeled CteA 
GluC-treated CteA was injected onto a 250  4.6 mm Nucleodur C18 Gravity 5 µm column 
(Machery-Nagel, Düren, Germany) pre-equilibrated with 95% A/5% B (A = 0.1% formic acid; B = MeCN 
+ 0.1% formic acid). Peptide fragments were then subjected to the following HPLC gradient: 5 min at 5% 
B prior to a gradient reaching 95% B over 45 min followed by a hold at 5 min at 95% B. Fractions were 
collected by monitoring the absorbance at 220 nm and analyzed by MALDI-TOF-MS. Fractions containing 
NEM-labeled core peptides of interest were lyophilized to dryness, reconstituted in 80% MeCN with 1% 
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acetic acid and directly infused into a ThermoFisher Scientific Orbitrap Fusion ESI-MS using an Advion 
TriVersa Nanomate 100. MS/MS analysis was carried out as described above for huazain and freyrasin.  
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5.6 Figures 
 
Figure 5.1 Sactipeptide biosynthesis and ring topologies. (A) Schematic overview of sactipeptide 
biosynthesis. (B) Proposed mechanism for the rSAM-dependent formation of the sactipeptide S–Cα 
thioether crosslink. (C) Precursor peptide sequence and ring topologies of all known sactipeptides (blue, 
S–Cα linkage; yellow, S-S linkage; black, uncharacterized). The requisite rSAM enzyme name is given in 
parentheses. Characterization of the six Cys in forty-five residues (SCIFFs) is limited to in vitro enzymatic 
assay for which only one thioether linkage was observed. Data shown later in this manuscript support a 
Cys-Thr linkage different to what has been previously reported and further that SCIFFs are not 
sactipeptides. * Hyicin 4244 has not been structurally characterized, thus the linkages indicated are 
speculative. 
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Figure 5.2 Huazacin from Bacillus thuringiensis serovar huazhongensis. (A) Biosynthetic gene cluster. 
The sactipeptide synthases HuaB and HuaC (NCBI accession identifiers: EEM79976.1 and EEM79977.1, 
respectively) feature an N-terminal RRE domain and C-terminal SPASM domain similar to other 
sactisynthases.27,68 (B) Precursor peptide sequence and chemical structure of huazacin. 
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Figure 5.3 Sequence similarity network of rSAM enzymes. rSAM enzymes involved in sactipeptide and 
SCIFF biosynthesis were used as BLAST inputs to gather additional rSAM enzymes predicted to form 
RiPP thioether linkages. Sequences were analyzed by EFI-EST,43 and visualized using Cytoscape.72 Nodes 
are colored based on the category of its associated precursor peptide (see legend). Sequences sharing >70% 
identity are conflated as a single node, and connected nodes indicate a similarity score of < 1e-50.43,71,72 
Sequence logos for core peptides associated with these rSAMs are shown in Figures 5.7 and 5.15. QhpD, 
non-RiPP rSAM involved in modifying quinohemoprotein amine dehydrogenase.40  
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Figure 5.4 Freyrasin biosynthetic gene cluster and related peptides. (A) Biosynthetic gene cluster diagram. 
(B) Freyrasin precursor peptide sequence with six CX3D motifs and thioether topologies highlighted. (C) 
Alignment of additional freyrasin members. Leader peptide residues are negatively numbered relative to 
the core peptide, which we predict begins with Gly.  
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Figure 5.5 Freyrasin contains beta-linked thioethers. (A) Cys-Asp (S–Cβ) connectivity with hydrogens 
colored pink (Cys) or blue (Asp). (B) 1H-1H NOESY correlations confirming a S–Cβ thioether linkage 
between Cys26-Asp30. (C) Same as panel B but for Cys20-Asp24. 
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Figure 5.6 Thermocellin contains a Cys-Thr (S-Cγ) thioether. (A) Coexpression of the thermocellin 
precursor containing labeled Thr (blue) features a -2 Da shift relative to unmodified peptide, demonstrating 
a S-Cγ linkage was formed. The modified peptide was treated with endoproteinase GluC and unmodified 
Cys were alkylated with N-ethylmaleimide (red) Residues are numbered based on the sequence after GluC 
treatment. (B) Structure of the isotopically labeled thioether linkage. (C) MS/MS analysis yielded 
fragmentation consistent with a macrocycle formed between Cys9 and Thr11. Error tables for assigned ions 
are available in Table 5.6.  
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Figure 5.7 Bioinformatic analysis of sactipeptide precursor peptides. (A) Precursor peptides form distinct 
clusters at an alignment score of 6 and conflated at an identity score of 100%, yielding 499 unique 
sequences. Characterized representatives of each grouping are shown as a diamond-shaped node. This 
alignment is strongly correlated with conservation of Cys residues as seen in the bottom panel. (B) Sequence 
logos of each cluster’s core peptides. While full length precursors were used to generate these logos, only 
the first three residues N-terminal of the first conserved Cys are shown. We have named the predicted group 
(6) “lachnocins” as the producing organisms of these compounds are predominated by the family 
Lachnospiraceae.  
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Figure 5.8 MALDI-TOF-MS of B. thuringiensis serovar huazhongensis extracts. (A) MALDI-TOF-MS 
spectra of crude methanolic extractions of B. thuringiensis serovar huazhongensis grown in BHI, LB, and 
TGY media. High intensity masses are labeled; red indicates a mass consistent with a modified huazacin 
precursor peptide. (B) Masses for different N-terminal truncations of the huazacin precursor peptide with 
thioether modifications (4 thioethers, one for each Cys highlighted in red).  
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Figure 5.9 HR-ESI-MS/MS of huazacin. (A) Structure of the sactipeptide after undergoing CID-dependent 
thioether dissociation, characteristic of sactionine linkages, which results in regenerated Cys sulfhydryl 
groups and dehydro-amino acids at the acceptor residue.60 Observed b and y ions are annotated. (B) MS/MS 
spectrum of the sactipeptide used to localize acceptor amino acids. A previously unseen phenomenon 
resulting in the formal loss of 62.0037 Da, consistent with formal loss of carbonic acid, is observed for ions 
containing the Asp acceptor residue. The required decarboxylative dehydration would be similar to known 
chemistry that occur on carboxylic acid-bearing alkenes.81 Error for assigned fragments are listed in Table 
5.6. 
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Figure 5.10 Amide-side chain 1H-TOCSY correlations and assignments of huazacin. Amino acids were 
identified by canonical TOCSY correlation patterns and assigned sequentially based on NH-NH NOESY 
correlations. Residues that did not generate NH-NH NOESY correlations were assigned based on side chain 
correlations. Pro11 and Pro23 did not generate TOCSY correlations due to a lack of protonated amides, and 
residues Trp2 and Ala35 did not generate amide TOCSY correlations. Thioether receptor residues were 
assigned based on side chain correlations, with the exception of Asp26, which could not be assigned. 
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Figure 5.11 NH-NH NOESY correlations of backbone amides of huazacin. Amino acids are assigned based 
on their amide proton chemical shifts along the diagonal, and neighboring residue correlations are labelled 
off-diagonal. Residues that did not generate NOESY correlations were assigned based on the known 
precursor peptide sequence, process of elimination and side chain proton correlations. While His38 was 
confidently assigned by amide-amide correlation, no diagnostic NOESY couplings to Cys4 were found, 
and Asp26 was not able to be assigned due to a lack of any NOESY correlations to neighboring residues.  
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Figure 5.12 NOESY correlations supporting the S-Cα thioether linkage of huazacin. (A) Structure of the 
core region of huazacin. (B) Observed NOESY correlations establishing an S-Cα linkage. Additional 
correlations between the Cys and Tyr/Thr side chains are not evident due to long coupling distances and 
side chain orientations. The absolute stereochemistry of the thioether linkage was not determined. 
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Figure 5.13 TOCSY correlations of the H-Cα region of huazacin. NMR spectrum used for the assignment 
of amino acid residues lacking amide-side chain (Pro11, Pro23, Thr30, and Ala35). 
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Figure 5.14 Abundance and sequence characteristics of annotated precursor peptides. (A) The number of 
rSAM proteins assigned to different groups. (B) The average number of Cys and standard deviation for 
identified precursor peptides within each major peptide group (see Figures 5.7 and 5.15). (C) The Cys 
length ratio is defined as the distance from the last Cys to the end of the predicted precursor peptide divided 
by the distance from the first Cys to the final Cys. Ratios > 1 indicate that a traditional sactipeptide hairpin 
structure is more likely to form because the distance between the Cys residues is shorter than the length of 
the remaining core region. Notably SCIFF/ranthipeptides have a ratio < 1 as their Cys tend to be distributed 
more evenly. (D) The Cys midpoint ratio represents an average of the positioning of the Cys residues within 
a precursor peptide. A lower midpoint indicates Cys tend to be more concentrated near the N-terminus of 
the precursor peptide. HVG, hypervariable group. 
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Figure 5.15 Bioinformatic analysis of SCIFF/ranthipeptide precursor peptides. (A) Precursor peptides form 
distinct clusters at an alignment score of 8. Nodes are conflated at an identity of 90%, yielding 567 nodes, 
and colored according to scheme illustrated in panel (B). (B) Histogram of Cys content of identified 
precursor peptides. As illustrated by the historical name SCIFF (six cysteines in forty-five residues), the 
vast majority of precursor peptides feature six Cys residues. (C) Sequence logos of the core peptide 
sequences of the six most populous groups. Groups 2, 3, 5, and 6 have no characterized members. 
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Figure 5.16 Phylogenetic analysis of organisms containing sactipeptide and SCIFF/ranthipeptide gene 
clusters. (A) Distribution of identified precursor peptides with accompanying rSAM as identified by 
RODEO. Phylogenetic data provided by NCBI Taxonomy records indicate that >95% originate from 
Firmicutes. (B) Genus distribution of sequences within Firmicutes with the top 5 most abundant genera 
denoted. 
  
223 
 
 
Figure 5.17 Parametric % GC analysis of rSAMs. The average % GC content of the entire genome is 
compared to the % GC of the rSAM gene. The plot contains a selection of known sactipeptides and putative 
SCIFFs, including those in this report, are highlighted in purple. Regression outliers with significantly 
higher rSAM % GC content relative to their genomes (>10% difference) are highlighted in orange and 
derive largely from Clostridium.  
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Figure 5.18 Unusual genomic contexts of SCIFFs. (A) Certain SCIFFs BGCs appear to encode additional 
genes that may further modify the product (Table 5.2), such as Orn/Lys/Arg decarboxylase. (B) SCIFFs co-
occur with tRNA-related enzymes (Table 5.2) with high frequency, which might be related to a possible 
biological role for these natural products. (C) Some biosynthetic operons for quinohemoprotein amine 
dehydrogenase also feature what appears to be a precursor peptide which may co-opt QhpD to produce a 
RiPP alongside of quinohemoprotein amine dehydrogenase. Further characterization will be needed to test 
these hypotheses. 
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Figure 5.19 Maximum likelihood tree of rSAMs involved in thioether formation. rSAM enzymes likely 
involved in thioether installation identified by PSI-BLAST were aligned using the E-INS-i algorithm in 
MAFFT 7.313 (https://mafft.cbrc.jp/alignment/software/).82 While NxxcB, which forms a thioether to the 
-carbon of Asn in a divergent RiPP54 was not part of the BLAST results, it was manually added to gauge 
similarity to sactipeptide and SCIFF/ranthipeptide enzymes. The MAFFT alignment was used to generate 
a maximum likelihood tree using FastTree 2.1.10, which is visualized here using iTOL 4 
(https://itol.embl.de/).83,84 The tree is rooted using TbtI, a rSAM enzyme involved in thiazole methylation, 
as an outgroup.22 Enzymes involved in S-Cβ and S-Cγ thioether formation (blue; PapB, NxxcB, and CteB) 
are closer to QhpD (green) than any characterized sactionine-forming rSAM (red) as evidenced by sum of 
appropriate branch lengths. This is further reflected in the percent identity matrix of the labeled rSAMs 
(Table 5.7).  
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Figure 5.20 Trypsin digest of the freyrasin precursor peptide. (A) Overview of experimental procedure. 
(B) When the peptide was expressed without the cognate rSAM enzyme, three disulfide bonds 
spontaneously formed for a loss of 6 Da (Cys are highlighted yellow). These S-S bonds protected several 
trypsin sites from digestion. (C) When co-expressed with the cognate rSAM enzyme, the mass of the 
product was 12 Da lighter than the precursor peptide. Additional mass spectrometry (Figure 5.21) and NMR 
spectroscopy (Figures 5.24-5.26) supported six Cys-Asp linkages (red and blue, respectively). 
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Figure 5.21 HR-ESI-MS/MS of freyrasin isolated via heterologous expression. (A) Proposed structure of 
freyrasin after TEV protease treatment to remove the MBP tag with proteolysis occurring at the canonical 
TEV cleavage site. Observed b and y ions are annotated. (B) CID spectrum of freyrasin ([M+5H]5+). The 
limited observation of b and y ions surrounding the thioether rings of freyrasin is reminiscent of a 
lanthionine linkage (β-linked thioethers) as fragmentation typically only occurs between rings.57-59 
Sactipeptides (S-Cα thioethers) readily undergo a dissociation reaction which allows for fragmentation 
within the ring.60 Error tables for assigned fragments are in Table 5.6. 
  
228 
 
 
  C 
Energy 
S-C
(kcal/mol) 
S-C
(kcal/mol) 
Difference 
(kcal/mol) 
Eelec 1,536,784 1,536,796 12 
ZPE 358 357 1 
 
Figure 5.22 Model of S-Cα and S-Cβ peptides. Two model peptides were used for quantum energy 
calculations: sulfur bound to the α-carbon (A) (S-C) or β-carbon (B) (S-C). Atom color-coding is as 
follows: carbon (grey), oxygen (red), nitrogen (blue), sulfur (yellow), and hydrogen (white). (C) Electronic 
(Eelec) and zero-point energies (ZPE) are provided and indicate that S-C crosslinks are 12 kcal/mol more 
stable than the S-C crosslinked isomer. 
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Figure 5.23 Removal of MBP tag and N-terminal residues from expressed freyrasin. (A) Overview of 
experimental setup. Three peptides arise upon digestion by TEV protease (dashed lines and corresponding 
masses). TEV protease’s canonical sequence and cut site are colored blue. (B) MALDI-TOF-MS spectrum 
of different samples of freyrasin showing canonical and non-specific digestion of the freyrasin peptide. (C) 
Fortuitously, the shortest TEV cleaved peptide resulted in most of the predicted leader peptide being 
removed, which was HPLC-purified and later employed for NMR analysis.  
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Figure 5.24 Amide-side chain 1H-TOCSY correlations and assignments of freyrasin. Amino acids were 
identified by known TOCSY correlation patterns and assigned sequentially based on NH-NH NOESY 
correlations (see Figure 5.25). Residues Asn5 and Asn16 were not distinguishable. Residue Cys17 was not 
observed. 
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Figure 5.25 NH-NH NOESY correlations of backbone amides of freyrasin. Amino acids are assigned based 
on their amide proton chemical shifts along the diagonal, and neighboring residue correlations are labelled 
off diagonal. Residues that did not generate NOESY correlations were assigned based on the known 
precursor peptide sequence, process of elimination and side chain proton correlations. 
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Figure 5.26 Amide proton-side chain correlations of S-Cβ linked Asp residues of freyrasin. Linked Asp 
residues demonstrate continuous scalar coupled protons from the amide proton through the side chain 
protons, a splitting pattern that would not be possible if freyrasin was alpha-linked. Additionally, formation 
of a thioether bond at Asp Cβ deshields the remaining Hβ, generating a TOCSY splitting pattern reminiscent 
of Ser. Spectral sliced are used to improve clarity. 
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Figure 5.27 Overexpression of Thr-labeled CteA with Ile and Gly supplementation. (A) Thermocellin 
precursor peptide, CteA, overexpressed in BL21(DE3) E. coli after purification and removal of the MBP 
affinity tag. (B) CteA purified from Thr-auxotroph RF2 E. coli grown in defined media supplemented only 
with L-[4-13C,2,3-2H2]-Thr results in a large amount of isotopic scrambling from Thr catabolism.62 (C) The 
addition of Ile and Gly suppresses the catabolism of the labeled Thr unit, resulting in near-perfect 
incorporation of labeled Thr into the CteA precursor peptide.62 
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Figure 5.28 MS/MS localization of isotopic labels to Thr in labeled CteA. (A) GluC treatment was used to 
remove a majority of N-terminal leader residues and subsequently (B) MS/MS was used to localize isotopic 
labels exclusively to Thr and showed no detectable scrambling, under-, or over-labeling. Error tables for 
assigned fragments are in Table 5.6. 
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Figure 5.29 Coexpression of CteB with labeled CteA results in 1H abstraction and S-Cγ thioether formation. 
Coexpression of CteB with labeled CteA under the same conditions that provided ideal labeling exclusively 
of Thr resulted in a loss of 2 Da, consistent with 1H abstraction from the γ-carbon of Thr and demonstrating 
the formation of a S-Cγ thioether.  
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Figure 5.30 MS/MS analysis of unmodified CteA containing isotopically-labeled Thr. (A) Unmodified 
peptide was treated with GluC to remove a majority of N-terminal leader residues and subsequently reacted 
with N-ethylmaleimide to alkylate unmodified Cys. (B) MS/MS analysis after akylation demonstrates 
fragmentation within the macrocycle observed in modified thermocellin (Figure 5.6), specifically ions y13, 
y14, and b10. Error tables for assigned fragments are in Table 5.6. 
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Figure 5.31 MS/MS analysis of modified CteA containing natural abundance Thr. (A) Modified 
coexpression product was treated with GluC to remove a majority of N-terminal leader residues and 
subsequently reacted with N-ethylmaleimide to alkylate unmodified Cys. (B) MS/MS analysis demonstrates 
that the thioether macrocycle still localizes to the same position as when the precursor peptide is isotopically 
labeled at Thr (Figure 5.6). Error for assigned fragments are provided in Table 5.6.  
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5.7 Tables 
Table 5.1 Primers used in this study. Restriction sites are highlighted in red.  
Primer Nucleotide sequence (5' to 3') 
MBP Fwd (for sequencing) ATGAAGCCCTGAAAGACG 
PapA_BamHI_Fwd AAAGGATCCCATGTTGAAGCAAATCAATGTTATTGCAGG 
PapA_NotI_Rev AAAGCGGCCGCCTAGGTATCCGATTTGATACAAAAATCACTTGC 
PapB_AatII_Fwd AAAGACGTCATGGCTAATCTGATTCAGGATAGAGAAGATG 
PapB_XhoI_Rev AAACTCGAGCTAACCAAAAAGGATGCTTCTTTGTTCC 
CteA_BamHI_Fwd AAGGATCCAATGAAACACATCAAAATCCTGAACGGC 
CteA_NotI_Rev AAGCGGCCGCTTAACGTTTTTCGCAGCTCTGATTCGCAACG 
CteB_Gibson_Insert_F GTTAAGTATAAGAAGGAGATATACATATGGCGATGATCCACAAATTCAGC 
CteB_Gibson_Insert_R GATATCCAATTGAGATCTGCTTACATTTCCTGTGCTTTAATCCACAGC 
CteB_Gibson_Backbone_F GCTGTGGATTAAAGCACAGGAAATGTAAGCAGATCTCAATTGGATATC 
CteB_Gibson_Backbone_R GCTGAATTTGTGGATCATCGCCATATGTATATCTCCTTCTTATACTTAAC 
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Table 5.2 Most common Pfams that co-occur within 8 genes of the rSAM. Listed are Pfams that co-occur 
with a frequency greater than 5%. 
PFAM Description Count 
PF04055 Radical_SAM  Radical SAM superfamily 4814 
PF13353 Fer4_12  4Fe-4S single cluster domain 3871 
PF00005 ABC_tran  ABC transporter 2370 
PF13165 DUF4001  Protein of unknown function (DUF4001) (SCIFF precursor peptide) 1703 
PF13304 AAA_21  AAA domain  putative AbiEii toxin  Type IV TA system 1234 
PF02355 SecD_SecF  Protein export membrane protein 942 
PF00664 ABC_membrane  ABC transporter transmembrane region 931 
PF00072 Response_reg  Response regulator receiver domain 676 
PF12670 DUF3792  Protein of unknown function (DUF3792) 650 
PF03176 MMPL  MMPL family 650 
PF00082 Peptidase_S8  Subtilase family 638 
PF00753 Lactamase_B  Metallo-beta-lactamase superfamily 629 
PF12706 Lactamase_B_2  Beta-lactamase superfamily domain 593 
PF01368 DHH  DHH family 592 
PF12833 HTH_18  Helix-turn-helix domain 582 
PF02518 HATPase_c  Histidine kinase-  DNA gyrase B-  and HSP90-like ATPase 572 
PF00156 Pribosyltran  Phosphoribosyl transferase domain 568 
PF02699 YajC  Preprotein translocase subunit 561 
PF08992 QH-AmDH_gamma  Quinohemoprotein amine dehydrogenase  gamma subunit 538 
PF09100 Qn_am_d_aIV  Quinohemoprotein amine dehydrogenase  alpha subunit domain IV 530 
PF02272 DHHA1  DHHA1 domain 524 
PF04607 RelA_SpoT  Region found in RelA / SpoT proteins 524 
PF04820 Trp_halogenase  Tryptophan halogenase 522 
PF13328 HD_4  HD domain 520 
PF01702 TGT  Queuine tRNA-ribosyltransferase 518 
PF09098 Dehyd-heme_bind  Quinohemoprotein amine dehydrogenase alpha subunit haem binding 506 
PF00528 BPD_transp_1  Binding-protein-dependent transport system inner membrane component 506 
PF02363 C_tripleX  Cysteine rich repeat 458 
PF07690 MFS_1  Major Facilitator Superfamily 434 
PF14681 UPRTase  Uracil phosphoribosyltransferase 422 
PF00152 tRNA-synt_2  tRNA synthetases class II (D  K and N) 416 
PF00171 Aldedh  Aldehyde dehydrogenase family 409 
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Table 5.2 (cont.) 
PF13393 tRNA-synt_His  Histidyl-tRNA synthetase 363 
PF02547 Queuosine_synth  Queuosine biosynthesis protein 362 
PF00392 GntR  Bacterial regulatory proteins  gntR family 350 
PF00587 tRNA-synt_2b  tRNA synthetase class II core domain (G  H  P  S and T) 348 
PF02580 Tyr_Deacylase  D-Tyr-tRNA(Tyr) deacylase 347 
PF12669 P12  Virus attachment protein p12 family 345 
PF02938 GAD  GAD domain 344 
PF07549 Sec_GG  SecD/SecF GG Motif 333 
PF00106 adh_short  short chain dehydrogenase 330 
PF05491 RuvB_C  Holliday junction DNA helicase ruvB C-terminus 329 
PF05496 RuvB_N  Holliday junction DNA helicase ruvB N-terminus 326 
PF01330 RuvA_N  RuvA N terminal domain 325 
PF01965 DJ-1_PfpI  DJ-1/PfpI family 324 
PF07992 Pyr_redox_2  Pyridine nucleotide-disulphide oxidoreductase 317 
PF00486 Trans_reg_C  Transcriptional regulatory protein  C terminal 317 
PF00155 Aminotran_1_2  Aminotransferase class I and II 316 
PF12730 ABC2_membrane_4  ABC-2 family transporter protein 314 
PF14520 HHH_5  Helix-hairpin-helix domain 313 
PF13561 adh_short_C2  Enoyl-(Acyl carrier protein) reductase 310 
PF01381 HTH_3  Helix-turn-helix 302 
PF13186 SPASM  Iron-sulfur cluster-binding domain 296 
PF02687 FtsX  FtsX-like permease family 287 
PF00990 GGDEF  Diguanylate cyclase  GGDEF domain 265 
PF12902 Ferritin-like  Ferritin-like 263 
PF01276 OKR_DC_1  Orn/Lys/Arg decarboxylase  major domain 257 
PF05193 Peptidase_M16_C  Peptidase M16 inactive domain 255 
PF00501 AMP-binding  AMP-binding enzyme 254 
PF00158 Sigma54_activat  Sigma-54 interaction domain 251 
PF00702 Hydrolase  haloacid dehalogenase-like hydrolase 246 
PF00512 HisKA  His Kinase A (phospho-acceptor) domain 246 
PF00132 Hexapep  Bacterial transferase hexapeptide (six repeats) 239 
PF14532 Sigma54_activ_2  Sigma-54 interaction domain 234 
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Table 5.3 1H Chemical shift values of assigned huazacin residues. Resonances are labeled based on their 
position within the indicated amino acid, i.e. H-Cα denotes the alpha carbon proton. Unassigned residues 
are denoted by “*” and bolded ppm values indicate aromatic proton resonances (for Tyr1, Trp2, Tyr34). 
The Trp indole proton is denoted by “H-Nind.” 
Residue NH H-Cα H-Cβ H-Cγ H-Cδ H-Cε H-Cζ H-Nind 
Tyr1 - * * 6.93 6.59    
Trp2 * * * 7.36 7.27 7.02 6.91 10.6 
Gly3 8.54 3.86, 3.52       
Cys4 7.47 3.82 3.71, 3.66      
Ala5 7.99 3.97 1.51      
Leu6 7.64 3.94 1.64 1.45 0.84, 0.80    
Lys7 7.11 3.92 1.72 1.32 1.55 2.74   
Cys8 8.3 3.71 3.17, 2.83      
Ala9 7.21 3.89 1.42      
Gly10 8.57 3.85, 3.7       
Pro11 - 4.11 1.79, 1.75 1.53 2.24, 2.17    
Cys12 7.99 3.79 3.61, 3.16      
Leu13 8.24 3.73 1.78, 1.69 1.57 0.79    
Gly14 8.2 3.62, 3.55       
Val15 7.37 3.76 2.02 1.02, 0.83     
Cys16 8.84 3.8 3.6 2.79     
Ala17 7.9 3.92 1.34      
Ile18 7.49 3.66 1.96 1.83, 1.19, 0.92 0.85    
Asp19 7 4.9 2.77, 2.51      
Thr20 8.24 4.29 3.97 1.25     
Ala21 8.47 4.39 1.41      
Ser22 7.4 4.99 3.8      
Pro23 - 4.94 2.02, 1.96 1.8 3.85, 3.80    
Val24 7.85 3.5 1.95 0.93, 0.87     
Met25 7.83 4.4 2.31, 2.25 2.62 - 1.94   
Asp26 * * *      
Ala27 7.24 3.79 1.51      
Val28 7.92 3.64 2.16 1.05, 0.93     
Gly29 9.59 4.12, 3.58       
Thr30 8.79 - 4.45 1.11     
Ala31 7.89 3.89 1.48      
Ser32 8.62 3.77 3.58      
Gly33 7.53 3.84 3.69      
Tyr34 9.57 - * 6.57 6.82    
Ala35 * 4.12 1.53      
Gly36 9.5 4.13, 3.67       
Gly37 7.97 4.11, 3.94       
His38 9.04 - * *     
Gly39 7..27 3.94, 3.47       
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Table 5.4 Antibiotic activity of freyrasin and huazacin. A small panel of Firmicutes (Gram-positive) and 
ɣ-Proteobacteria (Gram-negative; E. coli and P. aeruginosa) were evaluated for susceptibility (to the two 
new compounds from this study. Only huazacin displayed notable antibiotic activity. 
 
Organism Freyrasin (μM) Huazacin (μM) 
Bacillus subtilis str. 168  128 128 
Bacillus anthracis str. Sterne  128 128 
Clostridium sporogenes ATCC 19404  32 32 
Clostridium sporogenes ARS41091  64 64 
Clostridium sporogenes ATCC 155761  32 32 
Listeria monocytogenes 4b F2365  128 4 
Staphylococcus aureus USA300  128 128 
Escherichia coli DH5a  128 128 
Pseudomonas aeruginosa PAO1  32 32 
 
  
243 
 
Table 5.5 1H Chemical shift values of assigned freyrasin residues. Resonances are labeled based on their 
position within the indicated amino acid, i.e. H-Cα denotes the alpha carbon proton. Unassigned residues 
are denoted by “*” and bolded ppm values indicate aromatic proton resonances (for Tyr9, Phe10 and 
Phe25). Both Asn residues were identified based on TOCSY correlations, but no through-space correlations 
could be used to assign them within the linear sequence. 
 
Residue NH H-Cα H-Cβ H-Cγ H-Cδ H-Cε H-Cζ 
Gly1 - - - - - -  
Cys2 8.53 4.35 2.63, 2.75     
Ser3 8.68 4.26 3.75*     
Ala4 7.88 4.21 1.22     
Asn5 * * *     
Asp6 8.15 4.47 3.71     
Ala7 7.98 4.05 1.08     
Cys8 8.42 4.57 2.51, 2.65     
Tyr9 8.38 4.23 2.74 - 6.63 6.89  
Phe10 7.83 4.41 2.82, 2.94 - 7.04 7.13 7.17 
Cys11 7.86 4.35 2.80, 2.69     
Asp12 8.45 4.37 3.69     
Thr13 8.12 4.13 3.98 1.74, 1.69    
Arg14 7.77 4.23 1.58, 1.68 1.37, 1.42 3.02 7.03  
Asp15 8.31 4.55 3.55     
Asn16 * * *     
Cys17 - - -     
Lys18 8.39 4.23 1.81, 1.95 1.68 * 2.3  
Ala19 8.08 4.14 1.23     
Cys20 8.17 4.3 2.97, 2.65     
Asp21 8.58 4.48 3.75     
Ala22 8.33 3.94 1.25     
Ser23 7.69 4.27 3.67     
Asp24 7.83 4.58 3.58     
Phe25 7.92 4.46 2.93, 2.78 - 7.01 7.13 7.17 
Cys26 8.1 4.42 2.87, 2.65     
Ile27 8.22 3.89 1.73 1.31, 1.03, 0.77 0.76   
Lys28 7.99 4.1 1.95, 1.76 1.69 * 2.11  
Ser29 8.31 4.16 3.78, 3.73     
Asp30 8.35 4.66 3.71     
Thr31 8.3 4.47 4.01 2.58, 2.53    
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Table 5.6 MS/MS Expected and observed masses of diagnostic ions. 
Huazacin (spectrum shown in Figure 5.9) 
Species 
Predicted 
mass 
Observed 
mass 
Error 
(ppm)  
Species 
Predicted 
mass 
Observed 
mass 
Error 
(ppm) 
[M+3H]3+ 1241.53933 1241.53955 0.2  b202+ 1013.45631 1013.45752 1.2 
[M-62]3+ 1220.87253 1220.87187 0.5  b212+ 1048.97487 1048.97547 0.6 
b2 350.14992 350.14981 0.3  b222+ 1092.99256 1092.99273 0.2 
b3 407.17138 407.17082 1.4  b242+ 1191.05315 1191.05521 1.7 
b4 510.18057 510.18023 0.7  [b27-62]2+ 1317.59731 1317.59761 0.2 
b5 581.21768 581.21798 0.5  y5 396.16261 396.16253 0.2 
b6 694.30174 694.30182 0.1  y6 557.21029 557.21025 0.1 
b7 822.39671 822.39702 0.4  y7 614.23175 614.23169 0.1 
b8 925.40589 925.40619 0.3  y8 701.26378 701.26471 1.3 
b9 996.44301 996.44306 0.1  y9 772.30089 772.30148 0.8 
b10 1053.46447 1053.46446 0.0  y10 871.33292 871.33271 0.2 
b12 1253.52642 1253.52465 1.4  y11 928.35438 928.35438 0.0 
b13 1366.61048 1366.60819 1.7  y12 1027.42280 1027.42247 0.3 
b14 1423.63194 1423.63275 0.6  y13 1098.45991 1098.45825 1.5 
b15 1522.70036 1522.70195 1.0  [y14-62] 1149.47082 1149.46942 1.2 
b16 1625.70954 1625.71313 2.2  [y15-62] 1280.51130 1280.51048 0.6 
b17 1696.74666 1696.74838 1.0  [y17-62] 1476.63248 1476.63383 0.9 
b18 1809.83072 1809.83142 0.4  [y18-62] 1563.66451 1563.66293 1.0 
b19 1924.85766 1924.85798 0.2  [y21-62] 1850.77624 1850.77531 0.5 
 
Freyrasin (spectrum shown in Figure 5.21) 
 
Species Predicted mass Observed mass Error (ppm) 
[M+4H]4+ 1397.60943 1397.61133 1.4 
[M+5H]5+ 1118.28900 1118.29030 1.2 
b272+ 1401.70896 1401.71077 1.3 
b273+ 934.80840 934.80967 1.4 
b362+ 1936.88826 1936.89112 1.5 
b363+ 1291.59460 1291.59643 1.4 
b453+ 1593.02409 1593.02567 1.0 
[b45-H2O]
3+ 1587.02056 1587.02267 1.3 
[b51-y23]2+ 1333.47910 1333.48131 1.7 
b45-y24 1974.65098 1974.65379 1.4 
b51-y7 692.30722 692.30800 1.1 
y6 664.29705 664.29729 0.4 
y7 811.36547 811.36650 1.3 
y16 1714.65057 1714.65354 1.7 
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Table 5.6 (cont.) 
L-[4-13C,2,3-2H2]-Thr-labeled unmodified CteA (spectrum shown in Figure 5.28) 
 
Species 
Predicted 
mass 
Observed 
mass 
Error (ppm) 
 
Species 
Predicted 
mass 
Observed 
mass 
Error (ppm) 
[M+H]2+ 1095.94439 1095.94163 2.5  y4 466.16022 466.15937 1.8 
b7 741.27044 741.27144 1.3  y5 580.20315 580.20212 1.8 
b8 812.30756 812.30598 1.9  y6 651.24027 651.23903 1.9 
b9 915.31674 915.31507 1.8  y7 750.30868 750.30716 2.0 
b10 1043.41174 1043.40885 2.8  y8 854.37227 854.37067 1.9 
b11 1147.47529 1147.47265 2.3  y9 957.38145 957.37931 2.2 
b12 1234.50732 1234.50495 1.9  y10 1044.41348 1044.41159 1.8 
b13 1337.51651 1337.51367 2.1  y11 1148.47707 1148.47586 1.1 
b14 1441.58009 1441.57645 2.5  y12 1276.57203 1276.57014 1.5 
b15 1540.64851 1540.64493 2.3  y15 1379.58121 1379.57763 2.6 
b16 1661.68562 1661.68172 2.3  y16 1450.61833 1450.61508 2.2 
b17 1725.72855 1725.72401 2.6  y17 1537.65036 1537.64719 2.1 
b18 1853.78712 1853.78280 2.3  y18 1665.70893 1665.70508 2.3 
b192+ 970.91321 970.91099 2.3  y19 1768.71812 1768.71454 2.0 
b202+ 1022.41781 1022.41581 2.0      
 
L-[4-13C,2,3-2H2]-Thr and NEM-labeled, modified CteA (spectrum shown in Figure 5.6) 
 
Species 
Predicted 
mass 
Observed 
mass 
Error (ppm) 
 
Species 
Predicted 
mass 
Observed 
mass 
Error (ppm) 
[M+H]2+ 1345.03247 1345.03170 0.6  y3 463.14933 463.14920 0.3 
b6 905.34215 905.34147 0.8  y4 591.20790 591.20768 0.4 
b7 991.36580 991.36502 0.8  y5 705.25083 705.25053 0.4 
b11 1395.55500 1395.55386 0.8  y6 776.28794 776.28771 0.3 
b12 1482.58703 1482.58546 1.1  y7 875.35636 875.35584 0.6 
b13 1710.64389 1710.64216 1.0  y8 979.41995 979.41898 1.0 
b14 1814.70748 1814.70552 1.1  y9 1207.47681 1207.47626 0.5 
b15 1913.77589 1913.77320 1.4  y10 1294.50884 1294.50876 0.1 
b16 1984.81300 1984.81037 1.3  y11 1627.66092 1627.65969 0.8 
b17 1049.93188 1049.93092 0.9  y12 1698.69803 1698.69764 0.2 
b18 1113.96117 1113.95969 1.3  y15 1785.73006 1785.72917 0.5 
b19 1157.47718 1157.47620 0.8  y16 957.39823 957.39054 8.0 
b202+ 1271.50561 1271.50439 1.0  y19 1071.42666 1071.42676 0.1 
     [y19-b15] 1557.66045 1557.66016 0.2 
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Table 5.6 (cont.) 
L-[4-13C,2,3-2H2]-Thr and NEM-labeled, unmodified CteA (spectrum shown in Figure 5.30) 
Species 
Predicted 
mass 
Observed 
mass 
Error (ppm) 
 
Species 
Predicted 
mass 
Observed 
mass 
Error (ppm) 
[M+3H]3+ 1034.11072 1034.10901 1.7  y7 989.44690 989.44584 1.1 
b2 357.12272 357.12257 0.4  y8 1060.48402 1060.48268 1.3 
b3 461.18630 461.18603 0.6  y9 1159.55243 1159.55112 1.1 
b4 548.21833 548.21797 0.7  y10 1263.61602 1263.61489 0.9 
b5 776.27520 776.27290 3.0  y11 1491.67288 1491.67100 1.3 
b10 1418.55474 1418.55342 0.9  y12 1578.70491 1578.70306 1.2 
b11 1522.61833 1522.61620 1.4  y13 1682.76850 1682.76643 1.2 
b12 1609.65036 1609.64826 1.3  y14 905.93564 905.93420 1.6 
b13 1837.70722 1837.70361 2.0  y15 1019.96407 1019.96172 2.3 
b14 1941.77081 1941.76571 2.6  y16 1055.48263 1055.48055 2.0 
b182+ 1177.49283 1177.49097 1.6  y17 1098.99865 1098.99674 1.7 
b212+ 1399.55857 1399.55562 2.1  y18 1163.02793 1163.02570 1.9 
y2 303.21392 303.21377 0.5  y19 1277.05637 1277.05399 1.9 
y4 660.31337 660.31282 0.8  y20 1320.57238 1320.56978 2.0 
y5 747.34540 747.34455 1.1  y21 1372.60417 1372.60160 1.9 
y6 875.40398 875.40285 1.3          
 
Natural abundance Thr and NEM labeled modified CteA (spectrum shown in Figure 5.31) 
Species 
Predicted 
mass 
Observed 
mass 
Error (ppm) 
 
Species 
Predicted 
mass 
Observed 
mass 
Error (ppm) 
[M+2H]2+ 1340.50860 1340.50916 0.4  y3 463.14933 463.14931 0.0 
b3 458.17040 458.17043 0.1  y4 591.20790 591.20782 0.1 
b4 545.20242 545.20226 0.3  y5 705.25083 705.25069 0.2 
b6 901.31786 901.31698 1.0  y6 776.28794 776.28751 0.6 
b7 988.34989 988.35046 0.6  y7 875.35636 875.35602 0.4 
b8 1059.38701 1059.38622 0.7  y8 976.40404 976.40332 0.7 
b11 1389.52318 1389.52279 0.3  y9 1204.46090 1204.46063 0.2 
b12 1476.55521 1476.55438 0.6  y10 1291.49293 1291.49281 0.1 
b13 1704.61207 1704.61144 0.4  y13 1621.62910 1621.62740 1.0 
b14 1805.65975 1805.65848 0.7  y14 1692.66622 1692.66574 0.3 
b15 1904.72817 1904.72745 0.4  y15 1779.69825 1779.69807 0.1 
b16 1975.76528 1975.76406 0.6  y192+ 1162.45061 1162.45016 0.4 
b172+ 1045.40802 1045.40767 0.3  [y19-b15] 1548.61273 1548.61283 0.1 
b182+ 1109.43730 1109.43665 0.6          
b192+ 1152.95332 1152.95293 0.3          
b202+ 1266.98175 1266.98086 0.7          
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Appendix A: PDF Reprints of other coauthored publications
 
A.1 A Prevalent Peptide-binding Domain Guides Ribosomal Natural Product Biosynthesis 
Reproduced with permission from Burkhart, B.J.; Hudson, G.A.; Dunbar, K.L.; Mitchell D.A. A prevalent 
peptide-binding domain guides ribosomal natural product biosynthesis. Nat. Chem. Biol. 2015, 11, 564-
570. PMCID: PMC4509860. Copyright 2015 Nature Publishing Group. 
 
I synthesized a fluorescently labeled leader peptide from the thiomuracin biosynthetic gene cluster which 
enabled fluorescence polarization studies that demonstrated TbtF, which contained a predicted RiPP 
recognition element (RRE), interacts with this leader peptide. I also generated mutants of TbtF (D19A, 
L24A, V30A, F68A, R71A, Q74A, R79A) which corroborated that binding was due to the predicted RRE 
domain (Table 2).  
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A.2 Targeting Reactive Carbonyls for Identifying Natural Products and Their Biosynthetic Origins 
Reproduced with permission from Maxson, T.; Tietz, J.I.; Hudson, G.A.; Guo, X.R.; Tai, H.; Mitchell D.A. 
Targeting reactive carbonyls for identifying natural products and their biosynthetic origins. J. Am. Chem. 
Soc. 2016, 138, 15157-15166. PMCID: PMC5148692. Copyright 2016 American Chemical Society. 
 
I cultured Streptomcyes sp. S-98 and characterized two peptidic protease inhibitors, β-MAPI and leupeptin, 
using tandem mass spectrometry which allowed these molecules with a previously-unknown biosynthetic 
origin to be assigned a biosynthetic gene cluster (Figures S23 and S24).  
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A.3 Reconstitution and Substrate Specificity of the Radical SAM Thiazole C-methyltransferase  
in Thiomuracin Biosynthesis 
Reproduced with permission from Mahanta, N.; Zhang, Z.; Hudson, G.A.; van der Donk, W.A., Mitchell, 
D.A. Reconstitution and substrate specificity of the radical SAM thiazole C-methyltransferase in 
thiomuracin biosynthesis. J. Am. Chem. Soc. 2017, 139, 4310-4313. PMCID: PMC5477235. Copyright 
2017 American Chemical Society.  
 
I generated a panel of thiomuracin precursor variants and reacted them with the heterocycle synthetase in 
vitro prior to methylation assays by TbtI, the rSAM methyltransferase from thiomuracin biosynthesis. This 
allowed the discernment that Asn3, Cys4, Phe6, and Cys6 of the core peptide are necessary and sufficient 
for methylation of Thz4 (Figure 4 and Table 1). Furthermore, I performed bioinformatic analyses of Class 
C rSAM methyltransferases and identified homologs predicted to perform similar enzymatic reactions in 
the biosynthesis of other natural products (Figures S17-S20).  
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A.4 Chimeric Leader Peptides for the Generation of Non-natural Hybrid RiPP Products 
Reproduced with permission from Burkhart, B.J.; Kakkar, N.; Hudson, G.A.; van der Donk, W.A.; 
Mitchell, D.A. Chimeric leader peptides for the generation of non-natural hybrid RiPP products. ACS Cent. 
Sci. 2017, 6, 629-638. PMCID: PMC5492250. Copyright 2017 American Chemical Society. 
 
I performed and analyzed the tandem mass spectrometry for all produced chimeric RiPPs in order to verify 
installation of the post-translational modifications as well as localize which residues were modified (Figures 
S5, S9, S11, S13-15, and S17-18).  
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A.5 Radical SAM Enzymes Involved in RiPP Biosynthesis 
Reproduced with permission from Mahanta, M.; Hudson, G.A.; Mitchell, D.A. Radical SAM enzymes 
involved in RiPP biosynthesis. Biochemistry 2017, 56, 5229-5244. PMCID: PMC5634935. Copyright 2017 
American Chemical Society.  
 
I assisted Dr. Mahanta in a literature survey of radical SAM enzymes involved in RiPP biosynthesis and 
created a majority of the figures used to illustrate the biosynthetic organization, natural product structures, 
and catalytic mechanisms of these enzymes. 
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A.6 Structural Insights into Enzymatic [4+2] aza-Cycloaddition in Thiopeptide Antibiotic 
Biosynthesis 
Reproduced with permission from Cogan, D.P.; Hudson, G.A.; Zhang, Z.; Pogorelov, T.V.; van der Donk, 
W.A.; Mitchell, D.A., Nair, S.K. Structural insights into enzymatic [4+2] aza-cycloaddition in thiopeptide 
antibiotic biosynthesis. Proc. Natl. Acad. Sci. U. S. A. 2017, 114, 12929-12933. PMCID: PMC5724283. 
Copyright 2017 National Academy of Sciences. 
 
I performed bioinformatic analyses of the [4+2] cycloaddition enzymes involved in thiopeptide biosynthesis 
via the use of sequence similarity networks (Figure 5), motif analysis (Figure S17), and maximum 
likelihood trees (Figure S18). Additionally, using crystallographic data, I identified additional residues 
beyond those identified in our seminal J. Am. Chem. Soc. Paper that may be involved in catalysis and 
assayed them by a MALDI-TOF-MS endpoint assay, revealing two Phe and Trp residues important for 
catalysis. Lastly, I compared the active sites of lantibiotic-like elimination domains ([4+2] enzymes 
included) and analyzed how they differ despite having a common catalytic fold.  
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A.7 Mechanism of a Class C Radical SAM Thiazole Methyl Transferase 
Reproduced with permission from Zhang, Z.; Mahanta, N.; Hudson, G.A.; Mitchell D.A., van der Donk, 
W.A. Mechanism of a class C radical SAM thiazole methyl transferase. J. Am. Chem. Soc. 2017, 139, 
18623-18631. PMCID: PMC5748327. Copyright 2017 American Chemical Society.  
 
I assisted in the creation of deuterated linear thiomuracin intermediates by performing in vitro 
cyclodehydration reactions. These intermediates were used as substrate to track atom abstraction over the 
course of the thiazole methylation performed by TbtI.   
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A.8 In Vitro Biosynthetic Studies of Bottromycin Expand the Enzymatic Capabilities of the  
YcaO Superfamily 
Reproduced with permission from Schwalen, C.J.; Hudson, G.A.; Kosol, S.; Mahanta, N.; Challis, G.L.; 
Mitchell, D.A. In vitro biosynthetic studies of bottromycin expand the enzymatic capabilities of the YcaO 
superfamily. J. Am. Chem. Soc. 2017, 139, 18154-18157. PMCID: PMC5915351. Copyright 2017 
American Chemical Society. 
 
I performed tandem mass spectrometry to verify and localize cyclodehydration dehydration reactions on 
bottromycin precursor variants, which contained either a thiazoline or macrolactamidine moiety (Figures 
S7 and S8). Additionally, I performed fluorescence polarization to demonstrate that the YcaO enzymes do 
not bind the bottromycin follower while the excised RRE domains from the various rSAM proteins do 
(Figure S13). 
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A.9 Enzymatic Reconstitution and Biosynthetic Investigation of the Lasso Peptide Fusilassin 
Reproduced with permission from DiCaprio, A.J.; Firouzbakht, A.; Hudson, G.A.; Mitchell, D.A. 
Enzymatic reconstitution and biosynthetic investigation of the lasso peptide fusilassin. J. Am. Chem. Soc. 
2019, 141, 290-297. Copyright 2019 American Chemical Society.   
 
I performed tandem mass spectrometry to verify and localize the macrocyclic isopeptide bond in various 
fusilassin lasso peptide analogs, including ring expansions, contractions, and core swaps with other 
characterized lasso peptide precursors (Figures S3 and S14).  
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